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 Galectin-3, a unique member of the growing family of β-galactoside binding 
lectins, contains a single carbohydrate recognition domain and a glycine rich N-
terminal domain through which it can form oligomers and functions to cross-link 
both carbohydrate and non-carbohydrate ligands.  Galectin-3 is widely expressed in 
adult tissues, particularly on and secreted by activated macrophages and monocytes.  
Galectin-3 has been implicated in many facets of the inflammatory response 
including neutrophil and macrophage activation and function.   
 In this thesis I have examined the role of galectin-3 during fibrosis, 
alternative activation of macrophages and pneumonia.  Galectin-3 expression is 
upregulated in established human fibrotic liver disease and in a mouse model of liver 
fibrosis induced by carbon tetrachloride.  Galectin-3 expression is temporally and 
spatially related to the induction and resolution of experimental hepatic fibrosis in 
this model.  In addition, disruption of the galectin-3 gene markedly attenuates liver 
and kidney fibrosis, induced by unilateral ureteric obstruction, with reduced collagen 
deposition and myofibroblast activation.  Results suggest that galectin-3 may 
promote fibrosis by stimulating myofibroblast activation by a transforming growth 
factor-β (TGF-β)-independent mechanism. 
 Recent reports suggest that alternative macrophage activation is one of the 
key steps toward the progression of fibrosis.  Disruption of the galectin-3 gene 
specifically restrains interleukin-4 (IL-4)/IL-13-induced alternative macrophage 
activation in vitro.  My results suggest that the key mechanism required for 
activation of an alternative macrophage phenotype is an IL-4-stimulated galectin-3 
feed back loop which directly activates CD98 causing sustained phosphatidylinositol 
3-kinase (PI3-K) activation. 
 The gram-positive Streptococcus pneumoniae (S. pn) is the leading cause of 
community acquired pneumonia worldwide, resulting in high mortality.  Galectin-3-/- 
mice demonstrate a clearance defect of S. pn with increased septicaemia and a 
greater extent of lung damage compared to wild type mice.  This phenotype is 
markedly reduced in pneumonia induced by the gram-negative Escherichia coli (E. 
 III
coli).  I have shown that presence of galectin-3 reduces the severity of pneumonia 
induced by S. pn and this is achieved through a number of processes: 1) Galectin-3 
has bactericidal properties towards S. pn in vitro.  2) Galectin-3-/- macrophages show 
reduced production of nitrite following incubation with both S. pn and E. coli and 
hence a reduction in bacterial killing.  3) Galectin-3 activates neutrophils to produce 
reactive oxygen species which enhances the bactericidal activity of neutrophils.  4) 
Activation of neutrophils by galectin-3 augments phagocytosis of bacteria.  5) 
Finally, initial data suggests that galectin-3-/- neutrophils apoptose more readily than 
wild type neutrophils in vitro and galectin-3-/- macrophages phagocytose apoptotic 
neutrophils less efficiently compared to wild type.  In vivo this would result in an 
accumulation of dying cells in the lung.  The damage these apoptotic cells would 
have on the lung tissue may enable the bacteria to enter the blood stream resulting in 
sepsis. 
 In summary, in response to chronic tissue injury, persistant upregulation of 
galectin-3 causes myofibroblast and alternative macrophage activation, thus 
enhancing collagen deposition and scarring.  However during an acute S. pn 
infection, galectin-3 plays a benefitial role to aid the clearance of bacteria through a 
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 Animals and plants contain a large number of carbohydrate binding proteins 
called lectins (from the latin word legere meaning “to select”).  Lectins are proteins 
which specifically bind or crosslink carbohydrates and initially consisted of two 
major families.  The C-type family binds carbohydrates in a calcium dependent 
manner and the S-type family.  All members are soluble and bind lactose and related 
saccharides (Lobsanov et al., 1993).  The S-type family was so called because its first 
discovered member was dependent on sulfhydryl residues but it has now been 
designated a new name, the galectins.  The first galectin was described in the mid 
1970’s by Teichberg et al. (Teichberg et al., 1975) from electric organ tissue of 
Electrophorus electricus (electric eel) and was given the name electrolectin.  Waard 
et al. confirmed the finding of β-galactoside binding lectins in homogenates of 
mammalian tissues (de Waard et al., 1976).   
 
1.1.2 Origin of the term “galectin” 
 The general name for galectins was proposed by Barondes et al. in 1994 
(Barondes et al., 1994a).  Before this proposal for a universal nomenclature, the 
galectins had been given many different names depending on the circumstances of 
their discovery.  Barondes suggested that membership into the galectin family 
requires the fulfilment of two criteria: “affinity for β-galactosides and significant 
sequence similarity in the carbohydrate binding site” (Barondes et al., 1994a).  Over 
time it was realised that some of these proteins discovered from different species had 
very conserved structure-function relationships and so they were grouped and 
numbered sequentially according to Barondes’ proposal (Barondes et al., 1994a).  
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Table 1.1 lists four well characterised galectins and their original names before 
Barondes’ proposal.  
 
Galectin Original names Molecular weight Gene 
Galectin-1 L-14-I, L-14, RL-14.5, galaptin, 
MGBP, GBP, BHL, CHA, HBP, HBL, 
HLBP14, rIML-1, and other names  
14,500 Da LGALS1 
Galectin-2 L-14-II 14,650 Da LGALS2 
Galectin-3 CBP-35, Mac-2, IgEBP, CBP-30, RL-
29, L-29, L-31, L-34, LBL, and other 
names 
Between 26,200 
and 30,300 Da 
LGALS3 
Galectin-4 L-36, RIH 36,300 Da LGALS4 
 
Table 1.1 – The proposed names for the well characterised mammalian galectins. 
 
1.1.3 The galectin family 
 As mentioned above, galectins are defined to have affinity for β-galactoside 
containing glycoconjugates and have conserved sequence elements in the 
carbohydrate-binding site.  The relevant amino acid residues that make up this 
sequence have been identified by X-ray crystallography (Lobsanov et al., 1993).  
Thus far, 15 members of the mammalian galectin family have been identified as well 
as galectins from many non-mammalian species and more are likely to be 
discovered.  Hirabayashi and Kasai classified galectins based on their biochemical 
structure into three groups (Hirabayashi and Kasai, 1993); the Prototype galectins 
(galectins-1, -2, -5, -7, -10, -11, -13, -14 and -15), which contain one carbohydrate 
recognition domain (CRD) and a short N-terminal sequence, exists as monomers or 
non-covalent homodimers; the Tandem Repeat group (galectin-4, -6, -8, -9, and -12) 
consist of two non-identical CRDs linked via a short peptide sequence; and the 
Chimera-type galectins (galectin-3), found in solution as monomers with an extended 
N-terminal tail containing a proline-, glycine-, tyrosine-rich domain fused onto the 
CRD (figure 1.1). 
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Figure 1.1 – Classification of the mammalian galectin family.
Figure 1.1
Schematic representation of the structure of different members of the galectin





Galectin-1, -2, -5, -7, -10, -11, -13, -14, -15
Galectin-3
Galectin-4, -6, -8, -9, -12
= Carbohydrate recognition domain
= Proline-, glycine-, tyrosine-rich domain 
= N-terminal domain
= Short linker sequence
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 Some galectins including the most characterised galectin-1 and -3 are found 
extracellularly as well as in the cytosol, however there is no evidence of a signal 
sequence classically used for externalisation through the endoplasmic 
reticulum/Golgi complex.  Therefore these galectins must be secreted via a non-
classical pathway, which has yet to be elucidated.  A partially characterised pathway 
of galectin-3 secretion suggests that this protein is concentrated in envaginations of 
the plasma membrane which pinch off and release galectin-3 into the extracellular 
space (Menon and Hughes, 1999; Gong et al., 1999; Hughes, 1999).  The advantage 
of non-classical secretion is that the galectins are segregated from potential 
glycoprotein ligands traversing the classical pathway until they have exited from the 
cell where they can then carry out their functions (Hughes, 1999). 
 
1.2 Galectin-3 
1.2.1 Distribution and localisation 
 Galectin-3 is widely expressed in adult tissues.  Particularly on activated 
macrophages and monocytes (Ho and Springer, 1982; Liu et al., 1995), basophils and 
mast cells (Liu, 1993), some epithelial cells (e.g. intestine and kidney) (Lotz et al., 
1993; Castronovo et al., 1996; Bao and Hughes, 1995) and fibroblasts (Moutsatsos et 
al., 1987).  Galectin-3 is also expressed in many tumours including thyroid and 
breast carcinomas where galectin-3 expression is inversely correlated with metastatic 
potential (Xu et al., 1995; Castronovo et al., 1996) and in colon carcinomas where 
the converse is seen, a direct correlation between galectin-3 expression and 
malignancy (Schoeppner et al., 1995).  Intracellularly, galectin-3 is located in both 
cytoplasm and nucleus of some cells.  In quiescent fibroblasts the distribution of 
galectin-3 is largely cytoplasmic, whereas in proliferating fibroblasts, the protein is 
located mainly in the nucleus, therefore distribution of galectin-3 in this cell type is 
coordinated with the proliferation state (Moutsatsos et al., 1987).  Galectin-3 is 
upregulated when monocytes differentiate into macrophages (Liu et al., 1995) and 
down regulated when macrophages differentiate into dendritic cells (Dietz et al., 
2000). 
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 Galectin-3 has numerous binding partners and demonstrates many autocrine 
and paracrine effects.  It can affect several biological processes via the mediation of 
cell adhesion (Inohara and Raz, 1995; Kuwabara and Liu, 1996; Sato et al., 2002), 
cell activation (Liu et al., 1995; Yamaoka et al., 1995; Karlsson et al., 1998; 
Fernandez et al., 2005; Frigeri et al., 1993; Hsu et al., 1996) and chemoattraction 
(Sano et al., 2000).  Galectin-3 plays a role in the maintenance of cellular 
homeostasis by affecting cell growth (Inohara et al., 1998; Joo et al., 2001; Yang et 
al., 1996), apoptotis (Hsu et al., 2000; Akahani et al., 1997; Yang et al., 1996; 
Fukumori et al., 2003) and controlling the cell cycle (Kim et al., 1999; Lin et al., 
2000) and during immune responses (Hsu et al., 2000; Colnot et al., 1998b; Chen et 
al., 2005), oncogenesis and tumour invasion and metastasis (van den et al., 2004; 
Takenaka et al., 2004; Iurisci et al., 2000; Buttery et al., 2004; Kim et al., 1999). 
 
1.2.2 Regulation of galectin-3 expression 
 The regulation of galectin-3 is a complex mechanism that involves numerous 
transcription factors and signalling pathways, and which depends on cell type, 
external stimuli and environmental conditions. 
 The gene for human galectin-3 LGALS3 is located on chromosome 14, locus 
q21-q22 (Raimond et al., 1997).  The human and mouse LGALS3 genes are 
composed of six exons and five introns.  Exon I and part of exon II encodes the 
untranslated region upstream of the translation initiation site located on exon II.  
Exon III of both the mouse and human LGALS3 gene encodes the N-terminal 
domain.  In mouse, the CRD is encoded by exons IV, V and VI (Gritzmacher et al., 
1992), whereas in human the sequence encoding the CRD was found entirely within 
exon V (Kadrofske et al., 1998).   
 The expression of galectin-3, on both transcription and translational levels, is 
affected by various stimuli.  Galectin-3 protein and mRNA levels are increased in 
proliferating fibroblasts compared to quiescent cells (Moutsatsos et al., 1987; Agrwal 
et al., 1989).  Galectin-3 can be considered a differentiation marker - galectin-3 is up-
regulated when monocytes differentiate into macrophages (Liu et al., 1995) and 
down-regulated when macrophages differentiate into dendritic cells (Dietz et al., 
2000).  Galectin-3 is also regarded as a macrophage activation marker due to the fact 
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that galectin-3 is upregulated by the activation of the monocytic THP-1 cell line by 
phorbol ester (Dabelic et al., 2005) and in macrophages exposed to granulocyte-
macrophage colony stimulating factor (GM-CSF) (Saada et al., 1996).  
 Despite a large body of data concerning galectin-3 expression, the 
mechanisms of regulation of galectin-3 expression are still poorly understood.  
Neither the human, nor the murine LGALS3 promoter contains a TATA box 
immediately upstream of the transcription start site. However, there are multiple GC 
box motifs for binding of the ubiquitously expressed Sp1 transcription factor which 
is a common feature of constitutively expressed, or so-called housekeeping, genes 
(Kadrofske et al., 1998). 
 In addition to five putitive Sp1 binding sites, the promoter region of the 
human LGALS3 gene contains several regulatory elements: five cAMP-dependent 
response elements (CRE), four AP-1- and one AP-4-like sites, two NF-κB-like sites, 
one sis-inducible element (SIE) and a consensus basic helix-loop-helix (bHLH) core 
sequence.  Although the LGALS3 promoter looks like that of a housekeeping gene, 
galectin-3 expression is increased in response to serum stimulation and can be 
characterised as an immediate-early gene.  The SIE is important for growth factor-
induced transcriptional activation of other immediate-early genes and it has been 
suggested that SIE is a possible candidate for the growth-induced activation of 
LGALS3 expression, caused by the addition of serum (Saada et al., 1996). 
 The presence of CRE and NF-κB-like sites in the promoter region implies 
that activation of galectin-3 expression could be regulated through signalling 
pathways involving the cAMP-response element-binding protein (CREB) or the NF-
κB transcription factor.  The involvement of NF-κB transcription factor and the Jun 
protein, a component of AP-1 transcription factor, in the regulation of galectin-3 
expression has been confirmed (Dumic et al., 2000; Kim et al., 2003). 
 
1.2.3 Intracellular binding partners, functions and signalling 
 Intracellular binding partners for galectin-3 include Bcl-2 (Yang et al., 1996; 
Akahani et al., 1997), Gemin4 (Park et al., 2001), CBP70 (Seve et al., 1993), 
cystidine/histidine-rich protein (Chrp) (Menon et al., 2000), cytokeratins (Goletz et 
al., 1997) and β-catenin (Shimura et al., 2004).  The majority of intracellular ligands, 
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with the exception of cytokeratins, interact with galectin-3 via protein-protein rather 
than lectin-glycoconjugate interactions. 
 Gemin4 is a component of the spliceosome, a macromolecular complex that 
coordinates pre-mRNA splicing, which is an important post-transcriptional process.  
Galectin-3 is an interacting partner of Gemin4 and this interaction has been 
implicated as an important event in spliceosome assembly (Park et al., 2001). 
 Bcl-2 was the first cytosolic ligand of galectin-3 to be discovered.  Galectin-3 
has significant sequence similarity with the anti-apoptotic protein Bcl-2, especially in 
that the lectin contains the NWGR motif conserved amongst the Bcl-2 family.  
Studies have shown that galectin-3 binds Bcl-2 and this interaction can be inhibited 
by lactose.  This was an interesting finding as Bcl-2 is not a glycoprotein.  The CRD 
of galectin-3 could be involved in this molecular interaction, or binding of lactose to 
galectin-3 may induce a conformational change in the region of the protein that does 
interact with Bcl-2.  Together these results imply that galectin-3 plays a role in cell 
growth and apoptosis (Yang et al., 1996; Akahani et al., 1997).  Other galectin-3 
ligands involved in apoptotic signalling have recently been identified; CD95 (APO-
1/Fas) is a member of the death receptor family (Fukumori et al., 2004), Nucling is 
involved in the regulation of apoptosis (Liu et al., 2004) and Alix/AIP1 is also 
involved in the regulation of apoptotic events (Liu et al., 2002).   
 Galectin-3 has been shown to elevate Protein Kinase B (Akt/PKB) levels, a 
Ser/Thr protein kinase involved in regulating the inhibition of apoptosis and the 
stimulation of cell proliferation (Oka et al., 2005); further evidence linking galectin-3 
with cancer progression. 
 Ras proteins are important small GTPases, playing a role in cell proliferation, 
differentiation, survival and death.  Galectin-3 is a specific binding partner of 
activated K-Ras but does not interact with activated H-Ras or N-Ras (Elad-Sfadia et 
al., 2004).  This specific binding promotes the activation of phosphatidylinositol 3-
kinase (PI3-K) and Raf-1 and augments extracellular signal-regulated kinase (ERK) 
activation.  Galectin-1, on the other hand, binds to both activated H-Ras and K-Ras 
thus deflecting the Ras signal towards Raf-1 and away from PI3-K.  K-Ras is the 
most important Ras oncoprotein in human tumours and as galectin-1 and galectin-3 
 7
levels vary amongst normal and cancer cells it is possible to conclude that the 
balance of these galectins defines the outcome of oncogenic K-Ras transformation. 
 Galectin-3 has also been shown as an important regulator of Wnt/β-catenin 
signalling.  Galectin-3 has structural similarity to and is a binding partner of β-
catenin.  β-catenin is a downstream component of the Wnt signalling pathway.  
Phosphorylation of β-catenin by casein kinase I (CKI) and glycogen synthase kinase-
3β (GSK-3β) is essential for signal initiation.  Galectin-3 can also be phosphorylated 
by this dual kinase system, however, it is unclear whether phosphorylation of 
galectin-3 affects the phosphorylation of β-catenin or vice versa, or of the exact role 
galectin-3 plays during Wnt signalling (Shimura et al., 2004; Shimura et al., 2005).  
β-catenin signalling regulates TGF-β-mediated epithelial to mesenchymal transition 
(EMT), a process which generates myofibroblasts and contributes to the progression 
of fibrosis.  Furthermore, Wnt4 upregulation in murine models of renal 
tubulointerstitial disease correlates with the appearance of fibrotic lesions thus 
implicating these proteins as mediators of renal fibrosis (Surendran et al., 2002). 
 Apical sorting is the process whereby proteins are directed to either the apical 
or basolateral domain of epithelial cells to maintain cellular polarisation.  The apical 
domains of epithelial cells face the organ lumen and the basolateral domains face 
neighbouring cells and the basal lamina (Delacour and Jacob, 2006).  Galectin-3 is 
found in lipid-raft-independent apical carrier vesicles and interacts with proteins 
bound for the apical domain in a glycan-dependent manner (Delacour et al., 2007).  
In galectin-3-depleted cells, the glycoproteins are misguided to the basolateral 
membrane.  Furthermore, galectin-3 causes glycoprotein clustering, and in 
glycosylation-deficient cells cluster formation and apical sorting are restrained.  Thus 
crosslinking glycoproteins by galectin-3 is required for apical sorting. 
 
1.2.4 Extracellular functions 
 Once outside the cell, galectins interact with various cell surface β-
galactosides containing glycans via the CRD.  In vivo galectin-3 binds to ligands 
containing lactose as the basic unit of recognition (Bachhawat-Sikder et al., 2001).  
In general, galectins bind to Type I Gal β1,3 GlcNAc or Type II Gal β1,4 GlcNAc 
units with higher affinity to polylactosamine chains (Ochieng et al., 2004; Hughes, 
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2001).  Expression of these glycan structures depends on the activity of 
glycosyltransferases.  β1,6-N-acetylglucosaminyl transferase (Mgat5, GnT-V) 
promotes the addition of N-acelyllactosamine on N-glycans, thus creating the 
preferred ligands for galectin-3 (Dumic et al., 2006). 
 The majority of extracellular functions and subsequent signal transduction of 
galectin-3 are thought to be due to the CRD binding to Mgat5-modified N-glycans on 
various cell surface receptors.  This is followed by the galectin forming oligomers 
via its N-terminal domain, thus functioning as a biological cross-linker among 
several glycoproteins.  Previous data has shown that a truncated form of galectin-3 
lacking the N-terminal domain, while still able to bind ligands, can not exert its 
functions (Kuwabara and Liu, 1996; Nieminen et al., 2005; Sato et al., 2002).  
Recent data has reinforced this proposal by demonstrating oligomerisation of 
galectin-3 at a cellular level in biological settings (Nieminen et al., 2007). 
 Integrins are highly glycosylated due to multiple glycosylation sites and 
galectin-3 is a binding partner of α3β1 integrin on the cell surface of endothelial 
cells.  A complex is formed between the integrin, galectin-3 and the NG2 
proteoglycan which may potentiate transmembrane signalling responsible for 
endothelial cell motility and morphogenesis (Fukushi et al., 2004).  This interaction 
may be important in angiogenesis and tumour vascularisation.   
 Binding of galectin-3 to Mgat5-modified N-glycans of epidermal growth 
factor (EGF) and transforming growth factor (TGF)-β receptors results in a delay of 
receptor removal by constitutive endocytosis.  Therefore, the galectin-3 lattice 
ensures upregulation of surface receptors and increased sensitivity to growth factors.  
For example, Mgat5-deficient mice display a loss of sentivitity to cytokines resulting 
in a loss of phosphorylation and nuclear translocation of ERK and reduced Smad2/3 
phosphorylation (Partridge et al., 2004). 
 Galectin-3 may therefore function to regulate cytokine receptors primarily 
through its ability to bind Mgat5-modified N-glycans on surface glycoproteins.  




1.2.5 Cell adhesion 
 Due to oligomerisation, galectin-3 can form multivalent aggregates 
suggesting that they act by crosslinking carbohydrate chains on cell surfaces and/or 
extracellular matrix (ECM) (Barondes et al., 1994b). 
 Extracellular binding partners of galectin-3 responsible for modulating cell 
adhesion include laminin (Ochieng and Warfield, 1995; Wang et al., 1992; 
Kuwabara and Liu, 1996; Massa et al., 1993), fibronectin and vitronectin (Matarrese 
et al., 2000; Sato and Hughes, 1992), hensin (Hikita et al., 2000), elastin (Ochieng et 
al., 1999) and collagen IV (Ochieng et al., 1998) as well as certain integrins 
including α1β1 integrins (Ochieng et al., 1998; Andre et al., 1999) and the α subunit 
of αMβ1 (CD11b/18, Mac-1 antigen) present on macrophages (Dong and Hughes, 
1997).  Galectin-3 also binds the heavy chain of CD98, promoting its dimerisation 
and, consequently, integrin activation (Dong and Hughes, 1997; Hughes, 2001; Dong 
and Hughes, 1996; Henderson et al., 2004). 
 Laminin, a key member of ECM proteins, is a heterotrimer that binds 
galectin-3 with high affinity (Massa et al., 1993) and this interaction is important in 
mediating cell adhesion.  Because disturbed cell adhesion is an important 
characteristic of all cancers, the interaction between galectin-3 and laminin may be 
an important factor in cancer progression by, for example, protecting cells against 
detachment-induced apoptosis (Matarrese et al., 2000).  Galectin-3 promotes 
adhesion of neutrophils to laminin (Kuwabara and Liu, 1996) which may aid 
neutrophils to traverse through basement membranes to reach the site of 
inflammation. 
 In general, galectin-3 positively regulates cell adhesion, however, it has been 
shown that galectin-3 can inhibit cell adhesion, for example, melanoma, breast 
cancer, fibrosarcoma and prostate cancer cell adhesion to laminin (Ochieng et al., 
1998) thus increasing the possibility for cancers to metastasise.  These differences 
rely on the proteins involved in cell adhesion and the concentration of soluble 
galectin-3 present.   
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1.2.6 Regulation of the immune response 
 Galectin-3 is highly expressed and secreted from activated macrophages and 
acts as a powerful pro-inflammatory signal.  As stated above, extracellular galectin-3 
mediates cell adhesion, activation, and acts as a chemoattractant for various cell 
types.  Numerous studies have been carried out investigating the effects of galectin-3 
on the cells involved in immune responses (figure 1.2).  Galectin-3 promotes the 
respiratory burst in neutrophils and monocytes (Yamaoka et al., 1995; Liu et al., 
1995) and this activity is dependent on the lectin property of the protein as it is 
inhibitable by lactose; it induces mediator release from mast cells (Frigeri et al., 
1993) and downregulates interleukin-5 (IL-5) production from eosinophils 
(Cortegano et al., 1998).  Galectin-3 promotes the survival of B cells by blocking the 
final differentiation into plasma cells thus allowing the rising of a memory B cell 
phenotype (Acosta-Rodriguez et al., 2004).  This process is important when the host 
meets a pathogen which it has previously encountered.  Memory B cells enable the 
immune system to eliminate the secondary infection quicker and more effectively.   
 A good deal of research has been carried out investigating the effect of 
galectin-3 on T lymphocytes.  Galectin-3 is expressed in activated, but not resting T 
lymphocytes (Joo et al., 2001).  Extracellular galectin-3 induces T cell apoptosis 
(Fukumori et al., 2003) whereas intracellular galectin-3 results in an inhibition of 
apoptosis (Yang et al., 1996).  Over expressing galectin-3 in the human leukaemia T 
cell line Jurkat enhances proliferation and confers resistance to apoptosis induced by 
anti-Fas antibody and staurosporine (Yang et al., 1996).  Furthermore, anti-sense 
oligonucleotides specific for murine galectin-3 inhibit the proliferation of activated T 
lymphocytes (Joo et al., 2001).  Inhibition of galectin-3 reduces naïve T-lymphocyte-
dendritic cell interactions (Swarte et al., 1998), a process crucial for the induction of 
immune responses.  Finally, Mgat5-dependent association of galectin-3 with T cell 
receptor (TCR) complex proteins restricts TCR recruitment to the site of antigen 
presentation thus inhibiting TCR-mediated signalling (Demetriou et al., 2001). 
 Regarding the influence of galectin-3 on neutrophil physiology, this protein 
increases CD66 expression on the surface of neutrophils (Fernandez et al., 2005) and 
binds to CD66a and CD66b (Feuk-Lagerstedt et al., 1999), the receptors most likely 
responsible for inducing neutrophil NADPH-oxidase activation.  Galectin-3 
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promotes the adhesion of neutrophils to laminin (Kuwabara and Liu, 1996), the 
extravasation of neutrophils in response to a streptococcal pneumonia but not an 
Escherichia coli (E. coli) infection (Sato et al., 2002) and enhances phagocytic 
activity (Fernandez et al., 2005). 
 Monocyte and macrophage biology is also affected by galectin-3.  In addition 
to enhancing superoxide anion production from human monocytes (Liu et al., 1995), 
galectin-3 acts as a chemoattractant for monocytes and macrophages (Sano et al., 
2000).  At high concentrations the protein is chemotactic, that is to say cell migration 
is directed.  At low concentrations galectin-3 is chemokinetic resulting in enhanced 
general motility.  Galectin-3 positive macrophages show increased phagocytosis of 
Immunoglobulin-G (IgG)-opsonised erythrocytes and apoptotic thymocytes both in 
vitro and in vivo when compared to macrophages from galectin-3 knockout (galectin-
3-/-) mice (Sano et al., 2003).  Furthermore, peritoneal macrophages taken from 
galectin-3-/- mice are more prone to undergo apoptosis than wild type macrophages 
(Hsu et al., 2000).  Galectin-3 also promotes monocyte-monocyte interactions that 
ultimately lead to polykaryon (multinucleated giant cell) formation, a phenotype 
associated with chronic inflammatory and fibrotic diseases (Okamoto et al., 2003). 
 The aforementioned effect on the different cells of the immune system 
signifies that galectin-3 must play an important role in certain disease states.  
Intracellular galectin-3 could promote the survival of inflammatory cells resulting in 
persistence of inflammation confirmed by the finding that galectin-3-/- mice 
demonstrate a reduced inflammatory response after the induction of peritonitis 
(Colnot et al., 1998b).  Galectin-3 recognises galactoside-containing glycoconjugates 
on pathogens and can bind to lipopolysaccharides (LPS) of a number of gram-
negative bacteria (Mandrell et al., 1994) implicating the importance of galectin-3 in 
pathogen recognition.  While endogenous galectin-3 is shown to play a role in the 
pathogenesis of asthma (Zuberi et al., 2004), galectin-3 applied therapeutically as 
gene therapy suppresses the inflammatory response in a rat asthma model (del, V et 
al., 2002) thus presenting novel therapeutic approach to the treatment of asthma. 
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Figure 1.2 – The effect of galectin-3 on immune cell 
function.
Figure 1.2
The effects of galectin-3 on immune cells. Red upwards arrows indicate positive 
effects, blue downwards arrows indicate negative effects.
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 Investigating galectin-3 in the immune response has demonstrated that this 
protein displays both pro- and anti-inflammatory roles depending on the target cell 
type, whether galectin-3 is acting exogenously or endogenously, its expression level 
and other inflammatory factors.  It is therefore imperative that all these factors be 
taken into consideration should galectin-3 be used therapeutically. 
 
1.2.7 Galectin-3 and cancer 
 Galectin-3 expression in cancer has been widely studied, however there are 
conflicting results which makes it difficult to come to a general conclusion about the 
expression profiles of galectin-3 in cancer.  The functional properties of galectin-3 
mentioned above have, however, convinced researchers in this field that galectin-3 
plays several roles in cancer pathogenesis, proliferation and metastasis.  Furthermore, 
some progress has been made in developing galectin-3 inhibitors as anti-cancer 
agents (Cumpstey et al., 2005; Pieters, 2006). 
 Initial studies inferred that galectin-3 expression in cancer was increased and 
directly correlated with metastatic potential.  Galectin-3 expression has been shown 
to be increased in a mouse fibrosarcoma cell line derived from a parent fibrosarcoma 
tumour induced by chronic UV irradiation (Raz et al., 1987).  Galectin-3 expression 
is also increased in thyroid malignancies (Xu et al., 1995), gastric cancer (Baldus et 
al., 2000), tumours of the central nervous system (Bresalier et al., 1997), human 
bladder carcinomas (Cindolo et al., 1999), pancreatic tumours (Schaffert et al., 1998) 
and renal carcinoma (Young et al., 2001).  Human colon cancer specimens 
demonstrate a positive correlation between the stage of progression of colorectal 
carcinomas and galectin-3 expression (Irimura et al., 1991).  In contrast, another 
group demonstrated decreased expression of galectin-3 in colon cancer specimens 
compared to corresponding normal tissue (Castronovo et al., 1992).  Furthermore, 
similar results have been obtained with skin (Konstantinov et al., 1994), head and 
neck (Choufani et al., 1999) and prostate cancer (Pacis et al., 2000; Ellerhorst et al., 
1999).  Galectin-3 is highly expressed in non-small cell lung cancer (NSCLC) yet 
very poorly expressed in small cell lung cancer (SCLC) which may be linked with 
variations in cellular behaviour (Buttery et al., 2004).  It has been suggested that the 
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apparent discrepancies in data could be due to different experimental approaches and 
techniques used and high specificity of each type of cancer (Dumic et al., 2006). 
 The intracellular distribution of galectin-3 determines its effect on cancers.  
Nuclear galectin-3 has anti-tumour effects whereas cytoplasmic galectin-3 is 
associated with tumour progression.  Neoplastic progression of colon carcinoma has 
been shown to be associated with increased cytoplasmic galectin-3 expression and 
loss of nuclear galectin-3 expression (Lotz et al., 1993).  Similar results have been 
shown with tongue (Honjo et al., 2000), prostate (Van Den Brule et al., 2000; 
Califice et al., 2004) and NSCLC (Puglisi et al., 2004).  In contrast, galectin-3 is 
highly expressed in the nuclear compartment of transformed thyroid cells (Paron et 
al., 2003). 
 Examining the expression levels and distribution of galectin-3 in cancers 
could act as a prognostic tool for the diagnosis of cancer severity.  This has 
particularly been shown for thyroid carcinoma whereby using galectin-3 to diagnose 
follicular carcinoma is over 95% sensitive and specific (Volante et al., 2004). 
 Metastasis of cancer is a fatal complication associated with malignancies.  
The metastatic cascade involves angiogenesis at the primary site, detachment from 
the primary site, invasion through the ECM, dissemination through the blood flow, 
tumour cell aggregation in capillaries, extravasation and growth at secondary sites.  
Galectin-3 is involved in tumour related angiogenesis (Nangia-Makker et al., 2000); 
inhibits or promotes cell adhesion as detailed previously; protects cells from anoikis 
(Kim et al., 1999);  increases tumour cell aggregation (Inohara and Raz, 1995) and 
contributes to tumour cell extravasation (Glinsky et al., 2001) – all of which add to 
the metastatic potential of cancers. 
 
1.2.8 CD98 
 Previously known as 4F2, CD98 is a disulfide-linked 125kDa heterodimeric 
type II transmembrane glycoprotein composed of a glycosylated 85kDa heavy chain 
(designated CD98) and a nonglycosylated 40kDa light chain (Verrey et al., 2004).  
CD98 was originally discovered as a T-cell activation antigen (Haynes et al., 1981) 
and has been implicated in a number of cellular processes including cell adhesion, 
giant cell formation and amino acid transport across cell membranes of various cell 
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types (Deves and Boyd, 2000).  CD98 is ubiquitously expressed in most tissues and 
tumour cells (Parmacek et al., 1989) and is highly conserved between species 
(Quackenbush et al., 1987).  It is expressed at low levels on the surface of quiescent 
cells but is rapidly upregulated following cellular activation. 
 Previous work from this laboratory has shown that CD98 promotes “integrin-
like signalling” and PI3-K activation causing elevation of intracellular PI(3,4,5)P3 
and PKB activation leading to cellular transformation (Rintoul et al., 2002; 
Henderson et al., 2004).   
 Galectin-3 binds to the heavy chain of CD98 promoting its dimerisation and 
integrin activation (Dong and Hughes, 1997; Hughes, 2001; Dong and Hughes, 
1996).  Crosslinking CD98 with anti-CD98 monoclonal antibodies promotes 
polykaryon (multinucleated giant cell) formation, a phenotype associated with 
chronic inflammatory conditions (Tajima et al., 1999).  Therefore modulation of 
galectin-3 expression and interaction with CD98 during macrophage differentiation 
may be important in the regulation of macrophage plasticity and control of 
macrophage fate.  Activation of CD98 by galectin-3 may therefore represent a 
mechanism whereby galectin-3 mediates its effects on macrophage function. 
 
1.2.9 The galectin-3-/- mouse 
 A considerable amount of work carried out in this study has utilised the 
galectin-3-/- mouse.  The galectin-3-/- mouse was generated both by Dr Françoise 
Poirier’s group at the Cochin Institute Paris, France (Colnot et al., 1998a) and by 
Professor Fu-Tong Liu’s group at the University of California (Hsu et al., 2000).  
Colnot et al. demonstrate that their galectin-3-/- mice do not manifest any obvious 
defect in implantation or early development.  These mice appear healthy and have a 
normal lifespan.  It was therefore concluded that galectin-3 does not play any 
essential role in fundamental physiological processes, however this only ruled out an 
absolute requirement for the protein.  Furthermore, the galectin-3-/- mouse 
demonstrates no reduced expression of galectin-1 (Colnot et al., 1998a).  As a result 
it has been possible to utilise this mutant for studies on the role of galectin-3 in 
various processes.  Positive or negative galectin-3 expression in the wild type mice 
or galectin-3-/- mice respectively was routinely confirmed during this study.  Figure 
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1.3 shows a galectin-3 Western blot of wild type and galectin-3-/- bone marrow 
derived macrophages (BMDM).  Furthermore, regular checks on these mice using 
polymerase chain reaction (PCR) verify the absence of galectin-3 in galectin-3-/- 
mice (data not shown). 
 Since being developed and made widely available, the galectin-3-/- mouse has 
been used in a number of studies.  Colnot et al. demonstrated that their galectin-3-/- 
mice have significantly less numbers of neutrophils in the peritoneal cavity 4 days 
after thioglycolate-induced peritonitis, indicating that galectin-3 plays a role in 
granulocyte maintenance during inflammation (Colnot et al., 1998b).  Hsu et al. also 
demonstrated attenuated peritoneal inflammatory responses in their galectin-3-/- mice 
following thioglycolate-induced peritonitis, however they did not verify Colnot’s 
findings of a reduction of neutrophils in the galectin-3-/- mouse peritoneal cavity 
(Hsu et al., 2000).  Both groups, however, showed that macrophage numbers in 
galectin-3-/- mouse peritoneal cavities were reduced following thioglycolate-induced 
peritonitis (Colnot et al., 1998b; Hsu et al., 2000).  Together, these results reveal 
galectin-3 as an important pro-inflammatory molecule. 
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Figure 1.3 – Galectin-3 expression in wild type and galectin-
3-/- bone marrow derived macrophages (BMDM).
Figure 1.3






1.3 Chronic inflammation and infection 
1.3.1 Fibrosis 
 Normal wound repair is tightly regulated by a sequence of events involving 
inflammation, recruitment, activation and proliferation of fibroblasts, and the 
production of ECM culminating in restoration of normal tissue architecture.  This 
process is essential for the replacement of dead or damaged cells after injury and 
critical for survival (Wynn, 2007). 
 Following pathological chronic tissue injury platelets become activated, 
aggregate to form clots and degranulation from platelets causes an increase in blood 
vessel permeability.  Leukocytes are recruited, activated and induced to proliferate 
by chemokines and growth factors such as platelet-derived growth factor (PDGF) 
and transforming growth factor (TGF-β).  These activated leukocytes secrete pro-
fibrotic cytokines such as IL-13 and TGF-β.  These profibrotic cytokines result in the 
activation of collagen-secreting, α-smooth muscle actin (α-SMA) positive 
myofibroblasts resulting in the production of matrix metalloproteinases (MMPs) 
which disrupt the basement membrane.  Activated myofibroblasts also secrete 
cytokines and chemokines that recruit more inflammatory cells to the site of injury.  
The source of myofibroblasts depends on the tissue and the nature of the injury.  
Myofibroblasts can be derived from resident tissue fibroblasts or from epithelial cells 
by a process of EMT (Hinz et al., 2007; Hinz, 2007; Zeisberg and Kalluri, 2004; 
Kalluri and Neilson, 2003).  There is also mounting evidence that myofibroblasts can 
arise from circulating mesenchymal cells or fibrocytes (Bucala et al., 1994; Wang et 
al., 2007; Quan et al., 2006).  Macrophages and neutrophils remove tissue debris and 
dead cells and any invading organisms.  This initial inflammatory phase is followed 
by the production of ECM components by myofibroblasts and the formation of new 
blood vessels.  Under normal conditions the myofibroblasts stimulate wound 
contraction with collagen fibres becoming more organised thus restoring the 
damaged tissue to its normal appearance.  During chronic injury, whereby the 
inflammatory response persists for several weeks or months, inflammation, tissue 
destruction and repair processes occur simultaneously resulting in persistent 
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myofibroblast activation and excessive ECM deposition forming a permanent fibrotic 
scar and loss of tissue architecture and function (Wynn, 2007). 
 
1.3.2 Alternative macrophage activation 
 Macrophages play an important role in the regulation and orchestration of 
tissue responses following chronic inflammation.  In particular, recent studies have 
demonstrated that macrophages display phenotypical heterogeneity in response to 
environmental factors that affect their role in inflammation. 
 The classically activated (M1 polarised) macrophage is the best studied 
macrophage phenotype and develops following an initial pro-inflammatory response 
during which T helper 1 (Th1)-type lymphocytes and natural killer (NK) cells 
produce interferon-γ (IFN-γ), and antigen presenting cells (APCs) produce an array 
of cytokines including  IL-12 and IL-18 (Gordon, 2003).  After an infection, LPS, a 
microbial trigger, classically activates macrophages following priming by IFN-γ.  
Once classically activated, macrophages produce the pro-inflammatory cytokines IL-
6 and tumour necrosis factor-α (TNF-α) (Munder et al., 1998; Welch et al., 2002).  
They also produce nitrites including nitric oxide (NO) by an inducible nitric oxide 
synthase (NOS2) (Hauschildt et al., 1990; Hesse et al., 2001), which is important for 
microbial killing. 
 In contrast, the resolution phase of inflammation is driven by alternatively 
activated (M2 polarised) macrophages, which are hypo-responsive to pro-
inflammatory stimuli.  Macrophages undergo alternative activation when stimulated 
with the Th2 cytokines, IL-4 or IL-13 (Gordon, 2003; Munder et al., 1999; Hesse et 
al., 2001).  Initially it was believed that IL-4 and IL-13 resulted in a deactivated 
phenotype similar to that seen with IL-10, whereby there is a deactivation of the 
respiratory burst and of inflammatory cytokine production, particularly TNF-α.  
However, it was discovered that the regulatory role of IL-4 and IL-13 on immune 
responses appeared to be more complex than first thought (D'Andrea et al., 1995).
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Figure 1.4 – Classical (M1) and alternative (M2) activation of 
macrophages.
Figure 1.4
Macrophages can be classically (M1) or alternatively (M2) activated as a result of 
competition between nitric oxide synthase 2 (NOS2) and arginase-1 for the 
common substrate L-arginine producing either nitric oxide (NO) or L-ornithine
respectively. (OAT; ornithine aminotransferase, ODC; ornithine decarboxylase). 
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 Incubation of macrophages with IL-4 or IL-13 causes upregulation of 
mannose receptor expression (Stein et al., 1992), arginase-1 activity (Hesse et al., 
2001), YM-1 (chitinase-like lectin) (Nair et al., 2005; Raes et al., 2002) and FIZZ-1 
(found in inflammatory zone-1, a resistin-like secreted protein) expression (Herbert 
et al., 2004; Nair et al., 2003).   
 One mechanism by which Th1 and Th2 cytokines induce opposing 
macrophage phenotypes is through differential regulation of NOS2 or arginase-1 
(Hesse et al., 2001) (Figure 1.4).  Th1 cytokines IFNγ and TNF-α cause macrophages 
to metabolise L-arginine by NOS2 to NO and L-citrulline.  The intermediate product, 
L-hydroxyarginine, inhibits arginase-1 activity resulting in a classical (M1) 
phenotype.  If Th2 cytokines IL-4 and IL-13 are present, less L-hydroxyarginine is 
produced and arginase-1 activity is not inhibited.  Consequently, the common 
substrate L-arginine is metabolised by arginase-1 resulting in the production of L-
ornithine and an alternative (M2) phenotype.  L-ornithine is a necessary metabolite 
for the production of proline (a critical amino acid for the synthesis of collagen) 
which links arginase activity to fibrosis (Hesse et al., 2001; Misson et al., 2004; Endo 
et al., 2003).  
Alternative macrophage activation and Fibrosis 
 Arginase expression and activity is raised in the blood and airways of patients 
with fibrotic diseases (Grasemann et al., 2005; Grasemann et al., 2006; Mora et al., 
2006) and in animal models of lung fibrosis (Hesse et al., 2001; Endo et al., 2003).  
Studies blocking arginase activity have demonstrated a direct role for the arginase 
biosynthetic pathway in pathological fibrosis (Liu et al., 2005).  IL-4/IL-13 
alternatively activated macrophages are hypothesised to serve as central regulators of 
fibrosis.  A shift to M1 or classical macrophage activation by administration of IL-12 
results in NOS2 expression and a reduction of fibrosis severity (Wynn et al., 1995).  
Co-culture of alternatively activated macrophages with fibroblasts increase the 
proliferation index and collagen synthesis of fibroblasts, suggesting that alternatively 
activated macrophages enhance fibrogenesis (Song et al., 2000).  Recent work has 
demonstrated that selective depletion of macrophages in models of hepatic 
inflammation and progressive glomerulonephritis significantly attenuates fibrosis 
(Duffield et al., 2005b; Duffield et al., 2005a).  However studies on murine silicosis 
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suggest that increased expression of arginase-1 is not a sole determinant for the later 
development of lung fibrosis (Misson et al., 2004).  Furthermore, 
macrophage/neutrophil specific knockout of the IL-4/IL-13 common receptor, IL-
4Rα, does not prevent collagen deposition and hepatic fibrosis in Schistosoma 
mansoni infected mice (Herbert et al., 2004).  Thus, further work is required to 
define the precise biological role of alternative M2 macrophages in chronic 
inflammation and fibrosis and the mechanisms regulating macrophage polarisation in 
these disease states. 
Alternative macrophage activation and Infection 
 Alternatively activated macrophages have been widely implicated in the 
progression of parasitic infections.  It has been shown that the M2 macrophage 
contributes to the susceptibility of cutaneous leishmaniasis (Holscher et al., 2006) 
and that certain parasitic infections result in the generation of alternatively activated 
macrophages.  Infection with the helminth parasite Fasciola hepatica induces a 
polarised Th2 immune response resulting in the alternative activation of 
macrophages (O'Neill et al., 2000; Donnelly et al., 2005).  In these studies, IL-4-/- 
mice, which mounted a Th1 response, demonstrated the lowest level of liver damage.  
Similar results have been shown with other helminth infections including Brugia 
malayi and Schistosoma (Loke et al., 2000; Noel et al., 2004). 
 Some research into the role of alternatively activated macrophages during 
bacterial infections has been carried out in recent years.  The presence of 
alternatively activated macrophages during progressive tuberculosis results in an 
inability to control bacterial replication (Kahnert et al., 2006).  Alternative 
macrophage phenotype has also been observed in Whipple Disease, a rare systemic 
disease caused by the bacterium Tropheryma whipplei (Desnues et al., 2005).  
Alternatively activated macrophages, it has been suggested, contribute to the 
pathophysiological properties of this disease. 
 
1.3.3 Pneumonia 
 Despite improvements in therapy and intensive-care support, mortality due to 
respiratory tract infections is ever increasing, the gram positive bacterium 
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Streptococcal pneumoniae (S. pn) being the major pathogen responsible. S. pn is the 
most common cause of community acquired pneumonia (CAP).  Mortality is high, 
especially in developing countries where pneumococcal pneumonia causes one 
million deaths per year in children under the age of 5 years (Paterson et al., 2005).  
Even with treatment, there is still an overall mortality rate of 23% among 
hospitalised patients (Bergeron et al., 1998; Dallaire et al., 2001).  Along with 
pneumonia, the pneumococcus pathogen is the common bacterial agent in a wide 
range of infections including mucosal infections (sinusitis and otitis media), arthritis, 
pericarditis, peritonitis and the severe invasive infections meningitis and septicaemia 
(Obaro and Adegbola, 2002).  Limitations of conventional therapies and emerging 
drug resistance amongst strains of S. pn to antibiotics, such as penicillin (Feldman, 
2004) and vancomycin (Novak et al., 1999), necessitates the continued study into the 
mechanisms involved in the pathogenesis of pneumococcal disease and the host 
immune defence against pneumococcal invasion. 
 Pneumonia caused by S. pn is a consequence of failure by the host to clear or 
kill pneumococci inhaled into the lung (Gordon et al., 2000).  Colonisation of the 
nasopharynx occurs in up to 40% of the population and aspiration of this small 
innoculum of bacteria is common (Dockrell et al., 2003).  Most cases of 
pneumococcal pneumonia occur when the host is unable to overcome and eliminate 
these small challenges.  Bergeron et al. (Bergeron et al., 1998) identified the essential 
steps that contribute to the pathogenesis of pneumococcal pneumonia beginning with 
partial but ineffective phagocytosis of bacteria by alveolar macrophages and the 
release of various pro-inflammatory cytokines in bronchoalveolar lavage (BAL) fluid 
(TNF and IL-6), lung tissues (IL-1 and IL-6) and serum (IL-6).  Recruitment of 
neutrophils follows with further release of pro-inflammatory cytokines, active 
oxygen metabolites and defensins (Sibille and Reynolds, 1990). While these products 
kill the invading pathogens, they can also severely damage the lung tissue itself 
(Sibille and Reynolds, 1990). Tissue injuries become visible and more leukocytes 
migrate from the blood to the lungs.  Alveolar architecture is destroyed with leakage 
of protein into the vasculature, unrestrained bacterial growth in both the lungs and 
the blood (bacteremia), loss of body weight and high mortality rate. 
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 However, successful clearance of an infection does occur in most individuals 
exposed to this small innoculum.  Alveolar macrophages phagocytose bacteria that 
reach the terminal bronchioles and alveoli (Jonsson et al., 1985; Franke-Ullmann et 
al., 1996), and secrete cytokines and chemokines which recruit leukocytes to the site 
of infection.  The recruited neutrophils also play an essential role in pneumococcal 
killing, and non-resident macrophages contribute to the resolution of inflammation 
by phagocytosing cell debris and apoptotic neutrophils.  Therefore, the mechanisms 
that orchestrate macrophage and neutrophil recruitment/activation are important for 
the clearance of bacteria and resolution of inflammation. 
Phagocytosis 
 Russian embryologist, Ilya Metchnikoff, popularised the idea of phagocytosis 
at the end of the 19th century and hypothesised that phagocytosis could play an 
important role in host defence and tissue homeostasis (Metchnikoff 1905). 
 Distinct cell surface receptors, or “pattern recognition receptors”, on 
phagocytes enable them to recognise and ingest foreign pathogens by recognising the 
particles directly or identifying targets coated with opsonic molecules.  
 Pathogens are recognised by a number of receptors on the alveolar 
macrophage cell surface including Fc receptors (which recognise the Fc component 
of associated immunoglobulin bound to bacteria), complement receptors (which 
recognise complement stabilised on bacterial surfaces), macrophage scavenger 
receptor, platelet-activating factor receptor, and CD14/toll-like receptor (TLR) 
complexes (Gordon et al., 2000). 
 Galectin-3 has been shown to have a critical role in phagocytosis of IgG-
opsonised erythrocytes and apoptotic thymocytes (Sano et al., 2003), however it’s 
role in the phagocytic clearance of microorganisms and apoptotic neutrophils has not 
been elucidated.    
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1.4  General aims and hypotheses 
 The aims of my PhD were to examine the role of galectin-3 in the 
development of fibrosis following chronic inflammation and in the response of 
macrophages and neutrophils to pneumococcal infection.  This was carried out using 
the galectin-3-/- mouse on a 129s/v background.  Comparisons were made using 
strain and age matched control mice.  In vitro experiments were used to further 
examine the role of galectin-3 during these disease states.  In addition, this thesis 




“Upregulation of galectin-3 expression during tissue fibrosis triggers hepatic stellate 
cell (HSC) activation and contributes to the pathogenesis of disease.” 
 
The scientific basis of this hypothesis derives from the following observations.  
Increased galectin-3 expression has been noted in tissue fibrosis (Hsu et al., 1999; 
Wang et al., 2000; Kasper and Hughes, 1996) and in vitro exogenous galectin-3 
stimulates myofibroblast proliferation via the MEK1/2-ERK1/2 signalling pathway 
(Maeda et al., 2003).  The relevance of these observations to the mechanistic role of 
galectin-3 in the pathogenesis of tissue fibrosis in vivo has not been examined. 
  
The chronic carbon tetrachloride (CCl4) model of liver fibrosis and the unilateral 
ureteric obstruction (UUO) model of kidney fibrosis in wild type and galectin-3-/- 
mice was used to test this hypothesis in vivo.  The CCl4 rat model of liver fibrosis 
had previously been established by Professor John Iredale’s group (University of 
Edinburgh) and subsequently applied to mice for this study.  The UUO model of 
kidney fibrosis had been used previously by Dr Jeremy Hughes’ group (University of 
Edinburgh) and was performed by Spike Clay.  This model is a very attractive model 
for studying renal fibrosis as many of the pathophysiological events occur within one 
week post obstruction (Klahr and Morrissey, 2002).  The model of UUO is 
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neutrophil and lymphocyte independent and is characterised by marked 
tubulointerstitial macrophage infiltration together with progressive scarring 
(Diamond et al., 1995; Diamond, 1995). In vivo work was followed by in vitro 




“Presence of galectin-3 and CD98 are necessary for alternative macrophage 
activation”. 
 
The scientific basis of this hypothesis derives from the following observations.  
Galectin-3 is highly expressed and secreted by macrophages and recent data suggests 
that galectin-3 plays a significant role in many facets of macrophage biology.  
Classical activation of macrophages by LPS has been shown to downregulate 
galectin-3 expression (Liu et al., 1995).  Previous work from this laboratory has 
shown that CD98 promotes “integrin-like signalling” and PI3-K activation causing 
elevation of intracellular PI(3,4,5)P3 and PKB activation leading to cellular 
transformation (Rintoul et al., 2002; Henderson et al., 2004).  A number of studies 
suggest that PI3-K activation may be the final common pathway to alternative (M2) 
macrophage activation.  The PI3-K/PKB pathway in macrophages negatively 
regulates NOS2 expression (Diaz-Guerra et al., 1999) and suppresses LPS-induced 
inflammation in endotoxaemic mice (Schabbauer et al., 2004). 
 
The activation status of in vitro differentiated bone marrow derived macrophages 
(BMDMs) and in vivo differentiated peritoneal macrophages from wild type and 
galectin-3-/- mice in response to Th1 or Th2 cytokines was assessed.  Galectin-3 and 
CD98 expression in the THP-1 macrophage-like cell line was manipulated to 






“Galectin-3 reduces the severity of pneumococcal pneumonia by augmenting 
immune cell function”. 
 
The scientific basis of this hypothesis derives from the following observations.  
Following pneumococcal infection of the lungs, galectin-3 accumulates in the 
alveolar space and this correlates with the onset of neutrophil extravasation (Sato et 
al., 2002).  However, although neutrophils are actively recruited into Escherichia 
coli (E. coli) pneumonia infected lungs there is no increase in galectin-3 expression.  
Furthermore galectin-3 is released by alveolar macrophages upon incubation with 
Streptococcal pneumoniae (S. pn) membrane fraction (Sato et al., 2002).  The 
relevance of these observations to the mechanistic role of galectin-3 in the host 
immune response to S. pneumoniae infection has not been examined. 
 
The in vivo models of infection used in this study were chosen due to the presence of 
expertise in the Centre for Inflammation Research (University of Edinburgh) at 
intratracheal (i.t.) administration of substances to mice.  Dr John Simpson’s group 
assisted us in infecting our mice with S. pn and E. coli and helped with the retrievals 
(details are given in Acknowledgements and Materials and Methods).  The S. pn and 
E. coli pneumonia models were chosen due to the findings by Sato et al mentioned 
above.  In vivo work was followed by in vitro experimentation to study the role of 




 Chapter 2  
Materials and Methods 
2.1 Materials 
2.1.1 Antibodies 
 Antibodies were obtained from the following sources: anti-actin, anti-α-
smooth muscle actin (α-SMA) (clone 1A4), anti-α-SMA-fluorescein isothiocyanate 
(FITC) (clone 1A4) and anti-MAP Kinase Activated (diphosphorylated extracellular 
signal-regulated kinase (ERK)-1&2) (clone MAPK-YT) were from Sigma-Aldrich.  
Anti-Protein Kinase B (Akt/PKB) [pS473] phosphospecific antibody (clone 14-6), 
anti-Jun N-terminal kinase (JNK) 1&2 [pTpY183/185] polyclonal phosphospecific 
antibody and anti-Smad-3 [pSpS423/425] polyclonal phosphospecific antibody were 
from Biosource.  Anti-arginase-1 (clone H-52), anti-human CD98 (clone C-20), anti-
mouse CD98 (clone M-20) and anti-pSmad2/3 (Ser433/435) were from Santa Cruz 
Biotechnology.  Anti-mouse CD11b (clone 5C6), anti-mouse F4/80 (clone CI: A3-1), 
anti-mouse F4/80-FITC (clone CI: A3-1) and anti-human CD206 (mannose receptor) 
(clone 15-2) were from Serotec.  Anti-mouse LY-6G and LY-6C-phycoerythrin (PE) 
(GR-1) (clone RB6-8C5), anti-human CD11b-allophycocyanin (APC) (clone 
ICRF44), anti-mouse CD11b-APC (clone M1/70), anti-mouse CD11b-PE (clone 
M1/70), anti-human CD16-FITC (clone 3G8), anti-human CD62L-PE (clone DREG-
56), FITC-mouse immunoglobulin G1 (IgG1) isotype control (clone MOPC-21), 
APC-mouse IgG1 isotype control (clone MOPC-21), PE-mouse IgG1 isotype control 
(clone MOPC-21) and APC-rat IgG2b isotype control (clone A95-1) were from BD 
Pharmingen.   Anti-phospho-Protein Kinase C (PKC) (Pan) (betaII Ser660), anti-
AKT/PKB and anti-phospho-STAT-6 (Tyr641) were from Cell Signaling 
Technology.  Anti-mouse Mac-2 (galectin-3) (clone M3/38) and anti-mouse Mac-2-
FITC (clone M3/38) were from Cedarlane.  Anti-galectin-3 (clone A3A12) was from 
Affinity Bioreagents.  Anti-human galectin-3 (clone 9C4) was from Novocastra.  
Anti-rat galectin-3 was kindly donated by FT Liu (University of California, Davis, 
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USA).  Anti-mouse YM-1 was kindly donated by Professor J Allen (University of 
Edinburgh, UK).  All anti-species specific horseradish peroxidase (HRP)-conjugated 
antibodies were from DakoCytomation.  All anti-species specific Alexa-Fluor-
conjugated antibodies were purchased from Invitrogen. 
 
2.1.2 General chemicals and tissue culture reagents 
 Tissue culture plates and dishes were purchased from Corning Life Sciences.  
15ml and 50ml conical tubes were purchased from BD Biosciences.  Tissue culture 
reagents Dulbecco’s Modified Eagle’s Medium (DMEM), RPMI, Iscove’s Modified 
DMEM (IMDM), Hanks’ Balanced Salt Solution (HBSS), Dulbecco’s Phosphate 
Buffered Saline (PBS), Foetal Bovine Serum (FBS), Foetal Calf Serum (FCS), 
penicillin/streptomycin and L-glutamine (200mM) were purchased from PAA (The 
Cell Culture Company).  DMEM-F12 was purchased from Gibco.   
 Recombinant mouse and human Interleukin (IL)-4 and IL-13, interferon-γ 
(IFNγ), lipopolysaccharide (LPS), recombinant mouse platelet-derived growth 
factor-BB (PDGF-BB) and recombinant transforming growth factor-β (TGF-β) were 
purchased from R&D.  All cytokines were reconstituted as indicated in the 
datasheets, aliquotted to avoid repeated freeze-thaw cycles and stored at -80°C. 
 
2.1.3 Small interfering RNA (siRNA) 
 Four siRNA duplexes against human and mouse galectin-3 and four duplexes 
against human CD98 were purchased from the Dharmacon siGENOME Collection of 
pre-designed siRNA reagents.  siGENOME siRNA reagents are designed using 
Dharmacon’s SMARTselection siRNA design algorithm to reduce off-target effects 
and decrease false positives.  5X siRNA buffer and nuclease-free H2O are provided 
within the package.  Upon receipt the siRNA was reconstituted to a stock 
concentration using the recommended amount of 1X siRNA buffer (diluted from the 
5X siRNA buffer with nuclease-free H2O) according to the quantity of siRNA 





 The double stranded RNA oligomer sequences for mouse galectin-3 were: 
Duplex  Sequence 
Sense 5’-GAUGUUGCCUUCCACUUUAUU-3’ Duplex 1 
Antisense 5’-P.UAAAGUGGAAGGCAACAUCUU-3’ 
Sense 5’-GCAGACAGCUUUUCGCUUAUU-3’ Duplex 2 
Antisense 5’-P.UAAGCGAAAAGCUGUCUGCUU-3’ 
Sense 5’-GGUCAACGAUGCUCACCUAUU-3’ Duplex 3 
Antisense 5’-P.UAGGUGAGCAUCGUUGACCUU-3’ 
Sense 5’-GGACAGGCUCCUCCUAGUGUU-3’ Duplex 4 
Antisense 5’-P.CACUAGGAGGAGCCUGUCCUU-3’ 
P represents phosphate 
 
 The double stranded RNA oligomer sequences for human galectin-3 were: 
Duplex  Sequence 
Sense 5’-GAAGAAAGACAGUCGGUUUUU-3’ Duplex 1 
Antisense 5’-P.AAACCGACUGUCUUUCUUCUU-3’ 
Sense 5’-GCAAUACAAAGCUGGAUAAUU-3’ Duplex 2 
Antisense 5’-P.UUAUCCAGCUUUGUAUUGCUU-3’ 
Sense 5’-GUACAAUCAUCGGGUUAAAUU-3’ Duplex 3 
Antisense 5’-P.UUUAACCCGAUGAUUGUACUU-3’ 
Sense 5’-CAGUACAAUCAUCGGGUUAUU-3’ Duplex 4 
Antisense 5’-P.UAACCCAUGAUUGUACUGUU-3’ 
P represents phosphate 
 
 The double stranded RNA oligomer sequences for duplex 1 human CD98 
were: 
Duplex  Sequence 
Sense 5’-AGAAUGGUCUGGUGAAGAUUU-3’ Duplex 1 
Antisense 5’-P.AUCUUCACCAGACCAUUCUUU-3’ 
P represents phosphate 
Duplexes 2-4 were of unknown sequence. 
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 Control duplex used was siCONTROL Non-targeting siRNA #2 
Duplex  Sequence 
Sense 5’-UAAGGCUAUGAAGAGAUACUU-3’ Control 
duplex #2 Antisense 5’-P.GUAUCUCUUCAUAGCCUUAUU-3’ 
P represents phosphate 
 
2.1.4 Primers 
 Primers were designed using Primer Express (Applied Biosystems) or using 
known/published primer sequences and purchased from MWG-Biotech unless 
otherwise specified. 
  
 The following primers were used in standard polymerase chain reactions 
(PCR) for the baculoviral expression system to verify the presence of the galectin-3 
gene in the recombinant bacmid DNA (underlined sections of the primer sequence 
indicate restriction sites, Ms = mouse, Hu = human ): 
 
 Primer Sequence 
Ms Galectin-3 BamHI (F) 5’-CATGGATCCGATGGCAGACACGTTTTCGCT-3’ 
Ms Galectin-3 EcoRI (R) 5’-GCGGAATTCTTAGATCATGGCGTGGTTAGC-3’ 
M13 (F) 5’-GTTTTCCCAGTCACGAC-3’ 
M13 (R) 5’-CAGGAAACAGCTATGAC-3’ 
Hu Galectin-3 (F) 5’-ATGCGTTATCTGGGTCTGGA-3’ 
Hu Galectin-3 (R) 5’-TATGAAGCACTGGTGAGGTCTATG-3’ 
Ms Galectin-3 (F) 5’-CGCGGATCCATGGCAGACAGCTTTTCGCTT-3’ 
Ms Galectin-3 (R) 5’-GCGGAATTCTTAGATCATGGCGTGGTTAGC-3’ 
(F = Forward, R = Reverse) 
 
 The following primers were used for SYBR Green real-time RT-PCR: 
Gene Primer Sequence 
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Hu β-Actin (F) 5’-CATCACCATTGGCAATGAGC-3’ 
Hu β-Actin (R) 5’-CGATCCACACGGAGTACTTG-3’ 
Hu Mannose Receptor (F) 5’-GCCAAATGACGAATTGTGGA-3’ 
Hu Mannose Receptor (R) 5’-CACGAAGCCATTTGGTAAACG-3’ 
Ms β-Actin (F) 5’-AGAGGGAAATCGTGCGTGAC-3’ 
Ms β-Actin (R) 5’-CAATAGTGATGACCTGGCCGT-3’ 
Ms Mannose Receptor (F) 5’-CATGAGGCTTCTCCTGCTTCT-3’ 
Ms Mannose Receptor (R) 5’-TTGCCGTCTGAACTGAGATGG-3’ 
Ms NOS2 (F) 5’-CAGCTGGGCTGTACAAACCTT-3’ 
Ms NOS2 (R) 5’-CATTGGAAGTGAAGCGTTTCG-3’ 
Ms Arginase-1 (F) 5’-TTGGGTGGATGCTCACACTG-3’ 
Ms Arginase-1 (R) 5’-TTGCCCATGCAGATTCCC-3’ 
Ms YM-1 (F) 5’-TCTCTACTCCTCAGAACCGTCAGA-3’ 
Ms YM-1 (R) 5’-GATGTTTGTCTTTAGGAGGGCTTC-3’ 
Ms FIZZ-1 (F) 5’-TACTTGCAACTGCCTGTGCTTACT-3’ 
Ms FIZZ-1 (R) 5’-TATCAAAGCTGGGTTCTCCACCTC-3’ 
Ms IL4Rα (F) 5’-ACCTGAGAACAGCGGAGGC-3’ 
Ms IL4Rα (R) 5’-TCGGAAAACAGGTTCTCAGTGAG-3’ 
(F = Forward, R = Reverse) 
  
 The following primers and probes, purchased from Applied Biosystems, were 
used for TaqMan real-time RT-PCR reactions: 
Gene Primer/Probe Sequence 
Ms Galectin-3 (F) 5’-TTGAAGCTGACCACTTCAAGGTT-3’ 
Ms Galectin-3 (R) 5’-AGCTTCTTCATCCGATGGTTGT-3’ 
Ms Galectin-3 (P) 5’-6-FAM-CGGTCAACGATGCTCACCTACTGCA-
TAMRA-3’ 
Ms α-SMA (F) 5’-TCAGCGCCTCCAGTTCCT-3’ 
Ms α-SMA (R) 5’-AAAAAAAACCACGAGTAACAAATCAA-3’ 
Ms α-SMA (P) 5’-6-FAM-TCCAAATCATTCCTGCCCA-TAMRA-3’ 
Ms Pro-collagen I (F) 5’-TTCACCTACAGCACGCTTGTG-3’ 
Ms Pro-collagen I (R) 5’-GATGACTGTCTTGCCCCAAGTT-3’ 
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Ms Pro-collagen I (P) 5’-6-FAM-ATGGCTGCACGAGTCACA-TAMRA-3’ 
Ms TGF-β (F) 5’-CACCGGAGAGCCCTGGATA-3’ 
Ms TGF-β (R) 5’-TGTACAGCTGCCGCACACA-3’ 
Ms TGF-β (P) 5’-6-FAM-CAACTATTGCTTCAGCTCCACAGAGAAG 
AACTG-TAMRA-3’ 
(F = Forward, R = Reverse, P = Probe) 
 
2.1.5 Animals 
 Generation of galectin-3 knockout (galectin-3-/-) mice by gene targeting 
technology has been described (358).  As controls, age- and sex-matched wild type 
littermate mice were used.  All procedures were undertaken with approved licence 
from the Animal Scientific Procedure Division of the Home Office. 
 
2.2 Tissue culture 
 HSC (Murine Hepatic Stellate cells), isolated from wild type and galectin-3-/- 
mice, were cultured in DMEM supplemented with 16% heat inactivated FBS, 1% 
penicillin and streptomycin and 1% L-glutamine.  Cells were grown in a humidified 
atmosphere of 95% O2 / 5% CO2 at 37ºC.  A detailed protocol for HSC isolation is 
given later in this chapter. 
 Sf9 (insect cell line, Invitrogen) cells cultured in Sf-900 II serum-free Insect 
Cell Culture Media (Invitrogen, Paisley, UK) plus 1% amphotericin B (Sigma-
Aldrich).  Cells were grown at 27ºC. 
 THP-1 (human monocyte cell line, ATCC) were cultured in suspension in 
RPMI supplemented with 10% heat inactivated FBS, 1% penicillin and streptomycin 
and 1% L-glutamine.  Phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich) 
treatment (100ng/ml) was used to differentiate into macrophage-like cells, resulting 
in adherence to tissue culture plastic.  Cells were grown in a humidified atmosphere 
of 95% O2 / 5% CO2 at 37ºC. 
 L929 (mouse fibroblast cell line) were cultured in DMEM-F12 supplemented 
with 10% heat inactivated FBS, 1% penicillin and streptomycin.  Cells were grown 
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in a humidified atmosphere of 95% O2 / 5% CO2 at 37ºC.  Cells were cultured to 
confluency and culture the media was removed, filtered and frozen at -80°C (this is 
L929 conditioned media). 
 BMDM (bone marrow derived macrophages) were isolated from wild type 
and galectin-3-/- mouse femurs and tibias.  Bone marrow was flushed with 10ml 
complete media (DMEM-F12 (Gibco) supplemented with 10% L929 conditioned 
media as a source of granulocyte-macrophage colony-stimulating factor (GMCSF), 
10% FBS, 1% penicillin and streptomycin) through a 25 gauge syringe needle into 
tubes and the number of bone marrow cells counted using a haemocytometer.  Cells 
were matured in complete DMEM-F12 at 10x106 cells per 10cm plate for 7 days, 
with the addition of a further 10ml media half way through the maturation process.  
Maturation of BMDMs was examined by dual immunofluorescence staining for 
CD11b and F4/80 and analysed by flow cytometry.  Macrophages were incubated 
with a 1:150 dilution of CD11b-PE antibody (clone M1/70) and a 1:25 dilution of 
F4/80-FITC antibody (clone CI:A3-1) for 30 minutes at room temperature in the 
dark.  Samples were washed and a 1:10,000 dilution of the vital dye ToPro-3 
(Invitrogen) was added to each tube just prior to flow cytometry analysis.  Samples 
were analysed using a BD FacsCalibur flow cytometer. 
 Bone marrow derived neutrophils were isolated from wild type and 
galectin-3-/- mouse femurs and tibias.  Bone marrow was flushed out with 10ml 
sterile PBS, through a 25 gauge syringe needle.  Cells were centrifuged at 400xg for 
5 minutes, resuspended in 6ml 0.2% NaCl for 45 seconds and osmolarity was 
immediately restored with the addition of 14ml 1.2% NaCl.  The suspension was 
poured into a 50ml conical tube through a 70µm nylon cell strainer (Falcon), to 
remove clots and any bone remnants, pelletted and resuspended in 5ml PBS.  5ml of 
62% Percoll (GE Healthcare) was layered at the bottom of a 15ml conical tube and 
the 5ml of cell suspension was gently layered on top.  Tubes were centrifuged at 
1000xg for 30 minutes at room temperature with acceleration and brake off.  At the 
end of the gradient-centrifugation there was a sharp interface atop the 62% Percoll 
containing the immature cells and non-granulocyte lineages and a cloudier pellet 
containing the neutrophils.  The cells at the interface were carefully discarded 
leaving 2-3ml of the 62% gradient to avoid disturbing the pellet.  The pellet was 
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transferred to another tube, washed x2, resuspended in 5-10ml of media and cells 
were counted using a haemocytometer.  Cytospins were obtained from each isolation 
and GR-1 and CD11b positivity was assessed by fluorescent-activated cell sorting 
(FACS) analysis using anti-GR-1-PE (clone RB6-8C5) and anti-CD11b-APC (clone 
M1/70) antibodies.  When needed, neutrophils were made apoptotic by culturing in 
suspension in RPMI supplemented with 10% heat inactivated FBS, 1% penicillin and 
streptomycin and 1% L-glutamine at 1x106 cells/ml for up to 96 hours. 
 Peritoneal macrophages were isolated by flushing out wild type and 
galectin-3-/- mouse peritoneal cavities.  Mice were anaesthetised with a lethal dose of 
avertin (Tribromoethanol anaesthetic – 1.25% 2,2,2-tribromoethanol plus 2.5% 2-
methyl-2-butanol (components from Sigma-Aldrich)) or using CO2 exposure and any 
sign of pain response was checked by paw pinching.  The peritoneal cavity was 
flushed out with 2x 5ml volumes of sterile PBS and peritoneal lavages were placed 
on ice.  Lavages were centrifuged, resuspended in DMEM containing 1% penicillin 
and streptomycin and adhered in 6-well plates at the required density. 
 Alveolar macrophages were isolated by flushing out wild type and 
galectin-3-/- mouse lungs with 3x 1ml sterile PBS.  Mice were anaesthetised with a 
lethal dose of avertin or using CO2 exposure and the lungs and trachea were exposed 
(with great care not to pierce any bit of the lungs).  Elastic string was placed under 
the trachea and a small incision was made at the top of the trachea.  A prepared 
plastic tube was inserted into the trachea and tied off using the elastic string.  A 1ml 
syringe was prepared with 1ml of sterile PBS and inserted into the top of the tubing.  
The lungs were flushed with 3x 1ml of PBS (ensuring that both sides of the lungs 
inflate) and each lavage was recovered by drawing the liquid back into the syringe.  
Lavage was placed into a sterile 1.5ml eppendorf tube on ice.  Lavages were 
centrifuged, resuspended in DMEM containing 1% penicillin and streptomycin and 
adhered in 6-well plates at the required density. 
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2.3 Sodium dodececyl-sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) and Western Blotting 
2.3.1 Cell Lysis 
 Cells were washed once with PBS and lysed at 4°C in an appropriate volume 
of lysis buffer.  Lysates were shaken for 20 minutes at 4°C and cleared by 
centrifugation at 13krpm for 10 minutes at 4°C, assessed for protein concentration 
using the BCA protein assay reagent (Pierce Biotechnology), and solubilised in 4x 
SDS-PAGE sample buffer at 95°C for 5 minutes.  Samples were analysed 
immediately or stored at -20°C for future analysis. 
 
2.3.2 SDS-PAGE and Western Blotting 
 Buffers used are detailed in section 2.3.3.  Samples were cooled or thawed 
from frozen and resolved on either 12% or 10% SDS-PAGE gel, under reducing and 
non-reducing conditions depending on the experiment, using a vertical 
electrophoresis tank Biorad Mini Protean II system.  Samples were electrophoresed 
at 100–150 volts using electrophoresis buffer for 1–2 hours, adjacent to pre-stained 
molecular weight markers (Invitrogen).  Proteins were transferred onto Hybond C 
nitrocellulose membranes (Amersham Pharmacia Biotech) in a methanol-based 
transfer buffer at 100 volts for 60 minutes, in a Mini Protean II blotting tank.  Equal 
protein loading was confirmed by staining with 1% Ponceau S (AMS Biotechnology) 
for 5 minutes to visualise protein bands.  Non-specific binding sites were blocked by 
incubation with Tris-buffered saline (TBS)-Tween 20 (0.1%) containing 5% non-fat 
dried milk powder for 1 hour at room temperature.  Membranes were probed with 
appropriate antibodies diluted in TBS-Tween 20 containing 5% non-fat dried milk 
powder overnight at 4ºC.  Membranes were then washed in TBS-Tween 20 (3x 10 
minutes washes), before exposure to appropriate species-specific HRP-conjugated 
secondary antibodies (1:1000) for 1 hour at room temperature, diluted in TBS-Tween 
20 containing 5% non-fat dried milk powder.  Membranes were then washed further 
in TBS-Tween 20 (3x 10 minute washes), immunoreactive bands identified using 
enchanced chemiluminescence (ECL) (Amersham Pharmacia Biotech) according to 
the manufacturer’s instructions and developed in a Konica SRX-101A film 
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processor.  Kodak MXB film (blue sensitive) was supplied by G.R.I 
Autoradiography (Genetic Research).  For assessment of phosphorylated proteins, 
blocking and subsequent incubation steps were carried out using 3% bovine serum 




25mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)  pH 7.4, 0.3M 
NaCl, 1.5mM MgCl2, 0.2mM ethylenediaminetetraacetic acid (EDTA), 0.5% Triton 
X-100 (v/v), 1mM sodium orthovanadate, 0.5mM dithiothreitol (DTT).  One 
CompleteTM protease inhibitor tablet (Roche) was added per 50ml of lysis buffer.  
Non-reducing buffer contains no DTT. 
4x SDS-PAGE sample buffer: 
50mM Tris-HCl, 10% glycerol (v/v), 2% SDS (v/v), 0.1% bromophenol blue (v/v), 
10% β-mercaptoethanol (v/v), pH 6.8.  Non-reducing buffer contains no β-
mercaptoethanol. 
SDS-polyacrylamide gels: 
Separating Gel:  
0.375M Tris base (pH 8.8), 0.1% SDS (v/v), 10-12% acrylamide (v/v), 0.1% 
ammonium persulphate (v/v), 0.02% Tetramethylethylenediamine (TEMED) (v/v). 
Stacking Gel:  
0.13M Tris base (pH 6.8), 0.1% SDS (v/v), 4.5% acrylamide (v/v), 0.1% ammonium 
persulphate (v/v), 0.02% TEMED (v/v). 
1x Gel electrophoresis running buffer: 
50mM Tris base, 250mM glycine, 0.1% SDS (v/v). 
Transfer buffer: 
210mM glycine, 24.7mM Tris base, 20% methanol (v/v) (Fisher Scientific) 
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TBS-Tween 20 wash buffer: 
150mM NaCl, 20mM Tris HCl (pH 7.4), 0.1% Tween 20 (v/v) 
 
Primary antibody Dilution Secondary Antibody Dilution 
Actin 1:5000 Anti-Rabbit HRP 1:1000 
Galectin-3 (A3A12) 1:2000 Anti-Mouse HRP 1:1000 
α-SMA (1A4) 1:15,000 Anti-Mouse HRP 1:1000 
pSmad-2/3 1:1000 Anti-Goat HRP 1:1000 
pSmad-3 1:1000 Anti-Rabbit HRP 1:1000 
pPKC 1:1000 Anti-Rabbit HRP 1:1000 
pERK 1-2 (MAPK-YT) 1:1000 Anti-Mouse HRP 1:1000 
pAKT/PKB (14-6) 1:500 Anti-Rabbit HRP 1:1000 
pJNK 1-2  1:500 Anti-Rabbit HRP 1:1000 
YM-1 1:1000 Anti-Rabbit HRP 1:1000 
Human CD98 1:1000 Anti-Goat HRP 1:1000 
Human Mannose R (15-2) 1:1000 Anti-Mouse HRP 1:1000 
pSTAT-6 1:500 Anti-Rabbit HRP 1:1000 
PKB 1:1000 Anti-Rabbit HRP 1:1000 
Arginase-1 1:500 Anti-Rabbit HRP 1:1000 
Mouse CD98 1:1000 Anti-Goat HRP 1:1000 
Table 2.1 – Immunoblotting antibody dilutions. 
 
2.4 Protein Purification 
2.4.1 Bacterial expression system 
 Escherichia coli (E. coli) BL-21 star (DE3) bacteria (Stratagene) transformed 
with pcDNA 3.1 vector containing a histidine (His)-tagged human galectin-3 insert, 
was used to extract His-tagged human galectin-3 protein. 
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Figure 2.1 – Map of pcDNA 3.1.
Figure 2.1
His-tagged galectin-3 was cloned into a pcDNA 3.1 vector between BamH I and 
EcoR I restriction sites by a previous member of this laboratory.  This 
recombinant vector was then used to transform BL-21 star bacteria.
Galectin-3
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 Transformation of BL-21 star bacteria was performed as follows.  0.5µg of 
pcDNA 3.1 vector, with a His-tagged galectin-3 insert (cloned by a previous member 
of this laboratory) (figure 2.1) was added to 100µl of bacteria, mixed gently and 
placed on ice for 30 minutes.  Bacteria were heat shocked for 50 seconds at 42°C and 
immediately transferred to ice for 2 minutes.  900µl of S.O.C (S.O.C is Super 
Optimal Broth (S.O.B) with glucose; 2% tryptone, 0.5% yeast extract, 8.6mM NaCl, 
2.5mM KCl, 20mM MgSO4 and 20mM glucose) was added and tubes were 
incubated for 45 minutes at 37°C shaking at 700rpm.  Bacteria were pelletted for 5 
minutes at 5krpm and resuspended in 200µl S.O.C.  Neat, 1:10, 1:50 and 1:100 
dilutions were plated onto Luria-Bertani (LB) (Sigma-Aldrich) agar plates containing 
50µg/ml ampicillin (Sigma-Aldrich).  A negative control plate was prepared by 
plating out untransformed BL-21 bacteria onto LB agar plates containing 50µg/ml 
ampicillin.  The next day colonies were selected and inoculated into 10ml of LB 
broth (made up using 1 LB broth base tablet (Sigma-Aldrich) per 50ml distilled H2O) 
containing 50µg/ml ampicillin and allowed to grow overnight.  The following day, 
2.5ml of the culture was inoculated into 500ml flasks in LB broth containing 
50µg/ml ampicillin.  Bacteria were allowed to grow to an optical density (OD)600 of 
0.7 to 0.8, induced with 1mM isopropyl β-D-thiogalactoside (IPTG) (Sigma-Aldrich) 
and then grown overnight at 37°C with shaking.  Cultures were centrifuged at 
8,000rpm in a Beckman J2-MC ultracentrifuge for 20 minutes.  Pellets were 
resuspended in 5ml of BugBuster Protein Extraction Reagent (Novagen) per gram of 
wet cell paste followed by the addition of 1µl/ml Benzonase (Novagen).  This was 
separated into 50ml conical tubes, placed on a rotary shaker for 20 minutes and 
centrifuged at 11,500rpm in a Heraus Multifuge 3 S-R for 20 minutes.  Galectin-3 
was purified from the cleared lysate using Ni-NTA His·Bind® Resin.  1ml of Ni-
NTA His·Bind® Resin (Novagen), per purification, was washed with 4ml 1X Ni-
NTA Bind Buffer (300mM NaCl, 50mM sodium phosphate buffer, 10mM imidazole, 
pH 8.0), the beads were allowed to settle by gravity or centrifuged at 1000rpm for 5 
minutes, and the top bind buffer layer was removed. 4ml of cleared lysate was loaded 
onto the prepared Ni-NTA His·Bind slurry and mixed gently by shaking at 4°C for at 
least 60 minutes.  This was then loaded onto a disposable polypropylene column (1-
5ml bed volume) (Pierce Biotechnology), flow through collected (aliquot taken for 
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SDS-PAGE analysis) and 3 washes were carried out using Ni-NTA Wash Buffer 
(300mM NaCl, 50mM sodium phosphate buffer, 20mM imidazole, pH 8.0), (aliquots 
of washes taken for SDS-PAGE analysis).  4x 500µl elutions were performed with 
Ni-NTA Elution Buffer (300mM NaCl, 250mM imidazole, 50mM sodium phosphate 
buffer, pH 8.0) and elutions were collected in 4x 1.5ml eppendorf tubes.  Fractions 
were analysed using SDS-PAGE and elutions dialysed against 1L cold 1X PBS 
overnight (dialysis tubing size – 14.3mm, molecular weight cut off 12-14KDa).  
Protein determination using Pierce BCA protein assay reagent was performed and 
Western blots used to verify the presence of galectin-3. 
 
2.4.2 Baculovirus Expression System 
 The Invitrogen Baculovirus Expression System was used to produce 
recombinant baculovirus containing the gene of interest, in this case human and 
mouse galectin-3.  Detailed protocols are given in the Bac-to-Bac Baculovirus 
Expression System manual (Invitrogen) and in Chapter 3.  Briefly, galectin-3 DNA 
was cloned into a pFastBac donor plasmid (Invitrogen) which comprises a 
baculoviral specific promoter.  The pFastBac construct was then transformed into the 
E.coli host strain DH10Bac (Invitrogen) which contains a baculovirus shuttle vector 
(bacmid) and a helper plasmid.  Recombinant bacmid was produced upon 
transposition of the pFastBac construct which was purified using the S.N.A.P midi-
prep kit (Invitrogen).  Bacmid was transfected into Sf9 insect cells and amplified 
using the method given in the manual.  When sufficient amount of virus was 
produced, 3x T162cm2 flasks containing 3x107 Sf9 cells in 30ml growth media were 
infected and protein purified using the Ni-NTA His bind® resin as detailed above. 
 
2.5 Immunohistochemistry (IHC) 
 10% Formalin (Sigma-Aldrich) fixed liver or kidney or methyl carnoys (60% 
methanol, 30% chloroform, 10% glacial acetic acid)-fixed kidney was paraffin 
embedded by the histology department at the University of Edinburgh who also 
prepared 3µm thick sections of tissue onto superfrost slides (Fisher Scientific) using 
a microtome.  10µm sections were prepared for PSR staining.  Archival human liver 
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samples were obtained from the University of Edinburgh Department of Pathology 
files.  Rat liver sections were obtained from Professor John Iredale (University of 
Edinburgh).  Samples had been fixed in formalin and embedded in paraffin wax. 
 Sections were dewaxed in xylene (Fisher Scientific) and rehydrated through 
graded ethanol solution from 100% to 50% ethanol.  Antigen retrieval was performed 
by microwaving the formalin-fixed tissue sections for 15 minutes at full power in 
antigen unmasking solution which is based on a citric acid formula (Vector).  F4/80 
IHC did not have an antigen retrieval step.  Endogenous peroxidase was blocked by 
incubating the sections in 3% hydrogen peroxide (H2O2) (VWR (BDH)) for 15 
minutes. After non-specific binding was blocked using the avidin/biotin blocking kit 
(Vector) and either Dako protein block or blocking serum from the Vector Quick Kit, 
the sections were incubated with the relevant antibody either overnight at 4°C or at 
room temperature for the required amount of time depending on the antibody used.   
 Antibodies used on formalin-fixed tissue included 1:200 anti-mouse Mac-2-
FITC monoclonal antibody (anti-mouse galectin-3) (clone M3/38), 1:100 anti-human 
galectin-3 (clone 9C4), 1:100 anti-rat galectin-3 and 1:15,000 anti-α-SMA-FITC 
(clone 1A4).  1:250 anti-mouse F4/80 (clone CI: A3-1) was used on methyl carnoys-
fixed tissue sections and did not get antigen retrieval.  After incubation with FITC-
labelled primary antibodies against mouse galectin-3 or α-SMA, sections were 
washed x2 with TBS and incubated with rabbit anti-FITC secondary antibody 
(1:4000) for 30 minutes at room temperature.  Sections were washed x2 with TBS 
then incubated with biotin-conjugated anti-rabbit antibody (1:200) for 30 minutes at 
room temperature, washed x2 with TBS, then incubated with an avidin:biotinylated 
enzyme complex (ABC) (Vector) for a further 30 minutes at room temperature.  The 
DakoCytomation EnVision+ System-HRP was used for human galectin-3 IHC, the 
Vector Quick Kit was used for mouse F4/80 IHC and biotinylated goat anti-rabbit 
secondary antibody (1:300) followed by the avidin:biotinylated enzyme complex was 
used for anti-rat galectin-3 IHC.  Diaminobenzidine (DAB) (DakoCytomation) 
solution was subsequently added for 5 minutes.  Sections were counterstained for 5 
minutes with haematoxylin (ThermoShandon) and 5 minutes with Scott’s tap water 
(83mM MgSO4, 7.1mM NaHCO3 in tap water), dehydrated in graded ethanol from 
50% to 100% and cleared in xylene.  Slides were mounted using Pertex mounting 
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solution (CellPath Hemel Hempstead, UK).  In each experiment, negative controls of 
secondary antibody only and relevant isotype controls (DakoCytomation) were 
performed. 
 Collagen fibres were stained with picrosirius red (PSR) as follows.  Sections 
were dewaxed and rehydrated as above and washed x2 in running tap water for 5 
minutes.  Slides were placed in PSR solution – 1  part 1% Sirius Red (1g Sirius Red, 
1g Fast Green, 100ml distilled H2O (dH2O)) with 9 parts saturated aqueous picric 
acid) – for 2 hours, washed in running tap water for 1 minute, dehydrated, cleared 
and mounted as above. 
 Haematoxylin and eosin (H&E) stain was performed as follows.  Sections 
were dewaxed and rehydrated as above and washed x2 in running tap water for 5 
minutes.  Tissue sections were incubated in haematoxylin for 5 minutes followed by 
1% acid alcohol solution (70% industrial methylated spirits, 1% HCl) for 5 minutes.  
Sections are incubated in Scott’s tap water for 1 minute and then Eosin for 1 minute.  
Sections were washed in running tap water for 1 minute, dehydrated, cleared and 
mounted as above. 
 Images were acquired using a Leica DM LB light microscope, Leica DC 300 
digital camera and Leica IM50 software. 
 
2.6 Quantitation of IHC using Openlab 
 Images of PSR and α-SMA staining in liver and kidney sections were 
quantified using the Openlab software.  Set-up of this protocol was carried out with 
the help of Dr Gareth Clegg (University of Edinburgh) who has substantial 
experience with the Openlab software.  This method uses the software’s density 
slicing module to locate objects by their colour or their intensity.  The resulting 
binary layer can be measured using Openlab’s measurement modules. 
 Morphometric measurements were made on 10 random fields from 10µm or 
3µm sections stained with PSR or α-SMA respectively using Openlab software 
(Improvision, UK).  Ten random fields from each tissue section from each mouse 
were analysed.  Each captured field was analysed by separation into red, green and 
blue (RGB) filters.  The area of staining was selected by altering the values of the 
red, green and blue channels in the density slicing module until all areas of positive 
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staining were highlighted.  The same values were used for each image.  Openlab then 
creates a binary layer highlighting all the areas of positive staining.  The 
measurement module of the software was used to measure the area highlighted by the 
density slice module.  The area of positive staining was mathematically divided by 
the RGB area and multiplied by 100%.  This represents the percentage area staining 
positively for collagen or α-SMA, providing a quantitative value on a continuous 
scale.  
 
2.7 HSC Isolation 
 Wild type and galectin-3-/- mouse HSC were extracted from mouse liver by in 
situ perfusion with pronase (Roche) and collagenase B (Roche) followed by density 
gradient centrifugation using Optiprep (Axis Shield).  Due to the nature of this 
protocol and the requirement for two people to perform this procedure, I performed 
the HSC isolations with the help of either Dr Neil Henderson or Dr Alison 
Mackinnon. 
 Enzymes were prepared, under sterile conditions, to the following dilutions in 
HBSS(+) containing calcium (Ca2+) and magnesium (Mg2+), fully dissolved and 
sterile filtered (the following volumes are for a maximum of 8 mice); 30ml of 
2mg/ml collagenase B, 30ml of 12mg/ml pronase, 80ml of 1mg/ml DNase I (Roche).  
12ml of enyme mix was prepared by mixing 6ml of filtered collagenase solution with 
6ml of filtered pronase solution.   
 Liver perfusions were carried out using autoclaved instruments soaked in 
ethanol before use and each mouse was sprayed with ethanol before surgery to avoid 
bacterial contamination.  Mice were anaesthetised with a lethal dose of avertin, the 
peritoneal cavity was opened and the portal vein cannulated with a 30 gauge needle 
(on a syringe containing 1ml enzyme mix), the Inferior Vena Cava was pierced with 
a needle and, immediately but slowly, the liver was flushed with the enzyme mix 
causing it to blanch.  The liver was removed and placed into a sterile tube containing 
a small volume of HBSS, enough to cover the livers. 
 Once back in the tissue culture laboratory, the rest of the protocol was carried 
out under sterile conditions using a sterile laminar flow cabinet.  The four livers in 
HBSS(+) were divided into 3x 25ml universals for each group (3 for wild type and 3 
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for galectin-3-/-).  The rest of the collagenase and pronase solution were combined 
and made up to 48ml with HBSS(+) and 8ml of this mix was added to each 
universal.  Livers were chopped up using autoclaved and ethanol sterilised scissors, 
the universals were sealed, wrapped in parafilm and shaken at 37°C for 20 minutes at 
290rpm.  5ml of filtered DNase solution was added to each digest, mixed by 
pipetting and the extracts from the four livers were combined by pouring through 
autoclaved 125U nybolt mesh (John Staniar and co.) carefully taped onto plastic 
sterilin pots (1 for wild type and 1 for galectin-3-/-).  The digest was carefully grinded 
through the filter using the end of a sterile 10ml stripette and HBSS(+) was used to 
wash as much of the pulp as possible through the filter, keeping the total volume 
collected in the sterilin <100ml.  The resulting digest was split into 50ml conical 
tubes (2 for wild type and 2 for galectin-3-/-) and centrifuged at room temperature for 
7 minutes at 400xg.  Supernatants were removed, without disturbing the pellet, and 
each pellet resuspended in 3ml filtered DNase solution, made up to 30ml with 
HBSS(+) and centrifuged at room temperature for a further 7 minutes at 400xg.  As 
much of the supernatant as possible was poured off, without disturbing the pellet, and 
each pellet was resuspended in 3ml DNase.  Volumes were measured using a 10ml 
stripette and made up to 8.9ml total volume with HBSS(+).  5.9ml neat Optiprep was 
added to each cell suspension and mixed.  In a 50ml conical tube, 21.6ml neat 
Optiprep was mixed with 14.4ml HBSS(+) and divided into 8x 15ml conical tubes, 
4ml per tube (this is the bottom layer of the gradient).  7.4ml of each cell 
suspension/Optiprep mix was very carefully and slowly layered on top of the 
gradient of each of the 15 ml conical tubes (4 for wild type and 4 for galectin-3-/-).  
500µl of HBSS(+) was layered on top and centrifuged at 4°C for 20 minutes at 
1400xg ensuring that the acceleration and brake is off.  After gradient centrifugation 
the top HSC layers were transferred to a 50ml conical tube, using a sterile Pasteur 
pipette, containing 3ml DNase, combining wild type together and galectin-/- together.  
30ml HBSS(+) was added to each tube and centrifuged at room temperature for 7 
minutes at 400xg.  The supernatants were carefully discarded, each pellet 
resuspended in 10ml complete DMEM and counted.  Extracted HSC were cultured 
on plastic until they were activated to a myofibroblast phenotype after 7-10 days and 
used for experiments after activation in primary culture or before the fourth passage.  
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Cells were cultured in DMEM supplemented with 16% heat inactivated FBS, 1% 
penicillin and streptomycin and 1% L-glutamine. 
 
2.8 Immunofluorescence (IMF) 
 Cells were seeded onto coverslips (Fisher Scientific) or into Lab-Tek 
chamber slides (Nunc) at the required density and treated as necessary (see Results 
Chapters for details).  Galectin-3 and α-SMA IMF was performed on HSCs and YM-
1 IMF was performed on alveolar macrophages.  Cells were fixed with 3% 
paraformaldehyde (PFA) and permeabilised with 0.05% Triton for galectin-3 and 
YM-1 IMF or both 0.1% and 0.05% Triton for α-SMA IMF.  Non-specific binding 
was blocked with fish skin gelatin (FSG) for 1 hour at room temperature.  Primary 
antibodies were added at the following dilutions in FSG; 1:20 for galectin-3 (clone 
A3A12), 1:100 for α-SMA (clone 1A4) and 1:1000 for YM-1 for 1 hour at room 
temperature or overnight at 4ºC.  Cells were washed with 3x 5 min PBS washes.  
Alexa-fluor-conjugated secondary antibodies were added at 1:1000 for 1 hour at 
room temperature followed by 3x 0.05% Triton washes and 1x PBS wash.  To stain 
the nuclei 0.1µg/ml 4',6-diamidino-2-phenylindole (DAPI) was added in the third 
triton wash.  Slides were immediately mounted in Mowiol 4-88 (Calbiochem) 
analysed using a Zeiss Axiovert S100 microscope and subsequently processed using 
Openlab software and Adobe Photoshop.  Mowiol was prepared by mixing 2.4g 
Mowiol 4-88 and 6g glycerol in 6ml water for several hours at room temperature.  
12ml of 0.2M Tris (pH 8.5) was added and heated at 50°C for 10 minutes.  After the 
Mowiol dissolved, the solution was clarified by centrifugation at 5000xg for 15 
minutes. 
 
2.9 siRNA transfections 
 HSCs were transfected with mouse galectin-3 siRNA and THP-1 cells were 
transfected with human galectin-3 or CD98 siRNA.  HSCs were seeded at 2x105 
cells/well in 6-well plates and transfected with siRNA after 7 days in culture (final 
concentration 125-250nM) using Oligofectamine Reagent (Invitrogen) according to 
manufacturer’s instructions. 
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 Oligonucleotide-Oligofectamine complexes were prepared as follows 
(volumes given represent one reaction for one well of a 6-well plate).  One tube was 
prepared containing the required concentration of siRNA plus 175µl serum-free 
media.  A second tube was prepared containing 4µl of Oligofectamine plus 15µl 
serum-free media.  After a 5-10 minute incubation of Oligofectamine with the media, 
the diluted siRNA and the diluted Oligofectamine were combined (total volume 
~200µl), mixed gently and incubated for 20 minutes at room temperature.  This 
allows the siRNA-Oligofectamine complexes to form.  While the complexes were 
forming, the growth media was removed from the cells, washed once with serum-
free medium and 800µl of serum-free medium was added to the well.  The 200µl of 
siRNA-Oligofectamine complex was gently mixed and added to the 800µl medium 
in the well.  The cells were incubated at 37°C in a CO2 incubator for 4 hours.  After 4 
hours the transfection mixture was removed and replaced with complete growth 
media.  HSCs were lysed after 96 hours or incubated with relevant treatments (see 
Results Chapters for details). 
 THP-1 cells were differentiated with 100ng/ml PMA for 24 hours, washed 
and transfected with 100nM galectin-3 siRNA duplexes or 120nM CD98 siRNA 
duplexes using Oligofectamine as described above.  Cells were incubated for 48 
hours in complete media prior to the addition of cytokines.  siRNA was purchased 
from Dharmacon Research (sequences given above).  Control duplex was 
siCONTROL nontargetting siRNA no. 2. 
 
2.10 Real-Time RT-PCR 
2.10.1 RNA extractions 
 RNA was prepared from cell lines and whole livers and kidneys using 
QIAshredder columns and the RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions.  RNA concentrations were determined using a WPA UV 
1101 Biotech photometer and RNA was stored at -80°C until further use. 
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2.10.2 RNA extraction from whole liver and kidney 
 Livers or kidneys were removed from mice, a piece of liver or one quarter of 
each kidney was snap frozen in liquid nitrogen and stored at -80°C until further use.  
5mm stainless steel, autoclaved beads (Qiagen) were placed into sterile 2ml lock 
eppendorf tubes, one bead per tube, under sterile conditions and remained sterile 
until further use. 
 Under sterile conditions, 600µl RLT buffer with 6µl β-mercaptoethanol (β-
Me) was added to each 2ml tube plus bead.  Livers or kidneys were transferred to dry 
ice and, under sterile conditions and using a separate sterile scalpel per piece of 
tissue, a small segment (less than 30mg) was removed and immediately placed into 
the sterile 2ml tube plus bead containing RLT/β-Me mix.  The remaining tissue was 
returned to the -80°C freezer as quickly as possible.  The tissue was homogenised by 
shaking the tubes in a TissueLyser (Qiagen) at 20Hz for 1-2 minutes (x2).  RNA was 
extracted by pipetting the resulting lysate into QIAshredder columns and purified 
using the RNeasy Mini Kit according to the manufacturer’s instructions. 
 
2.10.3 DNase treatment of RNA 
 In autoclaved 1.5ml eppendorf tubes, 2µl RQ1 RNase-Free DNase (Promega) 
and 2µl 10x reaction buffer (Promega) was added to 2µg RNA, made up to a final 
volume of 20µl with nuclease-free H2O (NFH2O) and incubated for 30 minutes at 
37°C.  Immediately, 2µl RQ1 DNase stop solution (Promega) was added to each tube 
for 10 minutes at 65°C to terminate the reaction.  ‘Clean’ RNA was stored at -80°C 
until further use. 
 
2.10.4 PCR to check for DNA contamination 
 After DNase treatment, clean RNA was checked for DNA contamination by 
PCR using β-actin primers (see Materials).  Appropriate positive (species matched 
complementary DNA (cDNA) in place of RNA) and negative (NFH2O in place of 




Reaction mix:   Amplification conditions: 
10x Taq Buffer (+MgCl2) (Promega) 2µl     
dNTP (Applied Biosystems) 0.4µl  94°C 2 min  
Taq DNA polymerase B (Promega) 0.2µl  94°C 30 sec  
Forward Primer 0.8µl  56°C 30 sec 40x 
Reverse Primer 0.8µl  72°C 30 sec  
NFH2O 13.8µl     
RNA 2µl     
Total volume 20µl     
 
 The PCR reaction was carried out in a PTC-100 programmable thermal 
controller (MJ Research Inc).  10µl of each PCR reaction was resolved on 2% 
agarose gels (Seakem) made with 1x TAE (Tris-Acetate-EDTA; 40mM Tris Base, 
0.1% Acetic Acid, 0.2% EDTA, pH 8) containing 0.3µg/ml ethidium bromide (VWR 
(BDH)) to enable UV visualisation.  100bp and 1kb DNA ladder were purchased 
from Promega.  Bands were visualised with a White/Ultraviolet TMV-20 
Transilluminator (UVP Ultraviolet Products) and pictures taken using UVP Grab-IT 
version 2.5 (UVP Ultraviolet Products). 
 
2.10.5 Real-Time Reverse Transcription-PCR (Real-Time RT-PCR) 
 DNase-treated RNA extracted from cell lines or whole kidney was reversed 
transcribed into cDNA using TaqMan® reverse transcription reagents (Applied 
Biosystems).  The following volumes represent one reverse transcription (RT) 
reaction: 
 
Reaction mix:   Conditions: 
10x TaqMan RT Buffer 4µl     
25µM MgCl2 8.8µl  25°C 10 min  
dNTP 8µl  48°C 40 min  
Random Hexamers 2µl  95°C 5 min  
RNase Inhibitor 0.8µl  4°C hold  
Multiscribe reverse transcriptase 1µl     
RNA 15.4µl     
Total volume 40µl     
 
 The RT reaction was carried out in a PTC-100 programmable thermal 
controller (MJ Research Inc).  Following the reaction, 40µl of NFH2O was added to 
each PCR tube and cDNA was stored at -20°C. 
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SYBR Green Real-Time PCR 
 Every experiment was carried out under sterile conditions using filter tips 
(Rainin) and sterile NFH2O.  Primers were reconstituted at a working stock 
concentration of 100µM and stored at -20°C.  Primer mixes containing 4.5µM of 
forward primer and 4.5µM of reverse primer in NFH2O were prepared.  The 
appropriate volume of master mix was prepared making the final concentration of 
each primer 0.3µM.  The following volumes represent one PCR reaction: 
 
1x Reaction mix: 
SYBR Green (Applied Biosystems) 12.5µl 




 A β-actin real-time PCR reaction was prepared for every cDNA sample for 
each experiment performed.  Each reaction was prepared in separate tubes, in 
duplicate, containing 2.5µl cDNA or NFH2O per reaction, and transferred to a Micro 
Amp Optical 96-well reaction plate (Applied Biosystems), 25µl per well.  Plates 
were sealed with an optical adhesive cover (Applied Biosystems) using the applicator 
provided and a compression pad was placed on the plate before inserting into the 
machine.  The PCR was carried out using the 7900HT Sequence Detection System 
from Applied Biosystems and samples were analysed using SDS 2.1 software. 
 
Taq Man Real-Time PCR 
 Every experiment was carried out under sterile conditions using filter tips and 
sterile NFH2O.  Primers and probes for TaqMan Real-Time PCR were purchased 
from Applied Biosystems.  Primers were reconstituted at a working stock solution of 
50µM and probes at a concentration of 10µM and stored at -20°C.  5X primer/probe 
mixes containing 4.5µM of forward primer, 4.5µM of reverse primer and 1.25µM 
probe in NFH2O were prepared.  18S rRNA Taqman primer probe mix was purchased 
from Applied Biosystems.  The appropriate volume of master mix was prepared 
making the final concentration of each primer 0.9µM and the final concentration of 
the probe at 0.25µM.  The following volumes represent one PCR reaction: 
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1x Reaction mix 
TaqMan Mastermix (Applied Biosystems) 12.5µl 
5X primer/probe mix 5µl 




 Each reaction was prepared in separate tubes, in duplicate, containing 2.5µl 
cDNA or NFH2O per reaction, and transferred to a Micro Amp Optical 96-well 
reaction plate, 25µl per well.  The PCR was carried out using the 7900HT Sequence 
Detection System from Applied Biosystems and samples were analysed using SDS 
2.1 software. 
 
2.11 MTT Assay 
 The MTT assay measures cellular proliferation.  Yellow MTT (3-(4,5-
dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide) is reduced to purple 
formazan in the mitochondria of living cells.  Dimethyl sulfoxide (DMSO) is added 
to dissolve the insoluble purple formazan product into a coloured solution, the 
absorbance of which can be measured at λ560nm on a spectrophotometer.  Primary 
mouse wild type and galectin-3-/- HSCs were seeded at a density of 5,000 cells per 
well in a 96-well plate in complete media.  Some galectin-3-/- HSCs were incubated 
with 30µg/ml galectin-3 over the time course.  At 1, 2, 3, 6, 7 and 8 days a 1:10 
dilution of 4mg/ml MTT (Sigma-Aldrich) solution in PBS was added to the media 
(0.4mg/ml final concentration) after 4 hours, the media was removed and DMSO was 
added to solubilise the formazan.  The purple solution was transferred to a 96-well 
plate and absorbance at λ560nm was determined.  The largest value was set to 100% 
growth and percentage growth was calculated. 
 
2.12 Cytokine Assays 
 TNF-α and IL-6 cytokine release from BMDMs were measured using the 
Mouse Inflammation Cytometric Bead Array (CBA) kit (BD Biosciences) according 
to manufacturer’s instructions.  Along with IL-6 and TNF-α this kit can also be used 
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to quantitatively measure IL-10, Monocyte Chemoattractant Protein-1 (MCP-1), 
IFN-γ and IL-12p70 protein levels in a single sample.  This study focused on TNF-α 
and IL-6 as the other cytokine concentrations were very low or undetectable.  The kit 
contains six bead populations with distinct fluorescence intensities coated with 
capture antibodies specific for the above analytes.  The six bead populations are 
mixed together to form the CBA which is resolved in the FL3 channel of a flow 
cytometer.  The capture beads, PE-conjugated detection antibodies and recombinant 
standards or test samples are incubated together to form sandwich complexes.  This 
study used a 96-well format of this assay which could be analysed using a BD FACS 
Array and FACS Array software. 
 A TGF-β Quantikine Enzyme-linked Immuno Sorbent Assay (ELISA) kit 
(R&D) was used to detect TGF-β concentrations in supernatants recovered from day 
4 wild type and galectin-3-/- HSCs cultured for 24 hours in serum free media 
according to manufacturer’s instructions.  Briefly, standards, controls and samples 
are pipetted into a plate pre-coated with a monoclonal antibody specific to TGF-β1.  
Any TGF-β1 present is bound by the immobilised antibody.  After washing away any 
unbound substances, an enzyme-linked polyclonal antibody specific for TGF-β1 is 
added to the wells to sandwich the TGF-β1 immobilised during the first incubation.  
Following a wash to remove any unbound antibody-enzyme reagent, a substrate 
solution is added to the wells and a colour develops in proportion to the amount of 
TGF-β1 bound in the initial step.  The colour development is stopped and the 
intensity of the colour is measured.  Prior to the assay latent TGF-β1 in the samples 
was activated to the immunoreactive TGF-β1 detectable by the assay by the addition 
of 20µl of 1N HCl to 100µl culture supernatant for 10 minutes at room temperature.  
The acidified sample was neutralised by adding 13µl of 1.2N NaOH/0.5M HEPES 
and assayed immediately. 
 
2.13 Nitrite Assay 
 Nitric oxide (NO) production was determined using the Griess reaction which 
measures the stable oxidation product nitrite.  Griess reagent (Sigma-Aldrich) was 
reacted in a 1:1 ratio with sample and measuring absorbance at λ560nm.  A standard 
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curve for nitrite was prepared by reacting known concentrations of sodium nitrite in 
the Griess reaction and measuring absorbance at λ560nm. 
 
2.14 Arginase Assay 
 This method utilises the technique optimised by Corraliza and colleagues for 
assaying arginase activity (Corraliza et al., 1994).  2x105 peritoneal or bone marrow 
derived macrophages were seeded in 96-well plates and treated as indicated.  The 
supernatants were removed and the cells were lysed for 15 minutes at 4°C in 100µl 
lysis buffer containing 0.1% Triton X-100, a 1:50 dilution of EDTA-free protease 
inhibitor solution (50x stock is one CompleteTM EDTA-free protease inhibitor tablet 
(Roche) per 1ml of PBS), and 1mM sodium orthovanadate.  50µl of lysate was then 
treated with 50µl 10mM MnCl2, 50mM Tris-HCl pH 7.5 for 10 minutes at 55°C 
(MnCl2 is an essential cation for arginase activity).  Arginine hydrolysis was carried 
out in eppendorf tubes and was initiated by the addition of 25µl of 0.5M L-arginine 
(pH 9.7) to a 25µl aliquot of the previously activated lysate for 1 hour at 37°C.  The 
reaction was stopped by the addition of 400µl of an acid mixture containing H2SO4, 
H3PO4 and H2O (1:3:7).  The urea formed was quantified after the addition of 25µl 
α-isonitrosopropiophenone (ISPF) dissolved in 100% ethanol and heating at 100°C 
for 45 minutes.  The OD at λ560nm was determined spectrophotometrically using 
200µl aliquots in a 96-well plate.  A standard curve was prepared with increasing 
amounts of urea (between 0.625 and 10mM).  In this case 100µl of urea solution, 
400µl of the acid mixture and 25µl ISPF were added and the procedure followed as 
described above.  Results are expressed as µm arginase activity/mg protein/hour. 
 
2.15 Antibacterial Assay 
 Streptococcal pneumoniae (S. pn) was incubated overnight on a blood agar 
plate at 37°C/5% CO2.  10ml of 100% heart infusion broth (Difco) was inoculated 
with one colony of S. pn and incubated overnight at 37°C with gentle shaking.  
Cultures were centrifuged at 3000rpm for 20 minutes, washed with broth and 
centrifuged again.  The culture was resuspended in broth to an OD600 = 0.1.  The S. 
pn were diluted 1:100 (this was the bacterial reaction mix).  75µl of the bacterial 
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reaction mix was incubated with 75µl antibiotic at 37°C for 2 hours at 800rpm on the 
thermomixer.  Antibiotics used were: recombinant mouse galectin-3 (final 
concentrations 6.25, 12.5, 25, 50 and 100µg/ml), galectin-3 denatured for 10 mins at 
95ºC (final concentrations 6.25, 12.5, 25, 50 and 100µg/ml) and ampicillin 
(20µg/ml).  A reaction was prepared for t = 0 which was plated out before the 2 hour 
incubation.  After 2 hours, the reactions were serially diluted into 900µl PBS and 
100µl of each dilution was plated out on blood agar plates.  Plates were incubated 
overnight at 37°C/5% CO2 and colonies counted the next day. 
 
2.16 FITC-labelling of bacteria 
 S. pn and E. coli were incubated overnight on blood agar plates or LB agar 
culture plates respectively at 37°C/5% CO2.  One colony of S. pn was inoculated into 
10ml Todd Hewitt Broth (Oxoid) (containing 0.5% yeast extract and 5% FBS) and 
one colony of E. coli was inoculated into 10ml LB.  Cultures were incubated at 
37°C/5% CO2 for 4-5 hours until they reached an OD660 of 0.5-0.6.  Cultures were 
heat inactivated for 1 hour at 60°C in a water bath and heat inactivation confirmed by 
plating an aliquot onto agar plates.  Heat inactivated cultures were centrifuged for 10 
minutes at 2500xg to pellet bacteria and excess media was removed.  The pellet was 
resuspended to an OD660 of 1.0 (approximately 1x109 bacteria per ml) with cold PBS, 
transferred to 1ml eppendorf tubes and centrifuged for 10 minutes at 2500rpm.  
Pellets were washed once with HBSS plus 1% BSA, centrifuged and supernatant 
removed.  Bacterial pellets were resuspended in 100µl 0.5mg/ml FITC solution 
(Sigma-Aldrich) in PBS, mixed thoroughly and rolled for 30 minutes at 4°C in the 
dark.  900µl ice cold HBSS plus 1% BSA was added to each eppendorf and 
centrifuged for 2 minutes at 10krpm.  Each pellet was washed twice with 1ml HBSS 
plus 1% BSA and resuspended in 1ml HBSS plus 1% BSA.  Labelled bacteria were 
aliquoted and stored at -80°C. 
 
2.17 Trypan Blue Viability Assay 
 Viability of BMDM treated with either S. pn or E. coli was determined using 
Trypan Blue exclusion.  Trypan blue is a stain that traverses only membranes of dead 
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cells and colours these cells blue.  Cells are washed with PBS, incubated in 2% 
trypan blue solution for 1-2 minutes, washed twice with PBS to remove any non-
absorbed trypan blue then incubated with DMSO to solubilise the absorbed trypan 
blue.  The absorbance at λ560nm was measured for each sample.  Methanol 
treatment of untreated wild type and galectin-3-/- BMDM, before the addition of 
trypan blue, was used as an indication of total cell count and percentage cell death of 
each experiment was calculated. 
 
2.18 Preparation of human neutrophils from peripheral blood 
 Blood was collected in tubes containing sodium citrate, at 1ml sodium 
citrate/10ml blood, and mixed gently.  Blood samples were centrifuged at 1250rpm 
for 20 minutes at 20°C.  The top platelet rich plasma layer was removed and 6% 
Dextran (GE Healthcare) added to sediment out the red blood cells (2.5ml 
dextran/10ml cell pellet was added and made up to 50ml with NaCl).  After 30 
minutes, the white blood cell layer was transferred to a 50ml conical tube and 
centrifuged at 1250rpm for 6 minutes.  The supernatant was removed and the cells 
were gently resuspended.  Cells were spun on a gradient made up of 81%, 68% and 
55% Percoll layers at 1750rpm for 20 minutes with acceleration and brake off and 
granulocytes were harvested from in between the 81% and 68% layers.  Neutrophils 
were washed in HBSS and counted on a haemocytometer.  When needed, apoptotic 
human neutrophils were prepared by culturing neutrophils for 24 hours in IMDM 
containing 10% autologous serum. 
 
2.19 Phagocytosis Assays 
 For FACS analysis of phagocytosis of bacteria by BMDM, wild type and 
galectin-3-/- BMDM were seeded in 6-well plates at 2x105 cells/well, and left to 
adhere overnight in serum-free media.  FITC-S. pn and FITC-E. coli were opsonised 
with 10% mouse serum for 1 hour at 37°C.  A 10:1 ratio of opsonised FITC-S. pn or 
FITC-E. coli to BMDM was incubated for 1 hour at 37°C or as indicated.  Excess 
bacteria were washed off and cells were incubated with 5mM EDTA on ice for 15 
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minutes.  Cells were gently agitated off the bottom of the well and percentage 
phagocytosis determined by FACS analysis using a BD FacsCalibur flow cytometer. 
 For confocal analysis of phagocytosis of bacteria by macrophages, wild type 
and galectin-3-/- BMDM (or alveolar macrophages) were seeded on coverslips at 
4x105 cells/well, and left to adhere overnight in serum-free media.  FITC-S. pn and 
FITC-E. coli were opsonised with 10% mouse serum for 1 hour at 37°C.  A 10:1 
ratio of opsonised FITC-S. pn or a 20:1 ratio of FITC-E. coli to BMDM was 
incubated for 1 hour at 37°C, excess bacteria were washed off and cells were fixed in 
3% PFA for 5 minutes at room temperature.  Cells were blocked in 3% BSA, 
containing 10% mouse serum, for 1 hour at room temperature, incubated with 1:500 
rhodamine phalloidin (Invitrogen) for 20 minutes at room temperature protected 
from light.  To stain the nuclei 0.1µg/ml DAPI in PBS was added for 5 minutes and 
coverslips were mounted onto slides (Fisher Scientific) using Mowiol.  Images were 
taken using a Leica SP5 confocal microscope and subsequently processed using 
Adobe Photoshop. 
 For FACS analysis of phagocytosis of apoptotic human neutrophils by 
BMDM, BMDM were seeded in 48-well plates, stained with 1µg/ml Cell Tracker 
Orange (CMTMR, Invitrogen) and incubated with 10:1 ratio of 1µg/ml Cell Tracker 
Green (CMFDA, Invitrogen) labelled day 1 apoptotic human neutrophils for up to 1 
hour at 37°C.  Excess neutrophils were washed off and BMDMs were incubated with 
5mM EDTA on ice for 15 minutes.  Cells were gently agitated off the bottom of the 
well and percentage phagocytosis determined by FACS analysis using a BD 
FacsCalibur flow cytometer. 
 For confocal analysis of phagocytosis of apoptotic mouse neutrophils by 
BMDM, BMDM were seeded on coverslips, stained with Cell Tracker Orange and 
incubated with 5:1 ratio of Cell Tracker Green-labelled day 2 apoptotic wild type 
mouse neutrophils for 1 hour at 37°C.  Excess neutrophils were washed off and cells 
were fixed in 3% PFA for 5 minutes at room temperature.  To stain the nuclei 
0.1µg/ml DAPI in PBS was added for 5 minutes and coverslips were mounted using 
Mowiol.  Pictures were taken using a Leica SP5 confocal microscope and 
subsequently processed using Adobe Photoshop. 
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 For FACS analysis of phagocytosis of bacteria by neutrophils, wild type and 
galectin-3-/- bone marrow derived neutrophils were incubated with a 10:1 ratio of 
opsonised FITC-S. pn and FITC-E. coli for 1 hour at 37°C, excess bacteria were 
washed off and percentage phagocytosis determined by FACS analysis using a BD 
FacsCalibur flow cytometer. 
 
2.20 Neutrophil Activation Assays 
2.20.1 Neutrophil Adhesion Molecule Expression 
 This assay was originally developed by Professor Adriano Rossi (University 
of Edinburgh) to examine the expression of adhesion molecules on neutrophil cell 
surfaces from human whole blood.  For this thesis, the assay was employed to 
measure adhesion molecule expression on neutrophils from human whole blood and 
modified by myself to assay mouse whole blood.  Upregulation of CD11b and 
shedding of CD62L are indicators of neutrophil activation.  Agonists used were N-
Formyl-Methionine-Leucine-Phenylalanine (fMLP) (0.1µM), LPS (100ng/ml) 
(R&D) and galectin-3 (up to 30µg/ml).  Whole human blood was collected in a 15ml 
conical tube with 10U/ml heparin.  Blood was added to the agonists in 2ml eppendorf 
tubes and incubated at 37°C for 30 minutes.  Tubes were then placed on ice for 15 
minutes and antibodies were added to separate 1.5ml eppendorfs and placed on ice.  
Antibodies used were anti-human CD11b-APC (clone ICRF44) (1:16.7) and anti-
human CD62L-PE (clone DREG-56) (1:16.7).  50µl blood/agonist mixture was 
added to the relevant antibody mixture and incubated for 30 minutes at 4°C.  
Samples were treated with 1ml 1X FACS Lysing Solution (Becton Dickinson) for 5 
minutes at room temperature to lyse the red blood cells and centrifuged at 300xg at 
4°C for 5 minutes.  The pellet was washed with 1ml PBS and centrifuged again.  The 
pellet was resuspended in 300µl of 1% PFA in buffer (PBS and 0.1% BSA).  
Samples were analysed using the BD FACSCalibur flow cytometer and neutrophils 
were identified by forward and side scatter properties.  The same method was carried 
out with wild type and galectin-3-/- mouse whole blood.  Approximately 1ml of 
mouse whole blood was collected from the vena cava of mice anaesthetised with 
avertin.  Whole blood was incubated with anti-GR-1-PE antibody (clone RB6-8C5) 
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(1:400) and analysed by FACS analysis to confirm the neutrophil population in the 
mouse blood.  Mouse whole blood was incubated with 30µg/ml galectin-3 followed 
by anti-mouse CD11b-APC (clone M1/70) (1:66.7) antibody.  Events within the GR-
1 positive population were gated on. 
 
2.20.2 Superoxide Anion Generation Assay 
 Cytochrome C molecules are reduced by the reactive oxygen species (ROS) 
O2- resulting in a change in absorbance which can be measured 
spectrophotometrically (Dahlgren and Karlsson, 1999).  There is a one-to-one molar 
stoichiometry between O2- molecules and cytochrome C molecules reduced. 
 Neutrophils isolated from human peripheral blood were resuspended in 
HBSS(+) containing calcium (Ca2+) and magnesium (Mg2+) to give a final 
concentration of 11.1x106 to 22.2x106 cells/ml – used 90µl (1x106 to 2x106 cells) per 
tube).  Neutrophils were primed with 1µM platelet-activating factor (PAF), HBSS(+) 
or varying concentrations of galectin-3 for 15 minutes at 37ºC. Cells were then 
activated with HBSS(+) or fMLP (0.1µM) in 1mg/ml warm cytochrome C for 15 
minutes and centrifuged for 2 minutes at 13krpm.  Supernatants were transferred to 
fresh tubes and stored at 4°C.  Colour change was detected using a scanning 
spectrophotometer 500nm – 600nm, peak height was measured at 550nm.  
Absorbance was converted to concentration using the calculation A = Σ.l.c where 
“A” is the absorbance at 550nm and “Σ” is the extinction coefficient.  The OD550 of 
the reaction mixture is converted to nmoles of cytochrome C reduced using the 
extinction coefficient 21.1x10-3 M-1.cm-1.  “l” is the length of light path (1cm) and 
“c” is the concentration of absorbing substance in nmoles/ml/number of neutrophils.  
Therefore c = A/(Σ.l).  With a light path of 1cm and a sample volume of 1ml, the 
conversion factor is 47.6 (1/21.1x10-3) since 1 mol of O2- reduced 1 mol of 
cytochrome C. 
 
2.20.3 Dihydrorhodamine (DHR) Activation 
 DHR is a fluorescent dye which is activated by various reactive oxygen 
species.  Neutrophils isolated from human peripheral blood were resuspended in PBS 
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at 10x106 cells/ml.  100µl of neutrophils (1x106 cells) were incubated with DHR 
(0.1mM) for 5 minutes at 37ºC and primed with PAF (1µM) or human (Hu) or mouse 
(Ms) galectin-3 (10µg/ml) for 15 minutes at 37ºC.  Cells were incubated with fMLP 
(0.1µM) for 15 minutes, 180µl PBS added to increase the volume and placed on ice 
in the dark.  DHR fluorescence was measured as a geo mean of FL-1 on the BD 
FacsCalibur flow cytometer. 
 
2.21 In vivo animal models 
2.21.1 Chronic Carbon Tetrachloride (CCl4) – induced liver injury model 
 This model of liver fibrosis was originally developed by Professor John 
Iredale et al in rats.  Dr Neil Henderson and I modified this protocol to use in mice 
and carried out the in vivo experiments together. 
 After overnight fast (with free access to water) age- and sex-matched mice 
were injected intraperitoneally (i.p.) with 1µl/g body weight sterile CCl4 in a 1:3 
ratio with sterile olive oil (Sigma-Aldrich) or olive oil (control) twice weekly for 8 
weeks.  The CCl4/olive oil mixture was prepared fresh before each time point.  
Tissue was harvested 24 hours after the last injection of CCl4.  Livers were harvested 
for analysis after 8 weeks and fixed in 10% buffered formalin or snap-frozen for 
subsequent real-time RT-PCR analysis (detailed in 2.10) or Western blot analysis.  
Formalin-fixed liver was paraffin embedded by the Histology department at the 
University of Edinburgh who also prepared 3µm thick sections of tissue onto 
superfrost slides using a microtome.  10µm sections were prepared for PSR staining. 
 
2.21.2 Model of Kidney Fibrosis using Unilateral Ureteric Obstruction 
(UUO) 
 Experimental unilateral ureteric ligation resulting in UUO was kindly 
performed by Spike Clay (University of Edinburgh) as described previously (Kipari 
et al., 2006).  UUO was performed by ligation of the left ureter of each animal at the 
ureteropelvic junction under anesthesia (i.p. injection of metatomidine and ketamine).  
The left flank area was shaved and the mouse was held into position with masking 
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tape on its right side on a warm heating pad to ensure the shaved area was under 
minor tension.  The shaved area was disinfected and 50µl of the analgesic 
buprenorphen was given subcutaneously.  A longitudinal incision was made and the 
ureter was brought to the opening in the skin.  The ureter was obstructed by applying 
a small titanium ligating clip (Weck ‘Hemoclip Plus’) and replaced in its original 
position.  A 5-0 silk suture was used to close the peritoneal wall ensuring muscle and 
fat layers were included in the stitch and the skin was closed using a standard metal 
skin clip.  The wound was disinfected with 10% Iodine solution and reversal agent 
(atipamezole) was injected subcutaneously.  The mouse was given fluids by injecting 
500µl saline into the scruff and allowed to recover.  I harvested kidneys at days 3, 7 
and 14 post obstruction with the help of Dr Alison Mackinnon and fixed in 10% 
buffered formalin or methyl carnoys reagent or snap-frozen for subsequent real-time 
RT-PCR analysis (detailed above).  Formalin- or methyl carnoys-fixed kidney was 
paraffin embedded by the Histology department at the University of Edinburgh who 
also prepared 3µm thick sections of tissue onto superfrost slides using a microtome.  
10µm sections were prepared for PSR staining. 
 
2.21.3 Pneumonia model 
 The method of intratracheal administration of bacteria to mice has been 
performed previously by Dr John Simpson and collegues (University of Edinburgh).  
Dr Neil Henderson and I planned and carried out the following experiment with the 
help of the collegues from Dr John Simpson’s laboratory – Lesley Farrell 
(intratracheal administration of bacteria and bronchoalveolar lavages (BAL)) and Dr 
Tom Wilkinson (assisted with plating out samples for bacterial detection on agar 
plates). 
 S. pn type 3 was used in this study (ATCC - 10813).  After overnight 
incubation on 5% sheep blood agar plates (BD), freshly grown colonies were 
suspended in heart infusion broth with 10% heat treated horse serum (HIB-S) (Gibco, 
UK) at an OD550 of 0.17 (PU8620 spectophotometer, Philips).  The bacterial 
suspension was diluted 100-fold with fresh HIB-S and was incubated for 4 hours at 
37°C with shaking, corresponding to a point compatible with logarithmic growth.  
The suspension was centrifuged at 3000rpm for 10 minutes at room temperature.  
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The supernatant was discarded and the pellet was resuspended with the same volume 
of PBS.  Serial dilutions were used for determination of exact bacterial 
concentration. 
 Escherichia coli (E. coli) (ATCC – 25922) were prepared using the above 
method but inoculated in LB broth instead of heart infusion broth and grown on LB 
agar plates instead of blood agar plates. 
 Galectin-3-/- mice or wild type mice were used.  Under anesthesia (avertin 
10µl/g body weight), mice were intratracheally (i.t.) inoculated with 1x105 colony 
forming unit (CFU) of S. pn or 1x107 CFU E. coli in 50µl volume.  15 hours after 
bacterial administration mice were sacrificed, blood collected aseptically, and 
bronchoalveolar lavage (BAL) was performed with two separate aliquots of 400µl 
sterile PBS as described in section 2.2.  The right lung was fixed in 10% buffered 
formalin and the left lung stored in 2ml PBS for bacterial counts.  BAL fluid and 
blood were serially diluted 10-fold with PBS, inoculated on a 5% sheep blood agar 
plate (for mice infected with S. pn) or on an LB agar culture plate (for mice infected 
with E.coli), and incubated at 37°C overnight.  The remaining BAL fluid was 
centrifuged at 3000rpm for 10 minutes at 4°C.  Protein concentration in BAL was 
determined by the BCA protein assay reagent according to manufacturer’s 
instructions.  The supernatant was stored at -20°C until further use.  The pellet was 
resuspended in 300µl of PBS, and total cell number was determined with a 
haemocytometer.  For differential cell counts, cytospins were prepared (280rpm, 3 
minutes at room temperature) and stained with Diff-Quick (Ragena) to enable the 
morphological discrimination between mononuclear cells and polymorphonuclear 
cells.  The left lung was homogenized in 2ml of PBS and the homogenates were 
serially diluted 10-fold with PBS, inoculated on 5% sheep blood agar plates or LB 
agar plates, and incubated at 37°C overnight.  Colonies formed from lung 
homogenates and BAL were counted and blood plates were examined for the 
presence (sepsis) or absence of colonies. 
 
2.22 Statistical analysis 
 Results are reported as pooled data from a series of n separate experiments 
and presented as mean ± Standard error mean (S.E.M.).  Statistical significance was 
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analysed by one-way analysis of variance (ANOVA) or two-tailed Student’s t test 
(Prism software).  Statistical significance was assigned to data returning a P value of 
less than 0.05. 
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Chapter 3 




 The Bac-to-Bac® Baculovirus Expression System is used to generate high-
level expression of a gene of interest in insect cells.  This method was chosen to 
overcome possible endotoxin contamination of recombinant galectin-3 when 
produced using the standard bacterial expression system. 
 This technique generates recombinant baculovirus by site-specific 
transposition in Escherichia coli (E. coli).  The gene of interest is cloned into a 
pFastBac vector, containing a gentamycin resistance gene.  This study uses the 
pFastBac HT vector supplied with the multiple cloning site in three reading frames 
(A, B and C) to enable cloning of the gene of interest in frame with the N-terminal 
6x histidine (His) tag.  The vector is then transformed into competent E. coli 
DH10Bac containing a baculovirus shuttle vector (bacmid) with a LacZ-mini-attTn7 
fusion and a kanamycin resistance marker.  Transposition occurs between the mini-
Tn7 element on the pFastBac vector and the mini-attTn7 target site on the bacmid, 
generating a recombinant bacmid.  A helper plasmid present in the bacteria provides 
the transposition proteins required for this reaction to take place.  This helper 
plasmid also confers resistance to tetracycline. 
 This transposition disrupts the expression of the LacZ gene, so these bacteria 
can no longer produce the β-galactosidase enzyme encoded by this gene.  5-bromo-4-
chloro-3-indolyl-β-D-galactopyranoside (X-gal) is included with isopropyl β-D-
thiogalactoside (IPTG) (an inducer of β-galactosidase), kanamycin, tetracycline and 
gentamicin within the agar medium on the culture plate.  X-gal is cleaved by β-
galactosidase yielding galactose and 5-bromo-4-chloro-3-hydroxyindole.  5-bromo-
4-chloro-3-hydroxyindole then is oxidized into 5,5'-dibromo-4,4'-dichloro-indigo, an 
insoluble blue product.  Colonies containing the recombinant bacmid are white, 
whereas blue colonies contain the unaltered bacmid.  White colonies are selected and 
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re-streaked on culture plates to verify E. coli colonies containing recombinant 
bacmid. 
 The bacmid DNA contains M13 Forward (-40) and M13 Reverse priming 
sites flanking the mini-attTn7 site to enable polymerase chain reaction (PCR) 
analysis of the recombinant bacmid (figure 3.1).  Additionally, a combination of the 
M13 primers and primers directed to the insert can be used to verify the presence of 
the gene of interest. 
 Once confirmed to contain the gene of interest, the recombinant bacmid is 
transfected into insect cells using a cationic lipid transfection reagent to produce 
recombinant baculovirus.  High transfection efficiency is determined by the 
following signs of infection: in the first 24 hours cells swell in diameter with 
increased size of cell nuclei, 24 to 72 hours cell growth ceases and there are signs of 
viral budding (granular appearance) and detachment.  Cell lysis is observed after 72 
hours.  Once high transfection efficiency is demonstrated the medium containing the 
P1 baculovirus stock is collected and stored at 4°C, protected from light, or at -80°C 
for long-term storage. 
 Once isolated the P1 baculovirus is amplified to generate a higher-titre P2 
stock.  Titre of viral stock is determined using a 12-well End-point Dilution Assay 
(EPDA) which relies on visual comparison of signs of infection of cells inoculated 
with 100, 10, 1 and 0µl of baculovirus.  A high titre stock at 2x108 plaque forming 
units (pfu)/ml shows equal signs of infection in all three (100, 10 and 1µl) infected 
wells 3 days post inoculation.  This high titre stock is then used for large scale 
inoculation for production of recombinant protein. 
 Once infected with recombinant baculovirus the insect cells express His-
tagged recombinant protein through the cell’s normal transcription/translation 














Figure 3.1 – Schematic diagram illustrating the M13 primer 
sites on the recombinant bacmid.
Figure 3.1
The bacmid DNA containing M13 forward (-40) and M13 reverse priming sites 
flanking the mini-attTn7 site enabling PCR analysis of the recombinant bacmid.
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3.2 Methods and Results 
3.2.1 Generating the Recombinant pFastBac Vector 
 The pFastBac HT vector was used in this study as it contains a 6xHis tag 
which was subsequently used to purify the recombinant protein.  The pFastBac HT 
vector is supplied with the multiple cloning site in three reading frames (A, B and C) 
to enable cloning of the gene of interest in frame with the N-terminal 6xHis tag.  
Mouse galectin-3 was cloned into pFastBac HT A and human galectin-3 was cloned 
into pFastBac HT B to ensure the gene was in frame with the initiation ATG and the 
N-terminal 6xHis tag (figure 3.2A-C). 
 Mouse galectin-3 was amplified from a pcDNA3.1 mouse galectin-3 clone, 
previously made in the laboratory using pcDNA3.1 vector (Invitrogen), using 
primers designed with a BamHI restriction site on the forward primer and an EcoRI 
restriction site on the reverse primer (see “Materials and Methods Chapter” for 
primer sequences).  The following reaction conditions were used: 
 
pcDNA3.1 1µl  Conditions 
dNTPs 1µl     
10x buffer 5µl  95°C 5 min  
Taq polymerase 0.5µl  95°C 1 min  
Pfu (1:50) 0.5µl  56°C 1 min 30x 
Forward primer (100pmol/µl) 2µl  72°C 1 min  
Reverse primer (100pmol/µl) 2µl  72°C 10 min  
NFH2O 38µl     
Total 50µl     
  
 The mouse galectin-3 PCR product flanked by BamHI and EcoRI sites and 
pFastBac HT A were digested using BamHI and EcoRI restriction enzymes 
(Promega) for 2 hours at 37°C.  Digests were prepared as follows: 
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Galectin-3
Figure 3.2 – Maps of the pFastBac HT vectors.
Figure 3.2 (A)
(A) The pFastBac HT vector used to clone galectin-3 in frame with the initiation 
ATG and the N-terminal 6xHis tag.
A)
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B)    pFastBac HT A Polylinker
C)    pFastBac HT B Polylinker
Figure 3.2 (B, C)
Multiple cloning site of (B) pFastBac HT A and (C) pFastBac HT B. Highlighted 
are the restriction sites used to clone in mouse and human galectin-3.
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 Insert digest pFastBac HT A digest 
Mouse galectin-3 PCR product 24µl - 
pFastBac HT A (1µg) - 2µl 
10x Buffer E (Promega) 3µl 3µl 
BamHI 1.5µl 1.5µl 
EcoRI 1.5µl 1.5µl 
NFH2O - 22µl 
Total 30µl 30µl 
  
 The digests were run on a 1% agarose gel (figure 3.3A) and gel extracted 
using the QIA quick gel extraction kit (Qiagen) as per manufacturer’s instructions. 
 Ligation of the digested pFastBac HT A vector and mouse galectin-3 insert 
was carried out overnight at 18°C as follows: 
 
 Ligation Vector only control 
Mouse galectin-3 insert 12µl - 
Cut pFastBac HT A  2µl 2µl 
5x Buffer (Promega) 4µl 4µl 
T4 Ligase (Promega) 2µl 2µl 
NFH2O - 12µl 
Total 20µl 20µl 
 
 For the remainder of this chapter this construct will be referred to as pFastBac 
MsG3. 
 A human galectin-3 insert was digested out of a pGEM-T Easy human 
galectin-3 clone, previously made in the laboratory using pGEM-T Easy Vector 
(Promega), and pFastBac HT B was cut using BamHI and EcoRI restriction 
enzymes.  Digests were prepared as follows: 
 
 pGEM-T Easy digest pFastBac HT B digest 
pGEM-T Easy galectin-3 3µl - 
pFastBac HT B (1µg) - 2µl 
10x Buffer E 3µl 3µl 
BamHI 1.5µl 1.5µl 
EcoRI 1.5µl 1.5µl 
NFH2O 21µl 22µl 




Human G-3 insert 
(~800 bp)




Mouse G-3 insert 
(~800 bp)





Figure 3.3 – Restriction digests of the recombinant 
pFastBac HT Vectors.
Figure 3.3 (A, B)
Restriction digests of (A) pFastBac HT A vector and the mouse galectin-3 insert 
and (B) pFastBac HT B vector and the human galectin-3 insert were carried out 
and run on 1% agarose gels. The relevant bands (indicated with arrows) were gel 
extracted and ligations were performed to make recombinant vector.
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 The digests were run on a 1% agarose gel (figure 3.3B) and the relevant 
bands were gel extracted using the Qiagen gel extraction kit according to the 
manufacturer’s instructions. 
 Ligation of the digested pFastBac HT B vector and human galectin-3 insert 
was carried out overnight at 18°C using the same procedure as detailed above.  For 
the remainder of this chapter this construct will be referred to as pFastBac HuG3. 
 
3.2.2 Transformation of the E. coli strain TOP10 with recombinant 
vector 
 To increase the yield of the recombinant vector, TOP10 competent E. coli 
(Invitrogen) were transformed and ampicillin-resistant transformants were selected. 
 50µl of TOP10 bacteria were incubated on ice with 5µl of pFastBac MsG3, 
pFastBac HuG3, or vector only controls for 30 minutes.  Tubes were placed at 42°C 
for 50 seconds to heat shock the bacteria and then immediately placed on ice for 2 
minutes.  500µl S.O.C. was added to each tube and incubated for 50 minutes at 37°C 
with shaking at 750rpm.  The bacteria were centrifuged, 400µl of supernatant 
removed and the bacteria were resuspended in the remaining S.O.C.  Bacteria were 
plated on Luria-Bertani (LB) agar plates containing 50µg/ml ampicillin and 
incubated overnight at 37°C.  The next day, colonies were observed on culture plates 
which had been plated with bacteria transformed with the recombinant vectors 
indicating that the ligations between inserts and cut vectors were successful.  There 
were no colonies seen on the negative control culture plates which had been plated 
with bacteria transformed with the vector only control ligation as predicted. 
 Separate colonies were selected using a sterile 200µl pipette tip which was 
then ejected into 3ml LB plus ampicillin and incubated overnight at 37°C.  The next 
day, mini-preps were performed on 1.5 ml of each suspension using the Promega 
‘Wizard’ mini-prep kit according to manufacturer’s instructions.  Restriction digests 
were performed on each mini-prep using enzymes BamHI and EcoRI to check that 
the vectors contained the inserts, and samples were run on a 1% agarose gel (figure 
3.4A and B).  All digests were positive for the insert. 
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1000bp
Human G-3 insert 
(~800 kb)
Mouse G-3 insert (~800 bp)
A)
B)
pFastBac HT A (~4 kb)
pFastBac HT B 
(~4 kb)
1000bp
Figure 3.4 – Restriction digests of mini-preps from 
transformed TOP10 bacteria.
Figure 3.4 (A, B)
Restriction digests of mini-preps prepared from TOP10 bacteria transformed with 
(A) pFastBac MsG3 and (B) pFastBac HuG3 recombinant vector.
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 The remaining 1.5ml of one starter culture of TOP10 bacteria containing 
pFastBac MsG3 and one starter culture of TOP10 bacteria containing pFastBac 
HuG3 were inoculated into 500ml LB plus ampicillin and incubated overnight at 
37°C.  Maxi-preps were performed on each culture using the Qiagen maxi-prep kit 
according to manufacturer’s instructions.  DNA yields, determined using a WPA UV 
1101 Biotech photometer, were 5.7µg/µl of pFastBac MsG3 and 3.13µg/µl of 
pFastBac HuG3. 
 
3.2.3 Generating Recombinant Bacmid 
 The recombinant vector was then transformed into DH10Bac E. coli 
(Invitrogen) to generate recombinant bacmid.  Transposition occurs between the 
mini-Tn7 element on the pFastBac vector and the mini-attTn7 target site on the 
bacmid and disrupts the expression of the LacZ gene enabling blue/white selection to 
identify colonies containing recombinant bacmid. 
 100µl of DH10Bac E. coli were transferred to pre-chilled 1.5ml tubes.  10ng 
of recombinant vector or 1ng of control vector pFastBac HT-CAT, provided in the 
Bac-to-Bac kit, was incubated with the bacteria for 30 minutes at 4°C.  The bacteria 
were heat shocked for 45 seconds at 42°C without shaking then transferred to ice for 
2 minutes.  900µl S.O.C. was added to each tube and incubated for 4 hours at 37°C 
with shaking at 750rpm.  Serial dilutions (1:10, 1:100 and 1:1000) of the suspension 
were inoculated onto LB agar culture plates containing 50µg/ml kanamycin, 7µg/ml 
gentamicin (Gibco), 10µg/ml tetracycline, 100µg/ml X-gal (Invitrogen) and 40µg/ml 
IPTG to select for DH10Bac transformants.  Culture plates were incubated for 48 
hours at 37°C. 
 Colonies containing the recombinant bacmid were white amongst a 
background of blue colonies containing the unaltered bacmid.  E. coli transformed 
with the control vector were blue.  White colonies were selected and re-streaked on 
culture plates to verify E. coli colonies with recombinant bacmid.  Once verified, 
white colonies were selected and each colony inoculated into starter cultures of 10ml 
LB containing 50µg/ml kanamycin, 7µg/ml gentamicin and 10µg/ml tetracycline 
overnight at 37°C with shaking.  2ml of each starter culture was inoculated into a 
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larger volume of 500ml LB plus antibiotics and incubated overnight at 37°C with 
shaking. 
 Recombinant bacmid was isolated using the S.N.A.P MidiPrep Kit 
(Invitrogen), which is designed for purifying highly pure plasmid DNA, according to 
manufacturer’s instructions. 
 
3.2.4 Analysing Recombinant Bacmid DNA by PCR 
 The bacmid DNA contains M13 Forward (-40) and M13 Reverse priming 
sites flanking the mini-attTn7 site to enable PCR analysis of recombinant bacmid 
(figure 3.1).  Once the gene of interest was inserted, a combination of the M13 
primers and primers directed against the insert were used to verify the presence of 
the galectin-3 gene.  The length of the transposed pFastBac sequence with the 
galectin-3 insert is approximately 2900bp, and if transposition has occurred, the 
length of the PCR product using the M13 Forward (-40) and M13 Reverse primers is 
approximately 3200bp.  If transposition has not occurred, the length of the PCR 
product is only approximately 270bp so it is easy to distinguish which bacmids 
contain the galectin-3 gene. 
 Primer sequences are listed in Materials and Methods Chapter 2.  10x 
Titanium Taq PCR Buffer and 50x Titanium Taq DNA polymerase were from BD 
Biosciences.  The following reaction conditions were used: 
 
Recombinant bacmid DNA (100ng) 1µl  Conditions 
10x Titanium Taq PCR Buffer 5µl     
10mM dNTP mix 1µl  93°C 3 min  
50x Titanium Taq DNA polymerase 1µl  94°C 45 sec  
Forward primer (10µM stock) 1.25µl  55°C 45 sec 35x 
Reverse primer (10µM stock) 1.25µl  72°C 5 min  
NFH2O 39.5µl  72°C 7 min  
Total 50µl     
 
 Combinations of primers used were as follows for PCR of both mouse 
galectin-3 bacmid and human galectin-3 bacmid.  A bacmid prepared from a blue 







PCR of human galectin-3 bacmid
M13 Forward (-40) + 
M13 Reverse (~3.2 kb)
M13 Forward (-40) + 
Gal-3 Reverse (~2.5 kb)
PCR of mouse galectin-3 bacmid
PCR of untransformed bacmid
M13 Forward (-40) + 
M13 Reverse (270 bp)
M13 Forward (-40) + 
M13 Reverse (~3.2 kb)
M13 Forward (-40) + 
Gal-3 Reverse (~2.5 kb)
Figure 3.5 – PCR analysis of the recombinant bacmids.
A)
B)
Figure 3.5 (A, B)
PCR of recombinant bacmid prepared from DH10Bac E. coli transformed with 
(A) pFastBac HT HuG3 recombinant vector and (B) pFastBac HT MsG3 
recombinant vector or untransformed.
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Forward Primer Reverse Primer 
M13 Forward (-40) M13 Reverse 
M13 Forward (-40) Galectin-3 Reverse 
 
 Samples were run on a 1% agarose gel (figure 3.5) and show that the 
galectin-3 gene was present in both the mouse and human galectin-3 recombinant 
bacmids. 
 
3.2.5 Transfecting Insect Cells with Recombinant Bacmids 
 Once confirmed to contain the galectin-3 gene for both human and mouse, the 
recombinant bacmids were transfected into Sf9 insect cells to produce recombinant 
baculovirus.  The cationic lipid used to carry out the transfection was Cellfectin 
(Invitrogen), recommended for transfection of Sf9 and other insect cells.  Grace’s 
Insect Cell Culture Medium (Invitrogen) was used to increase transfection efficiency.   
 Cellfectin, Grace’s medium and Sf-900 II serum-free growth medium were 
warmed up to room temperature before use.  Sf9 cells were seeded in a 6-well culture 
plate at 9x105 cells/well in 2ml of growth medium, and left to adhere for at least 1 
hour at 27°C in a humidified incubator.  For each transfection the bacmid 
DNA:Cellfectin reagent complexes were prepared as follows in sterile 5ml 
polystyrene round-bottom tubes.  1µg of purified bacmid DNA was diluted in 100µl 
of unsupplemented Grace’s medium.  The Cellfectin reagent was mixed thoroughly 
and 6µl was diluted with 100µl unsupplemented Grace’s medium.  The diluted 
bacmid DNA was then combined with the diluted Cellfectin reagent, mixed gently 
and incubated for 30 minutes at room temperature.  The growth media was removed 
from the Sf9 cells and cells were washed with unsupplemented Grace’s media.  After 
30 minutes, 800µl unsupplemented Grace’s medium was added to each tube 
containing the DNA:lipid complexes and mixed gently.  Wash media was removed 
and the ~1ml of DNA:lipid complexes were added to each well and incubated for 5 
hours at 27°C.  DNA:lipid complexes were removed and 2ml of growth media was 
added to each well.  Cells were incubated in a 27°C humidified incubator for 72 
hours or until signs of viral infection became visible.  Cellfectin-only negative 
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controls and cells transfected with untransformed bacmid, positive controls, were 
also performed. 
  
3.2.6 Isolating and Amplifying Baculoviral Stocks 
 Recombinant virus was released into the medium 72 hours after transfection.  
The medium was transferred into sterile 15ml snap-cap tubes, centrifuged for 5 
minutes at 500xg to remove cell debris and clarified supernatants transferred to fresh 
tubes.  Foetal bovine serum was added to a final concentration of 2% and the mouse 
galectin-3 and human galectin-3 P1 baculoviral stocks were stored at 4°C protected 
from light, with aliquots kept at -80°C for long term storage.  The titre of the P1 viral 
stock ranges from 1x106 to 1x107 pfu/ml. 
 Baculoviral stocks were amplified three times to P2, P3 and P4.  Sf9 cells 
were seeded in a 6-well culture plate at 2x106/well in 2ml of growth medium and left 
to adhere for at least 1 hour.  200µl of baculoviral stock was added to each well and 
incubated for 5 days at 27°C in a humidified incubator.  Virus was isolated after 5 
days using the technique described above. 
 Titre of the viral stocks was determined using a 12-well EPDA.  Sf9 cells 
were seeded in a 12-well culture plate at 1x105/well in 1ml growth medium and left 
to adhere for at least 1 hour.  Cells were inoculated with 100, 10, 1 or 0µl of each 
baculoviral stock and incubated for 3 days at 27°C in a humidified incubator.  After 3 
days equal signs of infection were seen in all 3 infected wells of cells inoculated with 
P3 and P4 mouse galectin-3 or human galectin-3 baculovirus indicating that these 
were high titre stocks and could be used for subsequent inoculation of insect cells for 
protein production. 
 
3.2.7 Expressing Recombinant Protein 
 Once suitable volumes of high titre baculoviral stocks had been produced, 
enough insect cells could be infected to produce enough recombinant protein to be 
used in future experiments.  For expression of each protein, three 162cm2 cell culture 
flasks were seeded with 3x107 Sf9 cells in 30ml growth media and left to adhere for 
at least 1 hour.  1ml of high titre baculovirus was added to each flask and incubated 
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for 5 days at 27°C in a humidified incubator.  Cells from each flask were scraped and 
pelletted and supernatant removed.  It was unclear whether galectin-3 would be 
released from the Sf9 cells into the growth medium and so initial experiments used 
both cell supernatant and cell lysate for protein purification.  Results indicated much 
greater protein concentration in the cell lysate.  Subsequent protein purification was 
therefore performed using cell lysate.  Pellets from equivalent infections were 
pooled, lysed at room temperature for 5 minutes in 6ml Cytobuster (Novagen) and 
split into 1.5ml tubes and centrifuged at 13krpm for 10 minutes at 4°C.  His-tagged 
recombinant protein was purified using the Ni-NTA His bind® resin as detailed in 
Chapter 2 (Materials and Methods).  Flow through (FT), washes (W1-3) and elutions 
(E1-5) were collected and aliquots were analysed using Sodium dodececyl-sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) with protein bands stained with 
Simply Blue Safestain (Invitrogen) (figure 3.6).  Elutions 2-5 were dialysed against 
1X PBS (dialysis tubing size – 14.3mm).  Protein determination using Pierce BCA 
protein assay reagent was performed and Western blots used to verify the presence of 
galectin-3 (figure 3.7).  Mouse galectin-3 protein expressed from the 6xHis tag 
vector is slightly larger at predicted weight 30.4 kDa compared to 29.1 kDa for 
human galectin-3.  Protein concentrations obtained using this method were in the 
range of 0.1 to 0.3mg/ml galectin-3. 
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FT W1 W2 W3 E1 E2 E3 E4 E5
Ms galectin-3
Hu galectin-3
Figure 3.6 – SDS-PAGE analysis of His-tagged recombinant 
mouse and human galectin-3.
A)
B)
Figure 3.6 (A, B)
His-tagged recombinant galectin-3 was extracted from Sf9 insect cells through 
binding to Ni-NTA His bind resin. Aliquots of flow through (FT), washes (W1-3) 
and elutions (E1-5) from mouse galectin-3 (A) and human galectin-3 (B) 
purifications were analysed using SDS-PAGE.
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Figure 3.7 – Western blot analysis of recombinant mouse 
and human galectin-3.
Figure 3.7




 Recombinant galectin-3 protein concentrations obtained using this method 
were relatively low and more work needs to be done to optimise this technique.  
Although yields were low, this technique did produce enough recombinant galectin-3 
to use in subsequent experiments.  Most importantly the protein produced was pure 
and will not be contaminated with endotoxin which is possible with protein purified 
from bacteria.  This is particularly true for galectin-3 as it has been shown to bind 
LPS (Mey et al., 1996).  Previous work in the laboratory has shown that attempts to 
remove endotoxin from bacterially-produced galectin-3 using an endotoxin removal 
column results in a reduction in the yield of protein recovered. 
 Insect protein processing pathways may not be equivalent to those of higher 
eukaryotes – however they produce proteins which are more authentic in 
glycosylation state and protein folding compared to protein produced using a 
bacterial expression system. 
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Chapter 4 
Galectin-3 plays a critical role in organ fibrosis 
 
4.1 Introduction 
 Fibrosis, the final common pathway of persistent tissue injury, is a wound 
healing response to a variety of chronic stimuli.  Chronic inflammation with the 
formation of scar tissue, loss of tissue architecture and organ failure is a 
characteristic feature of the pathogenesis of many human diseases and represents a 
major cause of morbidity and mortality worldwide. Currently our therapeutic 
repertoire is limited to immunosuppression and/or organ transplantation (Neuberger, 
2000).  The first liver transplant took place in 1963 and there have been vast 
improvements made since then with one-year survival rates exceeding 80% 
(Thalheimer and Capra, 2002).  However, donor organs are limited and effective 
alternative therapies are urgently required.   
 Until recently fibrosis was thought to be irreversible (Bonis et al., 2001).  The 
extent of clinical and experimental evidence for reversibility of fibrosis is ever 
increasing.  Results from a clinical trial of patients with hepatitis C showed that 49% 
of patients with cirrhosis demonstrated reversal of fibrosis after anti-viral treatment 
(Poynard et al., 2002).  Reversibility of other liver diseases and fibrosis in other 
organs such as the kidney and heart has also been observed (Elsharkawy et al., 2005).  
Iredale et al. used the well established carbon tetrachloride (CCl4) in vivo model of 
liver fibrosis to experimentally prove that liver fibrosis can be reversed.  Relatively 
advanced fibrosis in rat liver following injury induced by four weeks of CCl4 
injections can be resolved over a short time course (Issa et al., 2004; Iredale et al., 
1998).  This reversibility has provided another therapeutic target to fight organ 
fibrosis using anti-fibrotic therapies. 
 The fibroblast and myofibroblast are key cells in the initiation and 
perpetuation of organ scarring (Friedman, 2000; Bataller and Brenner, 2005). 
Classically, quiescent tissue fibroblasts become activated to a contractile, 
myofibroblast matrix-secreting phenotype.  Understanding the molecular 
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mechanisms that drive this phenotype switch may allow the development of targeted 
anti-fibrotic therapies.  
 Hepatic stellate cells (HSC); originally termed lipocytes, Ito cells or 
perisinusoidal cells, are the main collagen producing cells of the liver (Bataller and 
Brenner, 2005).  Chronic liver injury results in these cells acquiring fibrogenic 
properties with increased expression of alpha smooth muscle actin (α-SMA).  
Following culture on tissue culture plastic, HSCs activate to the myofibroblast 
phenotype and have been used as a paradigm cell type to study the pathogenesis of 
tissue fibrosis. 
 It is well known that type β transforming growth factor (TGF-β) is an 
important cytokine in the production, deposition and contraction of extracellular 
matrix (ECM) from fibroblasts resulting in excessive scarring and fibrosis.  TGF-β 
signalling occurs via the Smad family of transcriptional activators (figure 4.1).  TGF-
β receptor I kinase phosphorylates Smad-2 and Smad-3 which then bind Smad-4 and 
translocate to the nucleus where they induce gene transcription (Heldin et al., 1997; 
Roberts, 1999).  Smad-7 is an inhibitor of Smad signalling and exerts its effects 
through association with the activated type I receptor thus interfering with Smad-2 
and Smad-3 phosphorylation by the receptor (Nakao et al., 1997; Hayashi et al., 
1997).  Another major intermediate for TGF-β signalling are mitogen-activated 
protein kinases (MAPKs) including extracellular signal-regulated kinase (ERK), c-
Jun N-terminal kinase (JNK) and p38 MAPK, whose signalling pathways can further 
regulate Smad signalling (Derynck and Zhang, 2003).  Studies by Tsukada et al. 
have demonstrated the importance of both Smad and p38 MAPK signalling in HSC 
activation and collagen gene expression.  They showed that both pathways 
independently, yet additively, increase α1(I) collagen gene expression by 
transcriptional activation and contribute to the expression of α-SMA in HSCs. They 









Figure 4.1 – TGF-β/Smad signalling pathway.
Figure 4.1
TGF-βR-II phosphorylates TGF-βR-I on a cluster of serine/threonine residues. 
Activated TGF-βR-I propogates the signal downstream by directly 
phosphorylating Smad-2 and Smad-3. These form complexes with Smad-4 and 
translocate into the nucleus where they induce gene transcription. Smad-7 inhibits 























 Mechanisms of tissue fibrosis also exist that are TGF-β independent both in 
the liver and other organs.  Interleukin-13 (IL-13)-/- mice infected with Schistosoma 
mansoni show almost complete abrogation of fibrosis despite continued production 
of TGF-β (Kaviratne et al., 2004).  Angiotensin II, which contributes to the 
progression of vascular fibrosis, has been proven to activate Smad signalling in 
vascular cells, independently of TGF-β (Rodriguez-Vita et al., 2005). 
 In vitro galectin-3 has been implicated in a variety of biological processes 
including cell proliferation (Moutsatsos et al., 1987; Inohara et al., 1998), adhesion 
(Kuwabara and Liu, 1996; Inohara and Raz, 1995; Inohara et al., 1996) and survival 
(Yang et al., 1996; Akahani et al., 1997).  Initial in vivo studies demonstrated that 
galectin-3-/- mice have attenuated peritoneal inflammatory responses to thioglycollate 
instillation (Colnot et al., 1998b; Hsu et al., 2000), suggesting a role for galectin-3 in 
the development of acute inflammation.  However, the mechanisms that are involved 
in fibrogenesis are distinct from those involved in inflammation (Strieter and Keane, 
2004).  Increased galectin-3 expression has been noted in tissue fibrosis (Hsu et al., 
1999; Wang et al., 2000; Kasper and Hughes, 1996) and in vitro exogenous galectin-
3 stimulates myofibroblast proliferation via the MEK1/2-ERK1/2 signalling pathway 
(Maeda et al., 2003).  The relevance of these observations to the mechanistic role of 
galectin-3 in the pathogenesis of tissue fibrosis in vivo has not been examined. 
 The role of galectin-3 in the development of fibrosis will be examined using 
two well characterised models of liver and renal fibrosis.  The previously mentioned 
chronic CCl4 model of liver fibrosis established by Iredale et al. and unilateral 
ureteric obstruction (UUO) model of renal fibrosis.  This model is a very attractive 
model for studying renal fibrosis as many of the pathophysiological events occur 
within one week post obstruction (Klahr and Morrissey, 2002).  The model of UUO 
is neutrophil and lymphocyte independent and is characterised by marked 
tubulointerstitial macrophage infiltration together with progressive scarring 
(Diamond et al., 1995; Diamond, 1995). 
 This chapter aims to examine both the phenotypic and mechanistic 
consequences of an experimental model of chronic hepatic fibrosis using mutant 
mice lacking the galectin-3 gene.  Myofibroblast activation and collagen deposition 
were investigated and experiments were performed to try and elucidate the pathways 
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through which galectin-3 might signal to exert its effects.  Phenotypic examination of 
wild type and galectin-3-/- mouse kidneys following UUO-induced renal fibrosis has 
also been investigated as an additional model of organ fibrosis.  The following 




4.2.1 Galectin-3 expression is upregulated in human liver fibrosis 
 Archival human liver samples obtained from the University of Edinburgh 
Department of Pathology files were stained for galectin-3 using the DakoCytomation 
EnVision+ System-HRP (DAB) with the mouse anti-human galectin-3 (clone 9C4) 
antibody at a 1:100 dilution.  Images were acquired using a Leica DM LB light 
microscope, Leica DC 300 digital camera and Leica IM50 software.  In established 
human liver fibrosis, regardless of aetiology (hepatitis B or C, autoimmune, copper 
overload, or alcohol-induced), galectin-3 expression was negligible in normal liver 
compared to a dramatic increase of galectin-3 in the cirrhotic nodules of hepatocytes, 
particularly at the periphery of the nodules (figure 4.2).  Figure 4.2 inset images 
represent secondary only control staining (labelled polymer-HRP anti-mouse from 
the DakoCytomation EnVision+ System-HRP kit) of these tissue sections. 
 
4.2.2 Galectin-3 is temporally and spatially related to fibrosis in a 
reversible rat model of liver fibrosis 
 Galectin-3 and collagen expression was measured in the well established rat 
model of reversible CCl4-induced liver fibrosis (Issa et al., 2004; Iredale et al., 1998).  
Rat liver sections were obtained from Professor John Iredale (University of 
Edinburgh).  Sections included those from control rats injected intraperitoneally (i.p.) 
with olive oil alone, rats chronically injected i.p. with CCl4 twice weekly for 12 
weeks in a 1:3 ratio with olive oil and rats injected chronically for 12 weeks then left 




Figure 4.2 – Galectin-3 expression is upregulated in human 
liver fibrosis.
Figure 4.2
Galectin-3 expression in (i) normal human liver and in cirrhosis secondary to (ii) 
hepatitis C infection (n = 10), (iii) hepatitis B infection (n = 3), (iv) autoimmunity 
(n = 3), (v) copper overload (n = 2) and (vi) alcohol abuse (n = 2). Inset images 
demonstrate secondary antibody only control staining for each slide. (Scale bar: 
400µm.).
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(i) Normal (ii) Hepatitis C
(iii) Hepatitis B (iv) Autoimmune
(v) Copper overload (vi) Alcohol
Figure 4.3
Collagen expression stained with PSR (Upper panels, scale bar: 100µm) and 
galectin-3 expression (Lower panels, scale bar: 200µm.) in rat liver after 12 
weeks of twice-weekly i.p. olive oil vehicle only (Control) (Left), peak fibrosis in 
rat liver after 12 weeks of twice-weekly i.p. CCl4 (Middle) and resolution, 24 
weeks after cessation of CCl4 induced liver injury (Right). Inset image 
demonstrates secondary antibody only control staining.
Figure 4.3 – Galectin-3 is temporally and spatially related to 




Control 12 weeks CCl4 24 weeks 
post CCl4
 Collagen fibres were stained with picrosirius red (PSR) as a marker of 
fibrosis (figure 4.3 upper panels) and sections were also stained for galectin-3 using 
the rabbit anti-rat galectin-3 antibody kindly donated by Professor Fu-Tong Liu 
(University of California, San Diego) (figure 4.3 lower panels).  Figure 4.3 inset 
images represent secondary only control staining (biotinylated goat anti-rabbit) of 
this tissue section. 
 Images were acquired using a Leica DM LB light microscope, Leica DC 300 
digital camera and Leica IM50 software.  Galectin-3 expression was temporally and 
spatially associated with fibrosis, minimal in normal rat liver, maximal at peak 
fibrosis, and was visually absent again at 24 weeks once the liver had recovered from 
fibrosis.  This finding suggested that the development and resolution of fibrosis may 
be regulated by galectin-3. 
 
4.2.3 Galectin-3 plays a critical role in liver fibrosis 
 Initial data from liver sections obtained from human and rat, suggesting that 
galectin-3 may be involved in the occurrence of fibrosis, led on to the development 
of a model system for chronic liver fibrogenesis in mice expressing or deficient in 
galectin-3.  For the chronic fibrosis model mice were injected i.p. for 8 weeks, twice 
weekly, with olive oil alone (control) or for 8 weeks, twice weekly, with a 1:3 ratio 
of CCl4 to olive oil, giving a total of 16 injections.  Livers were removed, fixed in 
formaldehyde and paraffin embedded, sectioned and stained for mouse galectin-3, 
collagen and α-SMA as a marker of fibrosis.  Images were acquired using a Leica 
DM LB light microscope, Leica DC 300 digital camera and Leica IM50 software. 
 Sections were stained for mouse galectin-3 using the anti-mouse Mac-2-FITC 
antibody (clone M3/38) at 1:200 dilution.  After chronic CCl4 treatment, increased 
galectin-3 expression was observed in the periportal areas and dense staining was 
noted at the periphery of the inflamed damaged areas.  In liver from wild type control 
animals, galectin-3 was only expressed in bile duct epithelia and Kupffer cells in the 
liver (figure 4.4A).  Figure 4.4A inset image represents secondary only control 
staining (rabbit anti-FITC) of this tissue section.  Real-time RT-PCR for galectin-3 
was performed on RNA extracted from whole liver and galectin-3 protein expression 
was measured by Western blotting.  Both galectin-3 mRNA levels and protein 
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expression were increased with the development of hepatic fibrosis in the CCl4-
treated animals compared with control (figure 4.4D and E). 
 Collagen fibres on liver sections from wild type and galectin-3-/- mice treated 
chronically with CCl4 were stained with PSR as a marker of fibrosis.  Staining of 
wild type livers demonstrated the presence of hepatic collagen with the same 
distribution as galectin-3 (figure 4.4B).  Collagen was present in the periportal areas 
and areas of bridging fibrosis in wild type livers compared to significantly less 
collagen deposition in the galectin-3-/- livers.  Staining was quantified using Openlab 
software for digital image analysis (figure 4.4F).  Details of the quantitation are 
given in the Materials and Methods Chapter.  Procollagen (I) mRNA expression was 
analysed by real-time RT-PCR and was significantly decreased in the livers from 
galectin-3-/- compared to wild type mice after chronic CCl4 treatment (figure 4.4G).  
This result suggested that galectin-3 is associated with hepatic collagen deposition 
during liver injury.  It was therefore important to examine the mechanism underlying 
this important observation. 
 Following liver injury, HSCs activate to a proliferative, fibrogenic and 
contractile myofibroblast with increased expression of α-SMA, a widely accepted 
marker of myofibroblast activation (Friedman, 2000; Bataller and Brenner, 2005) in 
vitro and in vivo.  After 8 weeks of CCl4 treatment, liver sections were stained for α-
SMA using the anti-α-SMA-FITC antibody (clone 1A4) at 1:15,000 dilution.  α-
SMA expression was significantly increased in wild type compared to galectin-3-/- 
liver sections with the same spatial and temporal distribution as galectin-3 and 
collagen expression (figure 4.4C).  Figure 4.4C inset image represents secondary 
only control staining (rabbit anti-FITC) of this tissue section.  Staining was 
quantified using digital image analysis (figure 4.4H).  α-SMA mRNA expression was 
analysed by real-time RT-PCR and was significantly decreased in the livers from 
galectin-3-/- compared to wild type mice after chronic CCl4 treatment (figure 4.4I).  
This decrease in α-SMA mRNA expression was paralleled by a decrease in hepatic 
α-SMA protein expression assessed by Western blot analysis of whole liver tissue 
(figure 4.4I inset).  These data indicate that galectin-3 mediated activation of hepatic 
stellate cells in vivo is a central mechanism underlying hepatic fibrosis. 
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Figure 4.4 – Galectin-3 plays a critical role in liver fibrosis.
Figure 4.4 (A-C)
Mice were treated with olive oil (control) or CCl4 i.p. twice weekly for 8 weeks 
(n = 6 mice in each group). (A) Galectin-3 expression in control (Right) and after 
chronic CCl4 treatment (Left) in WT mouse liver. (Scale bar: 400µm). Inset 
image demonstrates secondary antibody only control staining. (B) Collagen 
staining with PSR of liver tissue after chronic CCl4 treatment of WT and galectin-
3-/- mice. (Scale bar: 200µm). (C) α-SMA staining of liver tissue after chronic 
CCl4 treatment of WT and galectin-3-/- mice. (Scale bar: 200µm). Inset image 






















Figure 4.4 (D, E)
(D) Real-time RT-PCR quantitation of galectin-3 expression (normalised to 18S) 
in total RNA extracts from livers from control (olive oil vehicle) and chronic 
CCl4 treated WT mice. ***, P < 0.0001 compared to control. Real-time RT-PCR 
results are expressed as fold change relative to control. (E) Representative 






















Figure 4.4 (F, G)
(F) Digital image analysis quantitation of collagen staining. *, P < 0.05 compared 
to WT CCl4. (G) Real-time RT-PCR quantitation of procollagen (I) expression 
(normalised to 18S) in total RNA extracts from livers from control (olive oil 
vehicle) and chronic CCl4 treated WT and galectin-3-/- mice. *, P < 0.05 
compared to WT CCl4. Real-time RT-PCR results are expressed as fold change 






















































Figure 4.4 (H, I)
(H) Digital image analysis quantitation of α-SMA staining. **, P < 0.01 
compared to WT CCl4. (I) Real-time RT-PCR quantitation of α-SMA expression 
(normalised to 18S) in total RNA extracts from livers from control (olive oil 
vehicle) and chronic CCl4 treated WT and galectin-3-/- mice. *, P < 0.05 
compared to WT CCl4. Real-time RT-PCR results are expressed as fold change 
relative to WT control. (I Inset) Representative Western blots of α-SMA and actin











4.2.4 Myofibroblast activation is galectin-3 dependent 
 HSC activation to a myofibroblast phenotype is a critical event in ECM 
deposition and cirrhosis (Friedman, 2000; Bataller and Brenner, 2005).  Mouse HSCs 
were isolated from wild type and galectin-3-/- livers as described in Materials and 
Methods.  HSCs were plated at 1x106 cells/well in a 6-well plate, in the presence of 
16% FCS and lysed at 0, 2, 7 and 10 days.  Galectin-3 protein expression was 
upregulated during myofibroblast activation in vitro on tissue culture plastic in 
primary mouse HSCs (figure 4.5A).  This well established in vitro method of HSC 
activation closely models in vivo myofibroblast activation (Issa et al., 2004; Iredale 
et al., 1998) and has been used extensively to model and examine changes that take 
place during the phenotype switch of fibroblasts to ECM-secreting contractile 
myofibroblasts.  After 7 days in vitro culture, α-SMA protein expression was 
significantly less in galectin-3-/- HSCs compared with wild type HSCs (figure 4.5B).  
Addition of exogenous recombinant murine galectin-3 to galectin-3-/- HSCs in vitro 
for 48 hours reversed the galectin-3-/- phenotype resulting in increased α-SMA 
expression (figure 4.5C).  Rescue of the pro-fibrotic phenotype by exogenous 
galectin-3 was confirmed with real-time RT-PCR, which demonstrated upregulation 
of procollagen (I) expression (figure 4.5D).  When plated on tissue culture plastic in 
vitro wild type primary murine HSCs (O) proliferate faster than galectin-3-/- HSCs 
( ) as judged by 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide 
(MTT) assay.  This defect in proliferation of the galectin-3-/- HSCs could be restored 
by the addition of recombinant murine galectin-3 ( ) (figure 4.5E).  Galectin-3-/- 
HSCs were seeded in immunofluorescence chambers at 50,000 cells per well in 
complete media and cultured for 4 days.  HSCs were incubated 30µg/ml recombinant 
mouse galectin-3 for 10, 30 or 60 minutes and immunofluorescence for galectin-3 
using 1:20 anti-galectin-3 (clone A3A12) antibody, was performed.  Figure 4.5F 
shows that galectin-3 is rapidly internalised (within 10 minutes) when added to 
galectin-3-/- HSCs and very little galectin-3 accumulates at the membrane. 
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Figure 4.5 (A-C)
(A) Western blot analysis of galectin-3 expression in primary mouse HSCs during 
transition from the quiescent to the activated phenotype on tissue culture plastic 
over 10 days in culture. (B) Western blot analysis of α-SMA and actin expression 
in WT and galectin-3-/- primary mouse HSCs cultured on tissue culture plastic for 
7 days in 16% FCS. (C) Western blot analysis of α-SMA in WT and galectin-3-/
primary mouse HSCs (day 4) after a 48 h treatment of recombinant mouse 
galectin-3 (30µg/ml) to galectin-3-/- HSCs in 16% FCS.


















(D) Real-time RT-PCR quantitation of procollagen (I) expression (normalised to 
18S) in WT and galectin-3-/- primary mouse HSCs (day 4) after 48 h treatment of 
recombinant mouse galectin-3 (30µg/ml) in 16% FCS (n = 3) *, P < 0.05 
compared to untreated galectin-3-/- HSCs. (E) Cell growth of WT ( ), galectin-3-
/- ( ), and galectin-3-/- HSCs plus recombinant mouse galectin-3 (30µg/ml) ( ) 
measured by MTT assay (n = 3) *, P < 0.05 compared to untreated galectin-3-/-
HSCs. P = 0.09 (ns), 0.20 (ns) and 0.17 (ns) for days 1, 2 and 3 respectively. (F) 
Internalisation of recombinant mouse galectin-3 by galectin-3-/- primary mouse 
HSCs. Cells were stained with DAPI (blue) and galectin-3 antibody (green). (i) 




































 A rationally designed small interfering RNA (siRNA) pool targeting galectin-
3 mRNA was used to inhibit galectin-3 expression in wild type primary murine 
HSCs.  All siRNA was purchased from the Dharmacon siGENOME Collection of 
pre-designed siRNA reagents.  siGENOME siRNA reagents are designed using 
Dharmacon’s SMARTselection siRNA design algorithm to reduce off-target effects 
and decrease false positives.   
 HSCs were isolated, activated on tissue culture plastic for 7 days and treated 
with PBS, liposome formulated non-targeted control duplex or 250nM liposome 
formulated galectin-3 siRNA duplex 1-4 using Oligofectamine.  All four duplexes 
cause over 95% knockdown of galectin-3 protein expression 96 hours post-
transfection with duplexes 1 and 2 causing the greatest knockdown (figure 4.6A).  
Subsequent experiments were carried out using mouse galectin-3 siRNA duplex 1.  
96 hours post transfection with galectin-3 siRNA, RNA was extracted using the 
Qiagen RNeasy Mini Kit, reverse transcribed to complementary DNA (cDNA) and 
processed using quantitative real-time RT-PCR.  Galectin-3 siRNA treatment 
reduced galectin-3 mRNA expression 10-fold as compared with non-targetting 
siRNA or mock transfection (figure 4.6B).  siRNA knockdown of galectin-3 in HSCs 
did not affect cell viability assessed by trypan blue exclusion.  This marked 
inhibition of galectin-3 expression resulted in a significant reduction in both α-SMA 
and procollagen (I) mRNA expression assessed by real-time RT-PCR (figure 4.6C 
and D respectively).  Western blot analysis confirmed almost complete inhibition of 
galectin-3 expression and a reduction in α-SMA protein expression after targeted 
siRNA treatment relative to control treatment (figure 4.6E).  This data supports the 
premise that galectin-3 expression is required for HSC differentiation into a 
myofibroblast phenotype. 
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Figure 4.6 – Galectin-3 siRNA inhibits myofibroblast 
activation and procollagen (I) expression in HSCs. 
Figure 4.6 (A)
(A) HSCs were transfected with 250nM galectin-3 siRNA duplexes (1-4 as 
indicated) as described in Materials and Methods. 96h post-transfection cell 










Real-time RT-PCR quantitation of (B) galectin-3, (C) α-SMA, and (D) 
procollagen (I) expression (normalised to 18S) in primary mouse HSCs after 96 h 
treatment with PBS, control duplex (CD) or 250nM mouse galectin-3 siRNA
duplex 1 (n = 3). ***, P < 0.0001 compared to PBS. Real-time RT-PCR results 
are expressed as fold change relative to CD. (E) Western blot analysis of 
galectin-3, α-SMA and actin expression in primary mouse HSCs 96 h after 



















































4.2.5 Disruption of the galectin-3 gene does not affect TGF-β 
expression and Smad signalling 
 TGF-β is a major profibrogenic cytokine involved in the pathogenesis of 
fibrosis in many different organ systems (Leask and Abraham, 2004; Uemura et al., 
2005; Qi et al., 1999).  However, mechanisms of tissue fibrosis also exist that are 
TGF-β independent both in the liver and other organs (Kaviratne et al., 2004; 
Rodriguez-Vita et al., 2005).   
 The tissue expression of TGF-β mRNA was markedly elevated as judged by 
quantitative real-time RT-PCR in whole liver samples following chronic CCl4 liver 
injury compared with control.  However, there was no significant difference in 
hepatic TGF-β mRNA expression between wild type and galectin-3-/- mice in this 
model of liver fibrosis (figure 4.7A).  A mouse TGF-β ELISA (R&D) was performed 
to determine the concentration of TGF-β in supernatants recovered from day 4 wild 
type and galectin-3-/- HSCs cultured for 24 hours in serum-free media (figure 4.7B).  
This assay demonstrated no difference in the levels of TGF-β expression from wild 
type and galectin-3-/- HSCs in tissue culture.  Thus disruption of the galectin-3 gene 
blocks fibrosis despite similar expression levels of TGF-β.  In the presence of TGF-β 
ligand, the receptor-activated Smad family of transcriptional activators, Smad-2 and -
3, are phosphorylated directly by the TGF-β receptor I kinase (Heldin et al., 1997; 
Roberts, 1999).  Smad-2 and Smad-3 activation in wild type and galectin-3-/- HSCs 
treated with TGF-β were analysed by Western blotting for pSmad-2 and pSmad-3 
using either the polyclonal anti-pSmad2/3 or anti-pSmad-3 antibody respectively.  
1x107 HSCs were seeded onto tissue culture plastic for 4 days, quiesced in serum-
free media for 24 hours and incubated with increasing concentrations of TGF-β for 
60 minutes.  TGF-β stimulated a similar increase in Smad-2 and Smad-3 
phosphorylation in wild type and galectin-3-/- HSCs (figure 4.7C) indicating that the 
pro-fibrotic responses were not due to galectin-3 signalling via the TGF-β/Smad 
pathway. 
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Figure 4.7 – Galectin-3 regulates myofibroblast activation 
and hepatic fibrosis despite similar levels of TGF-β
expression and signalling.
Figure 4.7 (A,B)
(A) Real-time RT-PCR quantitation of TGF-β expression (normalised to 18S) in 
total RNA extracts from livers from control (olive oil vehicle) and chronic (8 
weeks) CCl4-treated WT and galectin-3-/- mice (n=6 mice in each group). Real-
time RT-PCR results are expressed as fold change relative to WT control. P = 
0.37 (ns). (B) TGF-β concentration measured by ELISA in supernatants 
recovered from day 4 WT and galectin-3-/- HSCs cultured for 24 h in serum-free 






























Figure 4.7 (C, D)
(C) HSCs (day 4) were quiesced in serum-free media for 24 h and stimulated with 
increasing concentrations of TGF-β for 60 min. Lysates were Western blotted for 
phosphorylated Smad-2 (pSmad-2) and phosphorylated Smad-3 (pSmad-3) as a 
measure of Smad activation. (D) Western blot analysis of α-SMA expression in 
HSCs (day 4) quiesced in serum-free media for 24 h and stimulated with 5ng/ml 













Figure 4.7 (E, F)
(E and F) Real-time RT-PCR quantitation of (E) α-SMA expression and (F) 
procollagen (I) expression (normalised to 18S) in HSCs cultured in the presence 
of 5ng/ml TGF-β for 48 h (n = 3). Real-time RT-PCR results are expressed as 






























(G) Indirect immunofluoresence for α-SMA expression (green) in HSCs (day 4) 
quiesced in serum-free media for 24 h and stimulated with 5ng/ml TGF-β or 




















Figure 4.7 (H - J)
(H) Western blot of α-SMA expression in lysates from HSCs (day 4) quiesced in 
serum-free media for 24 h and stimulated with 5ng/ml TGF-β or TGF-β plus 
30µg/ml recombinant mouse galectin-3 for 48 h. Real-time RT-PCR quantitation
of (I) α-SMA or (J) procollagen (I) expression (normalised to 18S) in HSCs
treated as in (H). ***, P < 0.0001 compared to galectin-3-/- plus rGal-3 (n = 3). 
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 Previous data indicated that addition of exogenous galectin-3, in the presence 
of 16% foetal calf serum (FCS), to galectin-3-/- HSCs induced expression of α-SMA 
and procollagen (I) (figure 4.5C and D respectively).  To address specifically the 
contribution of TGF-β to this observation the experiments were repeated in serum-
free media augmented with 5ng/ml recombinant mouse TGF-β.  The galectin-3-/- 
HSCs still exhibited a reduced activation profile in the presence of TGF-β compared 
with wild type HSCs, as demonstrated by Western blotting for α-SMA (figure 4.7D) 
and real-time RT-PCR quantitation of α-SMA (figure 4.7E) and procollagen (I) 
(figure 4.7F).  Incubating with 30µg/ml exogenous recombinant galectin-3 for 48 
hours rescued this defect in galectin-3-/- HSCs stimulating an activated wild type 
morphology and α-SMA filament organisation (figure 4.7G).  Figure 4.7G (ii) was 
taken at longer exposure to show the defect in filament organisation of galectin-3-/- 
HSCs, however, overall α-SMA staining was reduced as confirmed by Western 
blotting for α-SMA (figure 4.7H) and real-time RT-PCR quantitation of mRNA 
transcripts for α-SMA (figure 4.7I) and procollagen (I) (figure 4.7J).  Although TGF-
β/Smad signalling remains unaffected in galectin-3-/- HSCs, it isn’t enough to cause 
HSC activation to the myofibroblast phenotype.  Although this work demonstrates 
that galectin-3 is essential for TGF-β driven myofibroblast activation, more work 
needs to be carried out to determine whether galectin-3 signalling and induction of 
myofibroblast activation is dependent upon TGF-β.  Until then I can hypothesise but 
not conclude that galectin-3-induced myofibroblast activation occurs through a TGF-
β-independent mechanism. 
 
4.2.6 Galectin-3 does not signal via the MEK/ERK pathway to exert its 
effects in this model of liver fibrosis 
 Platelet-derived growth factor (PDGF) is a key mitogen for fibroblasts, 
smooth muscle cells and other cells (Maeda et al., 2003; Heldin and Westermark, 
1999; Marra et al., 1995).  There are various isoforms including PDGF-BB (PDGF 
with a homodimer of B chains) which has been shown to induce HSC activation and 
migration in vitro (Ikeda et al., 1999).  One signalling pathway of PDGF via its 
receptor results in a kinase cascade triggering the activation of Raf-1, MEK and 
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ERK.  ERK has been shown to be important in the activation and proliferation of 
HSCs and is activated as a result of liver damage in vivo (Marra et al., 1999).  It was 
therefore important to investigate whether galectin-3 utilised this pathway to exert its 
effects in this model of liver fibrosis. 
 Maeda et al. (Maeda et al., 2003) previously suggested that galectin-3 
dependent ERK-1/2 activation in HSCs was Protein Kinase C (PKC) dependent 
using a pharmacological inhibitor of PKC.  However, Western blotting using anti-
pPKC and anti-pERK1/2 (clone MAPK-YT) antibodies demonstrated no difference 
in the activation of PKC and ERK1/2 in response to a 10 minute incubation with 




Western blot of ERK-1/2 and PKC activation in response to 10 min incubation 









Figure 4.8 – Galectin-3 does not signal via the MEK/ERK 
pathway to exert its effects in this model of liver fibrosis.
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4.2.7 Galectin-3 plays a critical role in kidney fibrosis 
 The development of renal fibrosis following UUO was then characterised as 
an extension of the above work.  The role of galectin-3 during renal fibrosis gave 
similar results as described below.   
 Following obstruction, kidneys were removed, fixed in methyl carnoys 
reagent (60% methanol, 30% chloroform, 10% glacial acetic acid) for assessment of 
macrophage infiltration or formalin for immunohistochemistry.  Samples were also 
snap frozen in liquid nitrogen for real-time RT-PCR analysis. 
 Hematoxylin and eosin stain (H&E) is a general purpose stain particularly 
used to detect tissue damage and inflammation.  Hematoxylin is a basic dye and 
binds the acidic parts of the cell, i.e. the nucleus, blue.  Eosin is an acidic dye and 
stains the basic parts of the cell, i.e. the cytoplasm, pink-orange.  Kidney 
macrophages were stained with F4/80 (clone CI: A3-1).  Obstructed kidneys from 
wild type and galectin-3-/- mice demonstrated equivalent tissue injury (figure 4.9A) 
and macrophage recruitment (figure 4.9B and C).  Despite this, galectin-3-/- mice 
demonstrated decreased fibrosis, collagen deposition and myofibroblast activation 
following UUO (figure 4.10). Figure 4.9B inset images represent secondary only 
control staining (biotinylated anti-rat from the Vector quick kit) of these tissue 
sections. 
 Collagen fibres on obstructed kidney sections from wild type and galectin-3-/- 
mice were stained red with PSR and α-SMA was stained using mouse monoclonal 
anti-α-SMA-FITC antibody (clone 1A4).  Denser collagen and α-SMA staining was 
observed in kidney sections from wild type compared to galectin-3-/- mice (figure 
4.10A and B).  Figure 4.10B inset image represents secondary only control staining 
(rabbit anti-FITC) of this tissue section.  Staining was quantified using Openlab 
software for digital image analysis (figure 4.10C and D).  Procollagen (I) and α-SMA 
mRNA expression was analysed by real-time RT-PCR and both were significantly 
decreased in kidneys from galectin-3-/- compared to wild type mice after UUO 
(figure 4.10E and F).  This result suggested that galectin-3 also regulates collagen 







Figure 4.9 – Disruption of the galectin-3 gene does not affect 
macrophage recruitment following UUO.
Figure 4.9 (A, B)
(A) Haematoxylin and Eosin (H&E) staining of kidneys from WT and galectin-3-
/- mice 3 days following sham operation or UUO. (B) Renal macrophages were 
stained with F4/80. (Scale bar: 100µm). Inset images demonstrate secondary 





























(C) WT (white bars) and galectin-3-/- (black bars) kidneys from day 3, 7 and 14 
days post-UUO were fixed and stained for F4/80.  Numbers of F4/80 positive
macrophages per high power field (x5 from each section) were counted. (n = 3 





Figure 4.10 (A, B)
Mice underwent control (sham operation) or UUO and were sacrificed at 7 days 
(n = 6 mice in each group) (A) Renal collagen deposition in WT and galectin-3-/-
kidneys after UUO was examined by PSR staining. (B) α-SMA staining in WT 
and galectin-3-/- kidneys after UUO. (Scale bar: 100µm). Inset image 
demonstrates secondary antibody only control staining.






























































Digital image analysis quantitation of collagen (C) and α-SMA (D) staining. *, P 
< 0.05 compared to WT UUO. (E) Real-time RT-PCR quantitation of procollagen
(I) expresion (normalised to 18S) in total RNA extracts from control kidneys and 
obstructed kidneys from WT and galectin-3-/- mice. *, P <  0.05 compared to WT 
UUO. (F) Real-time RT-PCR quantitation of α-SMA expression (normalised to 
18S) in total RNA extracts from control kidneys and obstructed kidneys from WT 
and galectin-3-/- mice. **, P < 0.01 compared to WT UUO. Real-time RT-PCR 
results are expressed as fold change relative to WT control.
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4.3 Discussion 
 This study has shown a fundamental role for galectin-3 in the regulation of 
HSC activation in vitro and in vivo, thereby identifying galectin-3 as a potential 
therapeutic target in the treatment of liver fibrosis.  This work has also shown that 
this may be a pan-organ effect as shown by a reduction of renal fibrosis following 
UUO in galectin-3 deficient mice. 
 Human biopsy data demonstrated that galectin-3 expression is increased in 
human liver fibrosis secondary to diverse types of injury including viral-mediated 
(Hepatitis B and C) and alcohol-induced.  This suggested that galectin-3 upregulation 
is a basic response within the liver regardless of the initiating agent or disease 
process.  The pattern of galectin-3 staining observed in the human tissue was 
different from the distribution observed in the animal models.  This difference related 
to the chronicity and intensity of the disease processes.  Human tissue was taken 
from patients with advanced cirrhosis following years (in many cases decades) of 
chronic injury and fibrosis.  In the mouse and rat models a much shorter time-course 
of injury (8 and 12 weeks respectively) leading to liver fibrosis was examined. 
 The experimental model of liver fibrosis showed a very close spatial and 
temporal relationship between galectin-3 expression, myofibroblast activation and 
collagen deposition.  Galectin-3 can be considered an immediate early gene and is 
upregulated rapidly in response to tissue injury (Kadrofske et al., 1998; Chiariotti et 
al., 2004).  These results demonstrated that spontaneous HSC activation occured in 
wild type but not galectin-3-/- HSCs and that this defect could be overcome by 
exogenous addition of galectin-3 (which was rapidly internalised by HSCs).  
Spontaneous activation of wild type HSCs was blocked by siRNA knockdown of 
galectin-3 expression.  There is perhaps a galectin-3 autocrine stimulation of HSCs 
causing HSC activation in vitro.  However, the peri-sinusoidal orientation and long 
cytoplasmic processes of HSCs facilitate their interactions with neighboring cell 
types including other non-parenchymal cells such as kupffer cells and sinusoidal 
endothelial cells and liver parenchymal cells (hepatocytes).  This may regulate HSC 
phenotype and function by facilitating both autocrine and paracrine activation of 
myofibroblasts by galectin-3 via cell-cell contacts, cell-matrix contacts and via 
soluble factors.  Furthermore, within the injured liver, injured epithelium 
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(hepatocytes) upregulate galectin-3 expression following injury and both recruited 
and resident tissue macrophages are abundant sources of galectin-3 (Sato and 
Hughes, 1994).  Thus both autocrine and paracrine galectin-3 stimulated HSC 
activation may exist during liver inflammation and fibrosis in vivo. 
 TGF-β is a major pro-fibrogenic cytokine and is a key mediator of fibrosis in 
many different organs (Leask and Abraham, 2004).  TGF-β mRNA expression was 
markedly elevated following hepatic injury, however expression of TGF-β was 
similar in whole liver homogenates from fibrotic liver in wild type and galectin-3-/- 
mice.  Secretion of TGF-β was the same in wild type and galectin-3-/- HSCs, and 
Smad-2 and Smad-3 signalling in HSCs was similar between the two genotypes 
when stimulated with TGF-β.  However, despite similar levels of TGF-β and intact 
TGF-β signalling pathways, the absence of galectin-3 markedly inhibited the fibrotic 
phenotype in vitro and in vivo in the animal model.  This would suggest that TGF-β 
stimulated HSC activation and procollagen production requires galectin-3. 
 Galectin-3 can form pentamers in the presence of multivalent ligands, cross-
linking glycoproteins at the cell membrane (Ahmad et al., 2004).  Mgat5-modified N-
glycans on cell-surface receptors such as the epidermal growth factor receptor can be 
crosslinked by galectin-3 (Partridge et al., 2004) thus regulating receptor cell surface 
expression and activity leading to effects on intracellular signalling.  The time-course 
experiments examining trafficking of exogenous recombinant galectin-3 added to 
primary HSCs suggest that galectin-3 is rapidly internalised.  Furthermore, siRNA 
mediated knockdown of galectin-3 inhibited myofibroblast activation and 
procollagen expression.  Intracellularly, galectin-3 can shuttle between the nucleus 
and the cytoplasm (Davidson et al., 2002) and is involved in fundamental processes 
such as pre-mRNA splicing (Dagher et al., 1995; Wang et al., 2004), cell-cycle 
progression (Kim et al., 1999; Lin et al., 2002), proliferation (Moutsatsos et al., 1987; 
Inohara et al., 1998; Shimura et al., 2004), and apoptosis (Yang et al., 1996; Akahani 
et al., 1997; Honjo et al., 2001; Yu et al., 2002) mainly through intracellular protein-
protein interactions rather than lectin-carbohydrate interactions.  However the precise 
mechanisms by which galectin-3 regulates these intracellular processes have still to 
be defined.  Recently it has been shown that TGF-β can induce renal fibrosis in a 
Smad-2/3-independent fashion (Moustakas and Heldin, 2005; Wang et al., 2005) and 
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activates additional signalling molecules such as p38 (Tsukada et al., 2005), bcr-abl 
(Wang et al., 2005) and PAK2 (Wilkes et al., 2003).  The present work is consistent 
with the hypothesis that TGF-β induced fibrosis requires galectin-3 and includes a 
mechanism that is independent of Smad-2 and Smad-3.  However, to fully test this 
hypothesis, more work needs to be done to ascertain that galectin-3-induced 
myofibroblast activation occurs through a TGF-β-independent mechanism. 
 
 In addition to this work carried out using the model of liver fibrosis, the UUO 
model of renal fibrosis demonstrated similar in vivo results.  As with the liver, 
galectin-3-/- mice demonstrated reduced renal fibrosis following UUO with reduced 
fibroblast activation as demonstrated by diminished α-SMA and procollagen (I) 
staining and mRNA levels despite comparable recruitment of macrophages.  This 
suggests that galectin-3 plays an important role in the progression of fibrosis in 
multiple organ systems. 
 RNA interference allows in-depth study of the molecular mechanisms of 
disease through specific gene target inhibition.  Furthermore, siRNAs hold direct 
therapeutic promise, as agents capable of attenuating the expression of disease-
causing genes (Soutschek et al., 2004).  siRNA duplexes were used to examine the 
role of galectin-3 in myofibroblast activation in vitro. siRNA silencing of galectin-3 
expression in mouse HSCs resulted in inhibition of myofibroblast activation and 
procollagen (I) expression.  Strategies to knockdown expression of galectin-3 in the 
liver may lead to the development of novel anti-fibrotic therapies. 
 Additional work from this laboratory has shown that administration of 
galectin-3 siRNA via the portal vein in vivo reduced HSC activation in response to 
CCL4 (Henderson et al., 2006).  In addition, preliminary work by N. Henderson has 
demonstrated a decrease in in vivo fibrosis following UUO by administration of 
galectin-3 siRNA via the renal artery (unpublished). 
 118
Chapter 5 
Regulation of alternative macrophage activation by galectin-3 
 
5.1 Introduction 
 Macrophages display broad phenotypic heterogeneity depending on their 
microenvironment (Gordon, 2003; Stout et al., 2005; Gordon et al., 1992).  During an 
inflammatory response, the microenvironment changes from an initial pro-
inflammatory/cytotoxic environment to an anti-inflammatory/tissue regenerative 
environment and the macrophage adapts to its surroundings by changing its 
functional phenotype.  The plasticity of macrophages enables the activation status to 
be skewed to an M1 or an M2 phenotype with the addition of Th1 or Th2 cytokines 
respectively.   
 The initial inflammatory response is predominantly mediated by classically 
activated (M1 polarised) macrophages, which eradicate invading organisms and 
tumour cells (Mantovani et al., 2002; Munder et al., 1998).  The pro-inflammatory 
and cytotoxic activities of classically activated M1 macrophages are enhanced in the 
presence of microbial agents endotoxin (Lipopolysaccharide - LPS) and/or Th1 
cytokines such as Interferon-γ (IFNγ) or Interleukin-12 (IL-12) (Holscher et al., 
2001; Louis et al., 1998). Classical activation by IFNγ in particular is associated with 
nitric oxide synthetase 2 (NOS2) expression and the production of large amounts of 
nitric oxide and pro-inflammatory cytokines including Tumour necrosis factor-α 
(TNF-α) and IL-6 (Munder et al., 1998; Munder et al., 1999; Welch et al., 2002).  
Upon classical activation, macrophages release proinflammatory cytokines, and the 
metabolism of L-arginine is driven towards the production of nitrite via the enzyme 
NOS2 (Hesse et al., 2001). 
 In contrast, the resolution phase of inflammation is driven by alternatively 
activated (M2 polarised) macrophages, which are hypo-responsive to pro-
inflammatory stimuli.  Macrophages undergo alternative activation when stimulated 
with the Th2 cytokines, IL-4 or IL-13 (Gordon, 2003; Munder et al., 1999; Hesse et 
al., 2001).  Treatment of murine macrophages with IL-4 or IL-13 causes upregulation 
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of mannose receptor (Stein et al., 1992), arginase-1 (Hesse et al., 2001), YM-1 
(chitinase-like lectin) (Nair et al., 2005; Raes et al., 2002) and FIZZ-1 (resistin-like 
secreted protein) expression (Herbert et al., 2004; Nair et al., 2003).  Upon 
alternative activation, the metabolism of L-arginine is driven towards the production 
of L-ornithine and pro-fibrotic products via the enzyme arginase-1 (Hesse et al., 
2001) (Figure 1.4). 
 Initially it was believed that IL-4 and IL-13 resulted in a deactivated 
phenotype similar to that seen with IL-10, causing deactivation of the respiratory 
burst and of inflammatory cytokine production, particularly TNF-α, facilitating the 
elimination of infectious organisms with minimal damage to host tissues (Moore et 
al., 2001).  However, IL-10 acts on a distinct plasma membrane receptor to IL-4 and 
IL-13 and the regulatory role of IL-4 and IL-13 on immune responses appear to be 
more complex than first thought (D'Andrea et al., 1995; Gordon, 2003). 
 Alternative (M2) macrophage activation has been implicated in diverse 
disease pathologies in the host response to parasitic infection, asthma, wound repair, 
atheromatous plaques and tumour-associated macrophages (Herbert et al., 2004; Nair 
et al., 2003; Raes et al., 2005; Wynn, 2004; Sica et al., 2006).  Furthermore, the 
alternatively activated (M2) macrophage plays an important role in certain fibrotic 
diseases (Wynn, 2004) such as experimental silicosis (Misson et al., 2004), 
herpesvirus-induced lung fibrosis (Mora et al., 2006) and hepatic fibrosis (Hesse et 
al., 2001; Chiaramonte et al., 2001; Reiman et al., 2006).  Inhibitors of alternative 
macrophage activation may restrict fibrosis in granuloma formation (Hesse et al., 
2001) and enhance host immunity against cancers (Sica et al., 2006).  In disease 
states where alternatively activated macrophages limit tissue injury or promote 
repair, it might be helpful to augment their activity, for example in stabilising 
atherosclerotic plaques.  In order to exploit M1 and M2 macrophages for future anti-
inflammatory and anti-cancer therapies it is important to understand the mechanism 
and extracellular ligands that determine M1 and M2 macrophage programming. 
 Galectin-3 is highly expressed and secreted by macrophages and recent data 
suggests that galectin-3 plays a significant role in many facets of macrophage 
biology.  Galectin-3 is up-regulated when monocytes differentiate into macrophages 
(Liu et al., 1995) and down-regulated when macrophages differentiate into 
 120
dendriticcells (Dietz et al., 2000).  Galectin-3 also promotes monocyte-monocyte 
interactions that ultimately lead to polykaryon (multinucleated giant cell) formation, 
a phenotype associated with chronic inflammatory and fibrotic diseases (Okamoto et 
al., 2003).  Previous work detailed in chapter 4 of this thesis has demonstrated that 
mice deficient in galectin-3 exhibit reduced hepatic fibrosis following chronic 
administration of carbon tetrachloride (CCl4) (Henderson et al., 2006).  CD98 is a 
disulfide-linked 125 kDa heterodimeric type II transmembrane glycoprotein 
composed of a glycosylated 85 kDa heavy chain (designated CD98) and a 
nonglycosylated 40-kDa light chain (Verrey et al., 2004).  CD98 is highly expressed 
on macrophages and has been shown to be a receptor for galectin-3 (Dong and 
Hughes, 1997; Hughes, 2001; Dong and Hughes, 1996).  Furthermore crosslinking 
CD98 with anti-CD98 monoclonal antibodies promotes polykaryon formation 
(Tajima et al., 1999).  Therefore modulation of galectin-3 expression and interaction 
with CD98 during macrophage differentiation may be important in the regulation of 
macrophage plasticity and control of macrophage fate. 
 Chapter 4 of this thesis described galectin-3 playing a critical role during 
fibrosis, stimulating myofibroblast activation, resulting in collagen production and 
the enhancement of fibrosis (Henderson et al., 2006).  As highlighted above, 
alternatively activated macrophages have been implicated as important augmenters 
of fibrosis.  It was therefore hypothesised that galectin-3 is involved in alternative 
macrophage activation thus contributing to the progression of fibrosis.  This chapter 
aims to investigate the importance of galectin-3 in alternative macrophage activation 
and presents preliminary work investigating the role of the alternatively activated 
macrophage during the unilateral ureteric obstruction (UUO) model of renal fibrosis. 
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5.2 Results. 
5.2.1 Disruption of the galectin-3 gene in macrophages causes a 
specific defect in alternative activation of in vitro and in vivo 
differentiated macrophages 
 To investigate the role of galectin-3 in macrophage activation, in vitro 
derived bone marrow derived macrophages (BMDMs) from wild type and galectin-3-
/- mice were used.  BMDMs were flushed from the femurs and tibias of wild type and 
galectin-3-/- mice and matured for 7 days in media containing 10% L929 conditioned 
media as a source of granulocyte-macrophage colony-stimulating factor (GMCSF).  
Maturity was examined by dual immunofluorescence staining for CD11b and F4/80 
and analysed by flow cytometry.  Macrophages were incubated with a 1:150 dilution 
of CD11b-PE antibody (clone M1/70) and a 1:25 dilution of F4/80-FITC antibody 
(clone CI:A3-1) for 30 minutes at room temperature in the dark.  Samples were 
washed and a 1:10,000 dilution of the vital dye ToPro-3 was added to each tube just 
prior to flow cytometry analysis.  Wild type and galectin-3-/- BMDM matured to 
equal extents as measured by F4/80 and CD11b expression (figure 5.1A) and were 
over 95% viable (figure 5.1B). 
 Classical macrophage (M1) activation was assessed through the addition of 
IFNγ/LPS and alternative (M2) activation measured via the addition of IL-4 or IL-13.  
The following methods were performed to determine the macrophage activation 
status.  Complete methods are given in the Materials and Methods chapter.  The pro-
inflammatory cytokines TNF-α and IL-6 were measured using the cytometric bead 
array (CBA) mouse inflammation kit from BD Biosciences.  Nitric oxide (NO) 
production was measured using the Griess reaction first described in 1879 (Griess P, 
1879).  Nitric oxide is very unstable and rapidly oxidises to nitrite (NO2) and nitrate 
(NO3) by oxygen.  The Griess reagent reacts with the stable oxidation product nitrite 
to produce an intense purple colour which can be measured at 540nm.  Arginase-1 
activity was measured by activating the arginase-1 in the cell lysates (prepared using 
lysis buffer containing EDTA-free protease inhibitors) with manganese chloride and 















Figure 5.1 – Disruption of the galectin-3 gene does not affect 
BMDM maturation.
Figure 5.1 (A, B)
(A) FACS characterisation of WT and galectin-3-/- bone marrow-derived 
macrophages (BMDMs) matured for 7 days using 1:25 dilution of F4/80-FITC 
and 1:150 dilution of CD11b-PE antibodies added for 30 min at room 
temperature in the dark. (B) BMDM viability was measured by topro-3 exclusion. 







An acid mixture was added to stop the reaction and the urea formed was quantified 
after the addition of α-isonitrosopropiophenone (ISPF). 
 Following treatment with 100U/ml IFNγ and 100ng/ml LPS, wild type and 
galectin-3-/- macrophages produced similar levels of the proinflammatory cytokines 
TNF-α and IL-6 (figure 5.2A and B) indicating equal ability to classically activate.  
Incubation with 10ng/ml IL-4 or IL-13 alone had no effect on cytokine release 
(figure 5.2A and B) but significantly reduced LPS-stimulated TNF-α and IL-6 
release in wild type but not galectin-3-/- macrophages (figure 5.2C and D). 
 Classical activation with IFNγ and LPS produced a similar increase in nitrite 
production from both wild type and galectin-3-/- BMDM (figure 5.2E).  Alternative 
activation of wild type BMDMs with IL-4 and IL-13 induced a >5 fold stimulation in 
arginase-1 activity over untreated macrophages.  However IL-4 and IL-13 treated 
galectin-3-/- BMDMs induced significantly less arginase-1 activity when compared to 
wild type BMDMs (figure 5.2F and figure 5.3A).  True deactivation, induced by IL-
10, inhibited TNF-α, IL-6 and nitrite release by LPS in both wild type and galectin-3-
/- BMDMs (figure 5.2C, D and E) suggesting that galectin-3 is not essential for IL-
10-induced macrophage deactivation. 
 SYBR Green real-time RT-PCR analysis of untreated, IL-4- or LPS-
stimulated BMDMs showed equal expression of the IL-4/IL-13 common receptor, 
IL-4Rα, in wild type and galectin-3-/- macrophages (figure 5.3B).  To further 
characterise alternative activation in response to IL-4, BMDMs were treated with IL-
4 in the presence or absence of LPS and markers of alternative activation were 
analysed by SYBR Green real-time RT-PCR.  IL-4 produced a significant increase in 
the ratio of arginase/NOS2 expression in wild type BMDMs indicating a skew to the 
M2 phenotype.  However, the increased ratio was significantly less in galectin-3-/- 
BMDMs (figure 5.3C).  LPS alone caused a marked increase in NOS2 expression, 
decreasing the arginase/NOS2 ratio and this was not significantly different between 
wild type and galectin-3-/- BMDMs (figure 5.3C).  Expression of mannose receptor 
(figure 5.3D), YM-1 (figure 5.3E) and FIZZ-1 (figure 5.3F) significantly increased in 
response to IL-4 in wild type BMDMs.  However, galectin-3-/- macrophages 
demonstrated significantly less increase in the expression of these alternative 




































Figure 5.2 – Alternative macrophage activation by IL-4 and 
IL-13 is abrogated in galectin-3-/- BMDMs.
Figure 5.2 (A, B)
WT (white bars) or galectin-3-/- BMDMs (black bars) were cultured in the 
presence of IL-4, IL-13 (10ng/ml) or IFNγ (100U/ml) for 48h. Where indicated, 
LPS (100ng/ml) was added for the last 24h. Supernatants were harvested and 
analysed for TNF-α (A) and IL-6 (B) by cytometric bead array (CBA) (n = 3). 
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Figure 5.2 (C, D)
WT (white bars) or galectin-3-/- BMDMs (black bars) were cultured in the 
presence of IL-4, IL-13 or IL-10 (10ng/ml) for 48h. Where indicated, LPS 
(100ng/ml) was added for the last 24h.  Supernatants were harvested and 
analysed for TNF-α (C) and IL-6 (D) by cytometric bead array (n = 3). *, P < 





















Figure 5.2 (E, F)
WT (white bars) or galectin-3-/- BMDMs (black bars) were cultured in the 
presence of IL-4, IL-13, IL-10 (10ng/ml) or IFNγ (100U/ml) for 48h. Where 
indicated, LPS (100ng/ml) was added for the last 24h. (E) Nitrite release into 
supernatants was measured as described in Materials and Methods. For IFNγ/LPS 
treatment P = 0.13 (ns). (F) Arginase activity in cell lysates was measured as 
described in Materials and Methods (n = 3). *, P < 0.05 compared to WT. P = 





























































Figure 5.3 (A, B)
(A) WT (white circles) or galectin-3-/- (black circles) BMDMs were treated with 
IL-4 (0-10ng/ml) for 24h and arginase activity in cell lysates was determined (n = 
3). *, P < 0.05 compared to WT. P = 0.06 (ns) for both 0.5ng/ml and 1ng/ml IL-4 
treatment. (B) WT (white bars) and galectin-3-/- (black bars) BMDMs were 
treated with 10ng/ml IL-4 or 100ng/ml LPS for 24h and total RNA extracted for 
real-time RT-PCR analysis.  The results represent mean relative IL-4Rα gene 
expression compared to β-actin (n = 3). P = 0.15 (ns) and 0.28 (ns) for IL-4 and 
IFNγ/LPS treatment respectively.
Figure 5.3 – IL-4 and IL-13 induced alternative activation is 

























































Figure 5.3 (C, D)
WT (white bars) or galectin-3-/- (black bars) BMDMs were treated with 10ng/ml 
IL-4 +/- 100ng/ml LPS for 48h and total RNA extracted for real-time RT-PCR 
analysis.  The results represent Log[arginase/NOS2 expression ratio] (C) and 
relative mannose receptor expression (D) compared to β-actin (n = 3). *, P < 0.05 













































Figure 5.3 (E, F)
WT (white bars) or galectin-3-/- (black bars) BMDMs were treated with 10ng/ml 
IL-4 +/- 100ng/ml LPS for 48h and total RNA extracted for real-time RT-PCR 
analysis.  The results represent relative YM-1 (E) and FIZZ-1 (F) expression 






 LPS treatment alone or in combination with IL-4 reduced alternative 
activation marker expression in wild type BMDMs.  
 As an alternative method, in vivo differentiated mouse wild type and galectin-
3-/- peritoneal and alveolar macrophages were assayed for their ability to alternatively 
activate.  Macrophages were isolated from peritoneal and lung lavage as described in 
Materials and Methods and adhered to tissue culture plastic in quiescent media.  
Wild type and galectin-3-/- peritoneal macrophages were stimulated with IFNγ and 
LPS and nitrite and cytokine responses were compared.  There was no significant 
difference in TNF-α, IL-6 and nitrite release in response to IFNγ/LPS in peritoneal 
macrophages isolated from wild type or galectin-3-/- mice (figure 5.4A-C).  As with 
BMDMs, in vivo derived peritoneal macrophages from galectin-3-/- mice showed 
reduced IL-4 and IL-13 stimulated arginase activity (figure 5.4D).  Western blotting 
bronchoalveolar lavage fluid (BAL) from galectin-3-/- mice with anti-mouse YM-1 
(kindly donated by Professor J Allen) demonstrated a decrease in expression of the 
alternative activation marker YM-1 compared to wild type (figure 5.4E left).  In 
addition, wild type alveolar macrophages cultured for 24 hours in the presence of IL-
4 showed increased secretion of YM-1 into culture supernatants.  In contrast, IL-4 
did not stimulate increased YM-1 secretion from galectin-3-/- alveolar macrophages 
(figure 5.4E right).  Furthermore, wild type alveolar macrophages demonstrated 
dense intracellular YM-1 immunofluorescence, which was not observed in alveolar 
macrophages from galectin-3-/- mice (figure 5.4F). 
 These data suggest that both in vitro and in vivo differentiated galectin-3-/- 































Figure 5.4 – Galectin-3-/- peritoneal and alveolar 
macrophages display normal classical activation but 
impaired alternative activation.
Figure 5.4 (A, B)
Peritoneal macrophages were stimulated with IFNγ (100U/ml) for 48h and LPS 
(100ng/ml) was added for the last 24h.  Supernatants were assayed for (A) TNF-α
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Figure 5.4 (C, D)
Peritoneal macrophages were stimulated with IL-4, IL-13, IL-10 (10ng/ml) or 
IFNγ (100U/ml) for 48h. Where indicated LPS (100ng/ml) was added for the last 
24h. Supernatants were assayed for (C) nitrite. P = 0.46 (ns) for IFNγ/LPS 
treatment. (D) Cell lysates were assayed for arginase activity (n = 3). *, P < 0.05 
















Figure 5.4 (E, F)
(E) 1ml of PBS was administered intratracheally to WT and galectin-3-/- mice and 
BAL fluid was analysed for YM-1 protein expression by Western blot analysis 
(left). Alveolar macrophages were isolated and treated with IL-4 (10ng/ml) for 
24h and culture supernatants were analysed for YM-1 expression (right). (F) 
Immunofluorescence staining of YM-1 in alveolar macrophages isolated from 
lavage fluid of WT (top) and galectin-3-/- (bottom) mice.  (Scale bar: 5µm).
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5.2.2 IL-4 stimulated alternative macrophage activation is dependent 
on expression of galectin-3 and CD98 and activation of 
(phosphatidylinositol-3-kinase) PI3-K 
 CD98 is highly expressed on macrophages and is a receptor for galectin-3 
(Dong and Hughes, 1997).  CD98 has been shown to promote “integrin-like 
signalling” and PI3-K activation causing elevation of intracellular PI(3,4,5)P3 and 
Protein Kinase B (Akt/PKB) activation (Henderson et al., 2004; Rintoul et al., 2002).  
Signal transducers and activators of transcription (STATs) are involved in cytokine 
signal transduction.  STAT-6 is an important transcription factor in IL-4 signalling.  
IL-4 or IL-13 bind to IL-4Rα which causes the phosphorylation of Janus kinase (Jak) 
which is associated with the receptor on the cytoplasmic side of the membrane.  
Activated Jaks then phosphorylate IL-4Rα at three tyrosine residues providing a 
docking site for STAT-6.  Bound STAT-6 then becomes phosphorylated by the jaks, 
dimerises with a second phosphorylated STAT-6 (pSTAT-6) and translocates to the 
nucleus where it can modify transcriptional activity (Hebenstreit et al., 2006) (figure 
5.5).   
 The human monocyte leukaemia cell line THP-1 was used to establish 
whether galectin-3-dependent alternative activation was mediated via CD98 and 
activation of PI3-K.  Firstly, it was important to determine the expression levels of 
galectin-3 and CD98 in THP-1 cells.  It has previously been reported that galectin-3 
expression in THP-1 cells increases upon differentiation into macrophage-like cells 
following phorbol 12-myristate 13-acetate (PMA) treatment (Dabelic et al., 2005).  
Treatment of THP-1 cells with PMA, an activator of Protein Kinase C (PKC), results 
in the inhibition of growth at the G1-phase of the cell cycle prior to the initiation of 
differentiation (Traore et al., 2005).  This cell cycle arrest occurs through a complex 
mechanism involving the modulation of expression of several cell cycle regulators, 
initiated by the production of reactive oxygen species (ROS).  Once the cell cycle is 
arrested, THP-1 cells can undergo differentiation along the monocyte/macrophage 
pathway of development.  This differentiation is inhibited by staurosporine, a potent 
PKC inhibitor, thus demonstrating the necessity of PKC signalling in monocyte 




























Figure 5.5 – IL-4/IL-13 signalling via the JAK/STAT signalling 
pathway.
Figure 5.5
Jak/STAT signalling pathway utilised by IL-4 and IL-13. Phosphorylation of Jaks
by IL-4/IL-13 binding to IL-4Rα causes phosphorylation of IL-4Rα providing 
docking sites for STAT-6. Consequent phosphorylation of STAT-6 enables its 








 Differentiated THP-1 cells exhibit morphological and functional similarities 
to macrophages (Tsuchiya et al., 1982; Asseffa et al., 1993).  The characteristic of 
THP-1 cells to behave more like native monocyte-derived macrophages compared to 
other human myeloid cell lines provides a valuable human in vitro model for 
studying macrophage function. 
  THP-1 cells were differentiated into a macrophage phenotype with 100ng/ml 
PMA treatment for up to 48 hours.  Cell lysates were prepared at various time points 
and analysed by Western blotting for galectin-3 and CD98 using anti-galectin-3 
(clone A3A12) and anti-human CD98 (clone C-20) antibodies respectively.  This 
study has confirmed the finding of Dabelic et al. that galectin-3 expression increases 
upon THP-1 differentiation and, in addition, has demonstrated that CD98 expression 
also increases following PMA-treatment (figure 5.6). 
 To assess the role of CD98 and galectin-3 in the regulation of macrophage 
phenotype, a small interfering RNA (siRNA)-mediated strategy to inhibit expression 
was employed.  Four duplexes against human CD98 and galectin-3 were designed 
and synthesised by Dharmacon.  Duplexes were prepared as per manufacturer’s 
instructions, transfected into differentiated THP-1 cells (48 hours post PMA 
treatment) using Oligofectamine and inhibition was assessed 48 hours post 
transfection.  All four galectin-3 siRNA duplexes caused an approximate 90% 
knockdown of galectin-3 protein expression and CD98 siRNA duplexes 1 and 3 
reduced CD98 protein expression by >95% (figure 5.7A).  CD98 protein levels 
remained unaffected in THP-1 cells treated with galectin-3 siRNA and vice versa.  In 
subsequent experiments galectin-3 duplex 1 and CD98 duplex 1 were used and 
compared to non-targetting control duplex. 
 THP-1 cells transfected with control duplex or siRNA targeted to galectin-3 
or CD98 were incubated for 24 hours with 10ng/ml IL-4 or 100U/ml IFNγ and 
100ng/ml LPS.  Inhibition of galectin-3 or CD98 expression blocked IL-4 stimulated 
increase in mannose receptor expression as judged by Western blot analysis of cell 
lysates with anti-human CD206 (clone 15-2) and SYBR Green real-time RT-PCR 
analysis of RNA extracts (figure 5.7B and C).  Differentiated THP-1 cells were 
treated with 10µM of the PI3-K inhibitor LY294002 20 minutes prior to the addition 
of 10ng/ml IL-4, 10µg/ml 4F2 or 10µg/ml recombinant human galectin-3 for 20 
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minutes or 24 hours.  Cell lysates were analysed by Western blotting using anti-
pAkt/PKB (clone 14-6), anti-pSTAT-6, anti-Akt/PKB, and anti-human CD206 (clone 
15-2).  Cross-linking CD98 with the monoclonal antibody 4F2 or the addition of 
extracellular recombinant galectin-3 to THP-1 cells both stimulated PI3-K activation 
as measured by a sustained phosphorylation of Akt/PKB (evident at 20 minutes and 
maintained at 24 hours), and increased mannose receptor expression to a similar level 
as IL-4 (figure 5.7D).  Blocking PI3-K activity with LY294002 prevented IL-4-, 
galectin-3-, and 4F2-mediated Akt/PKB phosphorylation and mannose receptor 
expression (figure 5.7D).  IL-4 but not 4F2 or galectin-3 increased STAT-6 
phosphorylation and this was not inhibited by LY294002 (figure 5.7D).  Levels of 
non-phosphorylated Akt/PKB remained constant throughout all treatments. 
 Lysates from THP-1 cells transfected with siRNA targeted against CD98 
followed by 24 hour treatment with 10ng/ml IL-4 or 10µg/ml galectin-3 were 
analysed by Western blotting for CD98 and pAkt/PKB.  Results show that without 
CD98, IL-4 and galectin-3 can not stimulate Akt/PKB phosphorylation in THP-1 
cells (figure 5.7E).  BMDMs and primary human macrophages isolated from 
peripheral blood and allowed to mature for 5 days were treated for 48 hours with 
10ng/ml IL-4 or IL-13 and cell supernatants were analysed for galectin-3 by Western 
blotting.  Results show that IL-4 and IL-13 stimulated galectin-3 secretion from both 
macrophage types (figure 5.7F). 
 These data suggest that alternative activation is driven by an IL-4-stimulated 
galectin-3 feed back loop, which activates CD98 causing PI3-K activation. 
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Figure 5.6 – Galectin-3 and CD98 expression increases in 






THP-1 cells were differentiated with 100ng/ml of PMA for up to 48h. Cell lysates











(A) THP-1 cells were differentiated with 100ng/ml of PMA for 24h. Cells were 
transfected with 100nM galectin-3 or 120nM CD98 siRNA duplexes (1-4 as 
indicated) as described in Materials and Methods. 48h post-transfection cell 
lysates were resolved on 12% SDS-PAGE gels. Blots were probed for galectin-3, 
CD98 and β-actin expression.
Figure 5.7 – Alternative activation of human macrophages 























Figure 5.7 (B, C)
(B) THP-1 cells were transfected with duplex 1 of galectin-3, CD98 or control 
siRNA for 48h, followed by a 24h incubation with IL-4 (10ng/ml) or IFNγ
(100U/ml)/LPS (100ng/ml).  Cell lysates were resolved on 12% SDS-PAGE gels. 
Blots were probed for mannose receptor (MR), galectin-3, CD98 and β-actin. (C) 
THP-1 cells were differentiated and transfected with siRNA as in (B) followed by 
a 24h incubation with IL-4 (10ng/ml). Total cell RNA was extracted and 
mannose receptor gene expression determined by real-time RT-PCR.  Results are 
expressed as relative gene expression compared to β-actin (n = 3). *, P < 0.05 





















































(D) Differentiated THP-1 cells were treated with 10µM LY294002 20 minutes 
prior to addition of 10ng/ml IL-4, 10µg/ml 4F2 or 10µg/ml human recombinant 
galectin-3 for 20 min (top) or 24h (bottom) as indicated. Western blots of cell 
lysates were probed for phospho-Akt/PKB (pAkt/PKB), phospho-STAT-6 
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Figure 5.7 (E, F)
(E) THP-1 cells were transfected with siRNA against CD98 or control siRNA and 
stimulated with IL-4 or galectin-3 for 24h. Blots were probed for CD98, 
pAkt/PKB   or β-actin as indicated. (F) Human peripheral blood macrophages and 
WT mouse BMDMs were incubated for 48h with 10ng/ml IL-4 or IL-13. Western 
blots from cell supernatants were probed for galectin-3.
Control
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5.2.3 Galectin-3-/- mice show reduced expression of the alternative 
macrophage markers compared to wild type mice following UUO 
 Previous work detailed in Chapter 4 of this thesis described galectin-3 as an 
important protein in the pathogenesis of fibrosis.  The alternatively activated 
macrophage plays an important role in certain fibrotic diseases (Wynn, 2004).  It was 
therefore hypothesised that galectin-3 may also be involved in alternative 
macrophage activation and that this could contribute to the progression of fibrosis.   
 The UUO model of renal fibrosis is a well characterised fibrosis model and 
demonstrates rapid infiltration of macrophages which are essential for the 
development of progressive fibrosis. 
 To assess the role of galectin-3 in alternative macrophage activation and 
fibrosis in vivo, RNA was extracted from obstructed kidneys 7 days after UUO, as 
described in Materials and Methods, and alternative macrophage activation marker 
expression was determined by SYBR Green real-time RT-PCR.  Obstructed left 
kidneys from wild type mice showed a significant increase in the arginase/NOS2 
ratio, mannose receptor and YM-1 expression compared to control right kidney 
(figure 5.8A, B and C).  Obstructed kidneys from galectin-3-/- mice showed a reduced 
arginase/NOS2 ratio and significantly less mannose receptor and YM-1 expression 
compared to wild type. 
 In summary, obstructed kidneys from wild type mice revealed increased 
levels of alternative macrophage activation compared with control kidneys 
demonstrated by real-time RT-PCR of whole kidney RNA extracts.  Kidneys from 
galectin-3-/- mice also showed increased levels of alternative macrophage activation 
following UUO, however this increase was significantly less than that of wild type 
mice.  Chapter 4 of this thesis described that following UUO, galectin-3-/- mice 
demonstrate decreased severity of kidney fibrosis compared to wild type mice.  
Together, these data suggest that galectin-3-/- macrophages do not alternatively 
activate in vivo in contrast to wild type macrophages and the degree of alternative 












































































(A) WT (white bars) and galectin-3-/- (black bars) mice underwent UUO of the 
left kidney and both left and right (control) kidneys were harvested at day 7. 
RNA was extracted and arginase and NOS2 (A), mannose receptor (B) and YM-1 
(C) gene expression was measured by real-time RT-PCR. The results represent 
the mean relative gene expression normalised to β-actin (n = 3). *, P < 0.05 
compared to WT left kidney.
Figure 5.8 – Reduced alternatively activated macrophages in 































Proposed schematic showing potentiation of IL-4 mediated alternative 
macrophage activation by galectin-3. Dashed arrows indicate hypothesised
















Figure 5.9 – Proposed galectin-3 signalling mechanism for 
the alternative activation of macrophages.
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5.3 Discussion 
 Previous studies demonstrated that galectin-3 plays a critical role during a 
fibrotic response (Henderson et al., 2006) (and Chapter 4) whereby it plays a role in  
myofibroblast activation.  Work presented in this chapter suggests that, not only is 
galectin-3 important during alternative macrophage activation, but that this activation 
may be critical to the persistence of fibrosis.  This work has also provided the 
mechanism through which galectin-3 causes alternative macrophage activation. 
 Src homology 2-containing inositol-5’-phosphate (SHIP) is an important 
negative regulator of the PI3-K pathway.  It has been previously reported that in vitro 
derived BMDMs from SHIP-/- mice are M1 skewed unless exposed to TGF-β within 
normal mouse plasma during differentiation whereas peritoneal and alveolar in vivo 
derived macrophages are M2 programmed.  In vivo derived macrophages from wild 
type mice, however, have an M1 propensity (Rauh et al., 2005) demonstrating that 
macrophage phenotype can arise both during differentiation and once it’s completed.  
In addition to the main finding, that SHIP functions in vivo to repress M2 skewing, 
this study cautions against extrapolating in vitro derived BMDMs to more complex 
in vivo systems and therefore highlights the need to utilise both in vitro and in vivo 
differentiated macrophages. 
 Initial studies were performed to investigate the role of galectin-3 in the 
activation of both in vitro and in vivo differentiated macrophages.  In vitro derived 
BMDMs and in vivo differentiated peritoneal macrophages from wild type and 
galectin-3-/- mice were exposed to the Th1 cytokines IFNγ and LPS or the Th2 
cytokines IL-4 or IL-13 to induce a classical or an alternative macrophage phenotype 
respectively.  Alveolar macrophages were also isolated and YM-1 expression in BAL 
fluid and culture supernatants from macrophages treated with IL-4 was assessed by 
Western blotting.  YM-1 expression in alveolar macrophages was also determined by 
YM-1 immunofluorescence.  Results suggest that both in vitro and in vivo 
differentiated galectin-3-/- macrophages have a specific defect in IL-4/IL-13 
stimulated alternative activation. 
 Once it was established that galectin-3 was involved in alternative 
macrophage activation, subsequent studies were carried out to determine the 
mechanism.  The human monocytic cell line THP-1 was used to test the hypothesis 
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that galectin-3-dependent alternative activation was mediated via CD98 and 
activation of PI3-K.  Previous work demonstrated that CD98 interacts specifically 
with β1 integrins and promotes “integrin-like” intracellular signalling stimulating 
PI3-K activity and causing elevation of intracellular PI(3,4,5)P3 and Akt/PKB 
activation (Henderson et al., 2004; Rintoul et al., 2002).  A number of studies suggest 
that PI3-K activation may be the final common pathway to alternative (M2) 
macrophage activation.  The PI3-K/PKB pathway in macrophages negatively 
regulates NOS2 expression (Diaz-Guerra et al., 1999) and suppresses LPS-induced 
inflammation in endotoxaemic mice (Schabbauer et al., 2004).  Constitutive 
elevation of PI3-K and PI(3,4,5)P3 in SHIP-/- mice produces M2 skewing (Rauh et 
al., 2005).  These mice have high YM-1 concentrations in the lung, which may 
represent an exaggerated manifestation of immune tolerance and healing, which 
contribute to chronic lung inflammation and fibrosis. 
 The THP-1 cell line can be manipulated using siRNA techniques to 
knockdown various genes of interest.  In this study, both galectin-3 and CD98 
expression were successfully depleted as assessed by Western blotting.  These 
macrophages were then treated with IL-4, and mannose receptor protein and mRNA 
expression was determined as a marker of alternative macrophage activation.  
Results verified that both galectin-3 and CD98 were required for alternative 
macrophage activation. 
 Treatment of differentiated THP-1 cells with IL-4, 4F2 and galectin-3 
stimulated PI3-K activation, as measured by Akt/PKB phosphorylation.  Blocking 
PI3-K activation, with the inhibitor LY294002, inhibited IL-4-, galectin-3- and 4F2-
stimulated alternative macrophage activation, assessed by mannose receptor 
expression.  Furthermore, IL-4 but not 4F2 or galectin-3 increased STAT-6 
phosphorylation and this was not inhibited by LY294002.  CD98 is required for both 
IL-4 and galectin-3-induced PI3-K activation, demonstrated by an inhibition of 
Akt/PKB phosphorylation in THP-1 cells treated with CD98 siRNA.  IL-4 caused 
stimulation of galectin-3 expression in both mature human peripheral blood 
macrophages and mouse BMDMs.   
 The following additional work carried out by other members of this 
laboratory has expanded the volume of data regarding the role of galectin-3 during 
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alternative macrophage activation.  A high affinity inhibitor of galectin-3, Bis-(3-
deoxy-3-(3-methoxybenzamido)-ß-D-galactopyranosyl)-sulfane, blocked alternative 
macrophage activation suggesting that the carbohydrate recognition domain of 
galectin-3 is responsible for these effects and supports an extracellular mechanism of 
action.  STAT-6 siRNA in THP1 cells blocked IL-4 and galectin-3-stimulated 
alternative macrophage activation, suggesting that while STAT-6 activation is not 
sufficient to drive alternative macrophage activation, some basal activity is required 
to enable sustained PI3-K activation to drive alternative macrophage activation. This 
is consistent with the findings that STAT6-/- mice have significantly less collagen I 
kidney deposition than wild type mice following UUO 
 These results suggest that IL-4 stimulates a galectin-3 feed back loop causing 
sustained PI3-K activation and that this is the key mechanism required for activation 
of an alternative macrophage phenotype.  Figure 5.9 illustrates the proposed 
schematic showing potentiation of IL-4 mediated alternative macrophage activation 
by galectin-3.  IL-4 binding to the IL-4Rα chain recruits the IL-13Rα1 chain.  
Activation of the JAK/STAT pathway results in recruitment of insulin receptor 
substrate-1 (IRS-1) to the first cytoplasmic tyrosine residue (Y1) which binds to the 
p85 subunit of PI3-K resulting in the activation of the p110 catalytic subunit and 
phosphorylation of PIP2 to PIP3 and activation of downstream signalling 
intermediates such as Akt/PKB.  Phosphorylation of the second, third or fourth 
cytoplasmic tyrosine residues results in recruitment of STAT-6 which, when tyrosine 
is phosphorylated, dimerizes and migrates to the nucleus where it binds to consensus 
sequences found within the promoters of IL-4 regulated genes resulting in up 
regulation of genes associated with alternative activation.  CD98 when activated by 
galectin-3 or crosslinked with 4F2 results in integrin-dependent activation of PI3-K 
and Akt/PKB activation.  The schematic proposes that galectin-3 potentiates IL-4 
mediated alternative activation directly by activating CD98 and increasing PIP3 
levels thereby raising the threshold for alternative activation.  Galectin-3 may also 
potentiate IL-4 signalling by binding to N-Glycan residues expressed on the IL-4R 
and by homotypic aggregation may stabilise a high affinity complex of IL-4R/CD98 
and β1-integrin on the cell surface causing sustained activation of pathways leading 
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to alternative activation.  It is proposed that IL-4 stimulates galectin-3 expression and 
release leading to further potentiation of IL-4 mediated signalling. 
 Alternative macrophage activation has also been shown in this study to be 
important for the initiation and development of renal fibrosis following UUO.  Renal 
fibrosis had long been recognised as a prominent feature of diseased kidneys.  
However the pathologic mechanisms during the evolution of fibrotic changes in the 
kidney, including the role of infiltrating macrophages in each stage of the fibrotic 
process, have not yet been fully illucidated.  Macrophages are involved in all stages 
of the inflammatory process including fibrosis, tissue repair and healing (Nagaoka et 
al., 2000; Teder et al., 2002).  Evidence in mouse models of liver fibrosis, 
glomerulonephritis and renal fibrosis, suggest that macrophages also down-regulate 
injury and facilitate repair.  During progressive inflammatory injury, macrophage 
depletion results in amelioration of fibrosis.  By contrast, depletion during recovery 
results in a failure of resolution with persistence of cellular and matrix components 
of the fibrotic response (Duffield et al., 2005a).  Thus macrophages play distinct 
roles in injury and repair highlighting that macrophages may be both pathogenic and 
beneficial depending on the timing and injury. 
 Further work carried out by this laboratory utilised the CD11b-diptheria toxin 
receptor (DTR) mouse (Duffield et al., 2005b; Duffield et al., 2005a; Cailhier et al., 
2005) to confirm the role of macrophages in tubulointerstitial scarring.  These mice 
express the human DTR under the control of the CD11b promoter.  This system 
relies on the fact that the mouse DT receptor binds DT poorly compared with the 
human molecule.  Thus, transgenic expression of the human DTR confers sensitivity 
to DT and permits specific ablation of monocytes and macrophages in vivo when DT 
is injected (Duffield et al., 2005a; Cailhier et al., 2005).  Results showed that 
infiltrating macrophages drive myofibroblast activation and resultant interstitial 
fibrosis as indicated by reduced α-SMA and collagen expression evident in the 
obstructed kidney of macrophage depleted mice.  Moreover, adoptive transfer of wild 
type macrophages into galectin-3-/- mice drove the activation of interstitial 
myofibroblasts as indicated by significantly increased expression of α-SMA in 
contrast to galectin-3-/- macrophages which did not.  These results show that galectin-
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3-/- fibroblasts in the kidney have the potential to transdifferentiate into 
myofibroblasts when activated by wild type macrophages. 
 The dual function of macrophages may be due to their ability to alter 
phenotype under different microenvironments and represent a mechanism where they 
can be inflammatory or reparative depending on context.  Galectin-3-/- mice may 
develop reduced fibrotic damage due to their inability to adopt a “fibrotic” 
macrophage phenotype.  Moreover, this work suggests that increased galectin-3 
expression may be a feature of the alternative macrophage phenotype and this 
increased expression is driven by IL-4.  Increased galectin-3 expression and release 
by macrophages may also contribute to fibrosis by directly activating myofibroblasts. 
 Previous work highlighted in chapter 4 of this thesis demonstrated that 
galectin-3-/- mice are protected from renal fibrosis following UUO despite 
developing a macrophage infiltrate comparable to wild-type mice.  In vitro data 
demonstrated a deficiency of galectin-3-/- macrophages to alternatively activate, 
therefore the activation status of renal macrophages following UUO was determined 
by real-time RT-PCR analysis of total RNA extracts from kidneys.  Studying 
macrophage phenotype in situ was carried out as it is assumed that macrophages 
isolated from kidneys would rapidly alter their phenotype when cultured in vitro.  
Findings from this study revealed that the levels of alternative macrophage activation 
markers were significantly reduced in obstructed kidneys from galectin-3-/- mice 
compared to wild type mice.  Further work carried out by this laboratory 
demonstrated colocalisation of YM-1 and mannose receptor expression with 
macrophages in tissue sections from obstructed wild type kidneys.  Results 
demonstrated tubular expression of YM-1 in galectin-3-/- kidneys but no significant 
co-expression on macrophages and absent mannose receptor expression.  This study 
revealed that macrophages in obstructed kidneys from galectin-3-/- mice are 
significantly less alternatively activated than those from wild type mice. 
 This study provides insight into the mechanisms regulating alternative 
macrophage activation and may provide more clearly defined therapeutic targets in a 
wide range of human diseases.  Targeting the galectin-3/CD98/PI3-K pathway with 
specific inhibitors such as Bis-(3-deoxy-3-(3-methoxybenzamido)-β-D-
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galactopyranosyl)-sulfane may represent a novel therapeutic target for manipulating 
macrophage phenotype in the treatment of cancer, chronic inflammation and fibrosis. 
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Chapter 6 
Galectin-3 and pneumonia 
 
6.1 Introduction 
  Streptococcus pneumoniae (S. pn) is the leading cause of community 
acquired pneumonia (CAP) worldwide with resulting high mortality rates (Brown 
and Lerner, 1998).  Limitations of conventional therapies and emerging drug 
resistance amongst strains of S. pn to antibiotics, such as penicillin (Feldman, 2004) 
and vancomycin (Novak et al., 1999), necessitates the continued study into the 
mechanisms involved in the pathogenesis of pneumococcal disease and the host 
immune defence against pneumococcal invasion. 
 Previous studies have demonstrated the ability of galectin-3 to manipulate 
immune cell function.  Galectin-3 plays a role in cell adhesion (Inohara and Raz, 
1995; Kuwabara and Liu, 1996; Sato et al., 2002), activation (Liu et al., 1995; 
Yamaoka et al., 1995; Karlsson et al., 1998; Fernandez et al., 2005; Frigeri et al., 
1993; Hsu et al., 1996) and phagocytosis of apoptotic thymocytes by macrophages 
(Sano et al., 2003) and IgG-opsonised erythrocytes by macrophages (Sano et al., 
2003) and neutrophils (Fernandez et al., 2005).  I have also shown that galectin-3 
plays a role in skewing macrophages to the pro-fibrotic M2 phenotype (Chapter 5).  
The absence of galectin-3 can alter the outcome of certain disease states including 
fibrosis (examined Chapter 4) and, as shown in this chapter, of acute pneumococcal 
infection. 
 Alveolar macrophages, recruited macrophages and neutrophils play a key role 
in the clearance and killing of invading pathogens.  In the lung, resident alveolar 
macrophages are the first line of cellular defence and play a phagocytic role during 
the early stages of infection.  Interaction of these cells with pneumococcus provokes 
an inflammatory response inducing recruitment of the more efficient 
polymorphonuclear leukocytes (PMNs or neutrophils) and increased concentrations 
of serum opsonins at the site of infection.  Amongst the earliest leukocytes recruited 
to the site of infection are neutrophils.  Neutrophils play a critical role in the host 
 153
immune defence against infection through their ability to phagocytose and kill 
bacteria. 
 PMN migrate into an inflammatory site from the vascular space.  The selectin 
family of adhesion molecules tethers leukocytes to the endothelium via weak cell-
cell interactions.  This contact slows the circulating neutrophils down allowing them 
to roll on the endothelium.  The rolling process initiates stronger adhesion mediated 
by leukocyte integrins.  In the case of Escherichia coli (E. coli) infection, this tight 
adhesion is mediated by β2 integrins (Hogg and Doerschuk, 1995).  Conversely, 
neutrophil extravasation following pneumococcal pneumonia is selectin-independent 
(Mizgerd et al., 1996) and is observed in β2 integrin knockout mice (Mizgerd et al., 
1997; Mizgerd et al., 1999).  Therefore the mechanisms involved in the host response 
to different pathogens are distinct.  Work carried out in the study detailed in this 
chapter was prompted by these findings and also from those of Sato et al. who 
demonstrated that galectin-3 accumulates in the alveolar space of mice infected with 
S. pn and that this accumulation of galectin-3 correlates with the onset of neutrophil 
extravasation.  However, accumulation of galectin-3 was not observed when 
neutrophil extravasation was induced by an E. coli infection (Sato et al., 2002).  
Furthermore it was demonstrated that galectin-3 is released by alveolar macrophages 
upon incubation with S. pn membrane fraction.  It was therefore proposed that 
galectin-3 acts as a neutrophil adhesion molecule during pneumococcal pneumonia.  
In addition, lipopolysaccharide (LPS) expressed on E. coli has been shown to down 
regulate galectin-3 expression (Liu et al., 1995; Sato and Hughes, 1994).  In these 
studies, although a role for galectin-3 in response to pneumococcal pneumonia was 
implicated, it was not shown how galectin-3 may function to orchestrate the 
inflammatory response to infection or whether galectin-3 deficiency would result in 
animals succumbing to infection. 
 Activation of neutrophils and phagocytosis of microbes results in the 
increased consumption of molecular oxygen by professional phagocytes.  This 
process, catalysed by NADPH-oxidase, results in the production of superoxide (O2-) 
and hydrogen peroxide (H2O2).  The bactericidal activity of neutrophils is mediated, 
in part, through the generation of these reactive oxygen species (ROS) during the 
normal host defence against infectious disease.  There are numerous techniques used 
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to measure ROS production.  This study utilises two of these well established 
techniques, the reduction of cytochrome C by ROS and a flow-based assay 
measuring dihydrorhodamine 123 (DHR) fluorescence.  Cytochrome C molecules 
are reduced by ROS resulting in a change in absorbance which can be measured 
spectrophotometrically.  This method measures the O2- metabolite (Dahlgren and 
Karlsson, 1999).  DHR is a fluorescent dye which is specifically responsive to the 
H2O2 metabolite (Walrand et al., 2003).  DHR enters the membrane of the cell where 
it is oxidised by ROS to rhodamine 123 thus emitting a bright fluorescent signal 
which can be measured by flow cytometry. 
 Phagocytosis of apoptotic neutrophils by macrophages is a key process in the 
resolution of inflammation.  Clearance of potentially toxic apoptotic neutrophils by 
macrophages results in the release of anti-inflammatory and reparative cytokines 
such as Transforming Growth Factor-β1 (TGF-β1).  These steps help to limit the 
degree of tissue injury. 
 In this chapter, a direct comparison of the effect of galectin-3 expression on 
the development of pneumonic infection induced by the gram-positive S. pn and the 
gram-negative E. coli will address the hypothesis that upregulation of galectin-3 
expression by S. pn activates neutrophils, promotes bacterial clearance and plays a 
role in the resolution of inflammation. These data provide evidence for galectin-3 
based mechanisms as a potential therapeutic strategy for treating pneumonia. 
 
6.2 Results 
6.2.1 In vivo studies 
 To determine the effects of galectin-3 deficiency on the outcome of a 
pneumococcal and E. coli pneumonia infection, wild type and galectin-3-/- mice were 
inoculated with 1x105 colony forming units (CFU) S. pn or 1x107 CFU E. coli intra-
tracheally (I.T.).  These doses were calculated based on previous dose-finding pilot 
studies carried out by Dr N. Henderson and were chosen to produce acute 
inflammatory injury without significant mortality after 15 hours in wild type mice. 
 15 hours post inoculation mice were sacrificed and the severity of infection 
was ascertained by the following means: 
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1. Total cell counts and neutrophil and macrophage counts in bronchoalveolar 
lavage (BAL) fluid were calculated to determine the amount of cell recruitment 
to the site of infection. 
2. Pulmonary microvascular leakage, as determined by BAL protein concentration, 
was used to assess the extent of lung injury.   
3. Degree of septicaemia was measured by aseptically plating blood taken from 
each animal on a 5% sheep blood agar plate for S. pn or Luria-Bertani (LB) agar 
plate for E. coli and incubating overnight at 37°C.  The following morning, 
culture plates housing bacterial colonies indicated a positive result of septicaemia 
in the corresponding animal.   
4. Efficiency of bacterial clearance was assessed by calculating the numbers of 
bacteria present in BAL fluid and lung homogenate.  Samples were serially 
diluted, inoculated on 5% sheep blood agar plates for S. pn or LB agar plates for 
E. coli overnight at 37°C and bacterial counts of CFU/ml were determined. 
 
6.2.2 Galectin-3 plays a role in the clearance of S. pn from the lungs 
and protects the lung from damage 
 In vivo, galectin-3-/- mice demonstrated a clearance defect of S. pn with 
increased septicaemia and a greater extent of lung damage.  Protein concentration 
was significantly higher in BAL fluid from galectin-3-/- mice compared to wild type 
mice (figure 6.1A) indicating a greater degree of lung injury.  8 out of 8 (100%) 
culture plates inoculated with galectin-3-/- blood produced colonies following S. pn 
infection compared to just 2 out of 7 (28.6%) of wild type mice (figure 6.1B).  
Culture plates of lung homogenate from galectin-3-/- mice produced approximately 
450-fold greater bacterial load than culture plates inoculated with wild type lung 
homogenate (8.6x108 CFU/ml in galectin-3-/- compared to 1.9x106 CFU/ml in wild 
type) (figure 6.1C) indicating a clearance defect of galectin-3-/- mice against S. pn.  
However bacterial counts in BAL were not significantly different between the two 
groups (figure 6.1D).  There were reduced total cell numbers and neutrophil numbers 
in BAL fluid from galectin-3-/- mice (figure 6.1E and F), however, the numbers of 
macrophages retrieved was similar between the two groups (figure 6.1G) . 
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Figure 6.1 – Galectin-3 plays a role in the clearance of an 
acute pneumococcal infection. 
Figure 6.1 (A-C)
WT (white bars) and galectin-3-/- (black bars) mice were inoculated with 1x105
CFU Streptococcus pneumoniae (S. pn) for 15h (n = 7 WT, n = 8 galectin-3-/-). 
(A) Protein concentration in BAL fluid from WT and galectin-3-/- mice. *, P < 
0.05 compared to WT. (B) Blood samples from galectin-3-/- and WT mice were 
plated on blood agar plates, the percentage of plates showing the presence of 
bacterial colonies was taken and expressed as % bacteraemia. (C) Lungs from 
galectin-3-/- and WT mice were homogenised, serially diluted, plated on blood


































































(D) Bacterial counts in WT (white bars) and galectin-3-/- (black bars) BAL fluid. 
P = 0.43 (ns). Total cell counts (E), neutrophil (F) and macrophage (G) counts in 
lavage fluid of galectin-3-/- and WT mice inoculated with S. pn for 15h. *, P < 



























































 These data verify galectin-3 as a critical molecule in the clearance of a 
pneumococcal pneumonia infection. 
 
6.2.3 Galectin-3 does not play a significant role in the clearance of E. 
coli pneumonia 
 Galectin-3-/- and wild type mice demonstrated equal bacteraemia following E. 
coli infection with 5 out of 11 (45%) culture plates inoculated with galectin-3-/- blood 
and 5 out of 10 (50%) culture plates inoculated with wild type blood producing 
colonies (figure 6.2A).  This was in stark contrast to the response to S. pn infection 
(figure 6.1B).  Culture plates of lung homogenate from galectin-3-/- mice produced 
more bacterial colonies than wild type culture plates, although this result did not 
reach statistical significance (figure 6.2B).  Bacterial counts in BAL were not 
significantly different between the two groups (figure 6.2C).  Neutrophil and 
macrophage recruitment was comparable between wild type and galectin-3-/- mice 
treated with E. coli (figure 6.2D and E) and wild type and galectin-3-/- lung weights 
were similar (figure 6.2F). 
 The striking difference in disease outcome of a pneumococcal pneumonia 
infection in galectin-3-/- mice compared to wild type is not as prominent with an E. 
coli pneumonia infection.  This indicates that galectin-3 may still play a role in 
bacterial clearance of the latter infection but is not as critical for survival, however 
further experiments need to be performed to verify this result. 
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Figure 6.2 – Galectin-3 does not play a significant role in the 
clearance of an acute E. coli pneumonia infection. 
Figure 6.2 (A-C)
WT (white bars) and galectin-3-/- (black bars) mice were inoculated with 1x107
CFU Escherichia coli (E. coli) for 15h (n = 10 WT, n = 11 galectin-3-/-). (A) 
Blood samples from galectin-3-/- and WT mice were plated on LB agar culture 
plates, the percentage of plates showing the presence of bacterial colonies was 
taken and expressed as % bacteraemia. (B) Lungs from galectin-3-/- and WT mice 
were homogenised, serially diluted, plated on LB agar culture plates and colonies 
counted. P = 0.09 (ns). (C) Bacterial counts in lavage fluid from WT and 













































Neutrophil (D) and macrophage (E) counts per ml of lavage fluid of WT (white 
bars) or galectin-3-/- (black bars) mice inoculated with E. coli for 15h. P = 0.63 
(ns) and 0.49 (ns) for (D) and (E) respectively. (F) WT and galectin-3-/- lung 




















































6.2.4 Galectin-3 is bactericidal against S. pn at high concentrations 
 Galectin-3 has recently been described to have antimicrobial activity towards 
the pathogenic fungus Candida albicans (Kohatsu et al., 2006).  It was therefore 
important to investigate whether galectin-3 had a direct antimicrobial effect on S. pn.  
The same strain of S. pn used in the in vivo experiment was grown to an OD600 = 0.1.  
The S. pn were diluted 1:100 and 75µl of this bacterial reaction mix was incubated 
with 75µl of varying concentrations of galectin-3 or galectin-3 denatured for 10 min 
at 95ºC (6.25, 12.5, 25, 50 or 100µg/ml) for 2 hours in vitro as described in Materials 
and Methods.  Serially diluted samples of untreated bacteria were plated out at t = 0 
and at t = 2 hours after shaking (control).  A sample of S. pn was incubated with 
ampicillin (20µg/ml) as a positive antibiotic control.  2 hours post-incubation, 
samples were serially diluted and blood agar plates were inoculated with each 
reaction of S. pn.  Colonies were counted the following day and the numbers of 
viable bacteria were determined.  Addition of 100µg/ml galectin-3 to S. pn 
significantly inhibited growth with the lower concentrations of galectin-3 and 
denatured galectin-3 showing no effect on growth (figure 6.3).  This result could 
partially explain my in vivo findings that galectin-3-/- mice demonstrate reduced 
bacterial clearance. 
 
6.2.5 Galectin-3-/- macrophages produce less nitrite, compared to wild 
type, in response to both S. pn and E. coli in vitro 
 Alveolar macrophages and recruited macrophages and neutrophils play a key 
role in the clearance and killing of invading pathogens.  In vivo studies indicated a 
clearance defect of bacteria in galectin-3-/- mice.  This work led on to the hypothesis 
that the presence of galectin-3 secreted by resident and recruited macrophages in 
response to a pneumococcal pneumonia infection activates recruited leukocytes in 
the lung and subsequently promotes phagocytosis and bacterial clearance. Further in 
vitro studies were performed to investigate the mechanisms whereby galectin-3 













Figure 6.3 – Antimicrobial activity of galectin-3 to S. pn.
Figure 6.3
Percentage bacterial growth of S. pn following incubation with varying 
concentrations of galectin-3, denatured galectin-3 or ampicillin (Amp 20µg/ml) 
for 2 hours (n = 3). *, P < 0.05 compared to untreated control and 100µg/ml 
denatured galectin-3. P > 0.05 for all other treatments compared to untreated 
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 Nitric oxide (NO) release from macrophages in response to bacteria helps to 
restrain bacterial growth.  NO helps to control a variety of infections including 
parasitic (Liew et al., 1991; Petray et al., 1995), viral (Bi and Reiss, 1995) and fungal 
infections (Alspaugh and Granger, 1991).  Furthermore Tsai et al. demonstrated that 
NO plays a critical role in the antibacterial defence against Klebsiella pneumoniae 
infection (Tsai et al., 1997). 
 NO production from wild type and galectin-3-/- macrophages in response to S. 
pn and E. coli was examined to test the hypothesis that galectin-3-/- macrophages 
may be less efficient at killing S. pn.  Chapter 5 of this thesis demonstrated no 
difference in NO production from wild type and galectin-3-/- mice following 
treatment with the Th1 cytokines Interferon-γ (IFNγ)/LPS.  However, nitrite release 
in response to bacteria may be affected by a lack of galectin-3. 
 Wild type and galectin-3-/- bone marrow derived macrophages (BMDMs) 
treated with IFNγ/LPS produced equal concentration of nitrite (figure 6.4A).  This 
result confirms the finding in Chapter 5 that wild type and galectin-3-/- macrophages 
can classically activate to equal extents.  Galectin-3-/- BMDM produced significantly 
less nitrite in response to both S. pn and E. coli when compared to their wild type 
counterparts (figure 6.4B) suggesting a defect in bacterial killing.  In addition, 
galectin-3-/- peritoneal macrophages incubated with opsonised S. pn also 
demonstrated reduced levels of nitrite production compared to wild type peritoneal 
macrophages (figure 6.4C). 
 To test that the reduction in nitrite production was not due to greater cell 
death of the galectin-3-/- BMDM in response to bacteria, a trypan blue viability assay 
was performed as described in Materials and Methods.  This assay demonstrated no 
difference in cell death between wild type and galectin-3-/- BMDM after incubation 
with either S. pn or E. coli (figure 6.4D). 
 Reduced nitrite production from galectin-3-/- macrophages in response to both 

































Figure 6.4 (A, B)
BMDM prepared from WT (white bars) and galectin-3-/- (black bars) mice were 
incubated with (A) IFNγ (100U/ml)/LPS (100ng/ml) or (B) a 2:1 ratio of 
opsonised S. pn or E. coli to BMDMs for 24h. Supernatants were reacted in a 1:1 
ratio with Greiss Reagent and absorbance at λ560nm was measured. Nitrite 
concentration was calculated using the gradient equation from the standard curve 
(n = 5). ***, P < 0.0001 compared to WT. (A) P = 0.14 (ns) for IFNγ/LPS 
treatment.
Figure 6.4 – Galectin-3-/- macrophages release less nitrite in 
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Figure 6.4 (C, D)
(C) Nitrite release from WT (white bars) and galectin-3-/- (black bars) peritoneal 
macrophages incubated with a 2:1 ratio of S. pn for 24h (n = 3). **, P < 0.01 
compared to WT. (D) Percentage cell death, measured by trypan blue viability 
assay described in Materials and Methods, of WT (white bars) and galectin-3-/-











6.2.6 Galectin-3-/- macrophages demonstrate similar levels of 
phagocytosis to wild type macrophages 
 Previous studies have shown that galectin-3-/- macrophages exhibit reduced 
phagocytosis of IgG opsonised erythrocytes and apoptotic thymocytes (Sano et al., 
2003).  However, to date there has been no study investigating the role of galectin-3 
during phagocytosis of bacteria.  To test the hypothesis that the absence of galectin-3 
may result in macrophages being less efficient at phagocytosing bacteria in a 
pneumonic infection, BMDM and alveolar macrophages were incubated with FITC-
labelled heat-killed S. pn and E. coli in vitro and degree of phagocytosis assessed 
using both fluorescent-activated cell sorting (FACS) analysis and confocal 
microscopy.   
 Galectin-3-/- and wild type BMDM were incubated with a 10:1 ratio of 
opsonised FITC-labelled S. pn and E. coli for up to 1 hour, washed, removed from 
the culture plate and analysed using FACS analysis.  Macrophages were gated on 
according to forward and side scatter properties (R1) (figure 6.5A).  Figure 6.5B 
shows forward scatter versus FL1 properties of untreated BMDMs and BMDMs 
incubated with S. pn or E. coli as described above.  Percentage events in upper right 
quadrant indicates macrophages that have phagocytosed FITC-labelled bacteria.  The 
results from 3 independent experiments were pooled and percentage BMDMs 
containing FITC-labelled bacteria (compared to wild type, 60 minutes) was 
calculated and revealed to be similar for both galectin-3-/- and wild type BMDMs 
(figure 6.5C and D).  To confirm this finding, confocal analysis of wild type and 
galectin-3-/- BMDMs incubated with S. pn and E. coli, and alveolar macrophages 
incubated with S. pn, was performed.  Macrophages were seeded on coverslips, 
incubated with opsonised bacteria for 1 hour, washed, and incubated with rhodamine 
phalloidin to stain the actin cytoskeleton and 4',6-diamidino-2-phenylindole (DAPI) 
to stain the nucleus.  Coverslips were mounted on slides and analysed using a Leica 
SP5 confocal microscope and subsequently processed using Adobe Photoshop.   
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Figure 6.5 – Galectin-3 is not required for effective 
phagocytosis of S. pn or E. coli by BMDM or alveolar 
macrophages. 
Figure 6.5 (A)
BMDMs seeded in 6-well plates were treated with either S. pn or E. coli for up to 
1 hr, washed with PBS and lifted off the bottom of the well using 5mM EDTA. 
(A) Forward and side scatter properties of WT and galectin-3-/- BMDMs. The 
population of BMDMs gated on during FACS analysis is indicated by R1.
Forward Scatter
WT BMDM dot blot
A)











(B) Representative forward scatter versus FL1 dot blots of WT and galectin-3-/-
BMDM treated for 60 min with 10:1 ratio of FITC-S. pn or FITC-E. coli.  Gated 
on macrophages according to forward and side scatter properties (R1). % in upper 
right quadrant indicates macrophages that have phagocytosed FITC-labelled 
bacteria.
WT + FITC-S. pn (60 min)
42.08%
















WT + FITC-E. coli (60 min)
33.40%
Gal-3-/- + FITC-E. coli (60 min)
35.35%
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Figure 6.5 (C, D)
Phagocytosis of a 10:1 ratio of opsonised FITC-S. pn (C) and FITC-E. coli (D) by 
WT ( ) and galectin-3-/- ( ) BMDM measured using FACS analysis. Gated on 
macrophages according to forward and side scatter properties (R1). Results







































(E) WT and galectin-3-/- BMDM incubated with a 10:1 ratio of opsonised FITC-
S. pn (i and ii) or a 20:1 ratio of opsonised FITC-E. coli (iii and iv) and stained 



















(F) WT (i and ii) and galectin-3-/- (iii and iv) alveolar macrophages incubated 
with a 10:1 ratio of opsonised FITC-S. pn and stained with rhodamine phalloidin. 













 Ten random fields were photographed from each slide.  Figures 6.5E and F 
show representative images from each slide.  Wild type and galectin-3-/- BMDMs 
(figure 6.5E) phagocytosed similar numbers of S. pn (i and ii) or E. coli (iii and iv) 
and wild type and galectin-3-/- alveolar macrophages treated with S. pn also exhibit 
similar levels of phagocytosis (figure 6.5F).  Together, these studies indicate no 
significant phagocytosis defect in galectin-3-/- mice of either S. pn or E. coli 
pneumonia. 
 
6.2.7 Phagocytosis of apoptotic human neutrophils by mouse BMDMs 
 Phagocytosis of apoptotic cells is crucial for the resolution of inflammation 
by protecting tissues from exposure to inflammatory and immunogenic components 
of dying cells (Savill et al., 2002).  Therefore, the increased vasculature damage and 
bacteraemia in galectin-3-/- mice could be due to ineffective clearance of apoptotic 
cells by galectin-3-/- macrophages. 
 Human neutrophils were isolated from peripheral blood by density gradient 
centrifugation as described in Materials and Methods.  Apoptotic human neutrophils 
were prepared by culturing neutrophils for 24 hours in Iscove’s Modified Eagle’s 
Medium (IMDM) containing 10% autologous serum.  At this time point >90% of 
neutrophils were apoptotic as determined by Annexin V staining (data not shown). 
 Day 1 apoptotic human neutrophils labelled with CellTracker Green were 
incubated for up to 1 hour in a 10:1 ratio with CellTracker Orange-labelled BMDMs 
and phagocytosis assessed by FACS analysis.  Phagocytosis of apoptotic neutrophils 
by macrophages increased from 15 minutes to 1 hour incubation.  However, 
phagocytosis of apoptotic cells by galectin-3-/- BMDMs was significantly reduced 
compared to wild type at the 45 minute time point (figure 6.6). 
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Figure 6.6 – Galectin-3 may be required for effective 
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Phagocytosis of a 10:1 ratio of apoptotic human neutrophils by WT ( ) and 
galectin-3-/- ( ) BMDM measured using FACS analysis. Results represent the 
mean percentage phagocytosis (compared to WT 60 min) (n = 3).  ***, P < 
0.0001 compared to WT 45 min. P = 0.52 (ns), 0.09 (ns) and 0.52 (ns) for 15, 30 
and 60 min respectively.
***
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6.2.8 Exogenously added recombinant galectin-3 causes human 
neutrophil activation and the generation of ROS 
 The professional phagocytic cells recruited at early time points following 
pneumonia are neutrophils.  One hypothesis is that galectin-3 secreted from resident 
and recruited leukocytes can work in a paracrine manner to activate recruited 
neutrophils, and augment the clearance of invading bacteria.  Upon activation, 
neutrophils release ROS and upregulate CD11b and shed L-selectin (CD62L).  To 
further elucidate the mechanisms whereby galectin-3 activates neutrophils, human 
peripheral blood neutrophils were treated with galectin-3 and the above markers of 
neutrophil activation were assessed. 
 Human neutrophils were isolated from whole blood as described in Materials 
and Methods.  ROS release was assessed by two methods, cytochrome C reduction 
which measures the O2- metabolite (Dahlgren and Karlsson, 1999), and DHR 
fluorescence which measures the H2O2 metabolite (Walrand et al., 2003).  Details of 
each protocol can be found in Materials and Methods. 
 To measure superoxide release, human neutrophils were primed with 0.1 to 
10µg/ml recombinant human galectin-3 or 1µM platelet-activating factor (PAF) as a 
positive control for 15 minutes.  Subsequently, neutrophils were activated with 
0.1µM N-Formyl-Methionine-Leucine-Phenylalanine (fMLP) in 1mg/ml cytochrome 
C for 15 minutes (figure 6.7A).  Neutrophils primed with galectin-3 followed by 
fMLP produced significantly more superoxide compared with neutrophils treated 
with fMLP alone.   
 To measure H2O2 release, human neutrophils were incubated with the 
fluorescent dye DHR for 5 minutes, primed with 10µg/ml recombinant mouse or 
human galectin-3 or 1µM PAF as a positive control for 15 minutes prior to activation 
with 0.1µM fMLP for 15 minutes.  Figure 6.7B illustrates forward and side scatter 
properties of untreated human peripheral blood neutrophils and neutrophils treated 
with PAF, mouse or human galectin-3 followed by activation with fMLP.  Activated 
neutrophils undergo a shape change as demonstrated by altered forward and side 
scatter properties in flow cytometry.  Figures 6.7C and D display representative 
histograms and pooled data showing increased DHR fluorescence following fMLP in 
cells primed with galectin-3 compared with fMLP alone.   
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Figure 6.7 (A)
Cytochrome C assay. (A) Human peripheral blood neutrophils were incubated for 
15 min at 37°C with priming agent PAF (1µM) or human recombinant galectin-3 
(1-10µg/ml) followed by a 15 min incubation with 1mg/ml cytochrome C 
containing the activator 0.1µM fMLP (+) or PBS control (-). Free radical 
generation was measured by a colour change of cytochrome C using a scanning 
spectrophotometer 500nm – 600nm and concentration of O2- release was 
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Figure 6.7 – Exogenously added recombinant galectin-3 



























Dihydrorhodamine (DHR) fluorescence. Representative dot blots (B) and 
histograms (C). Human peripheral blood neutrophils incubated at 37°C with 1µM 
DHR for 5 min followed by a 15 min incubation with priming agent PAF (1µM) 
or mouse (Ms) or human (Hu) recombinant galectin-3 (10µg/ml) then a 15 min 
incubation with 0.1µM fMLP or PBS control. Free radical generation was 
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DHR fluorescence. (D) Human peripheral blood neutrophils were incubated at 
37°C with 1µM DHR for 5 min followed by a 15 min incubation with priming 
agent PAF (1µM) or mouse (Ms) or human (Hu) recombinant galectin-3 
(10µg/ml) then a 15 min incubation with 0.1µM fMLP (+) or PBS control (-).
Free radical generation was measured by DHR fluorescence using a BD 
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 When primed with galectin-3 followed by fMLP, the level of free radical 
generation from isolated human peripheral blood neutrophils exceeded that of 
neutrophils treated with fMLP alone (figure 6.7A, C and D) suggesting that galectin-
3 is acting as a neutrophil priming agent. 
 Subsequent experiments were performed to investigate adhesion molecule 
expression on human peripheral blood neutrophils in response to exogenous galectin-
3.  Human whole blood was treated with 0.1µM fMLP, 100ng/ml LPS or various 
concentrations of recombinant human galectin-3 followed by incubation with anti-
CD62L-PE and anti-CD11b-APC antibodies.  Red blood cells were lysed in FACS 
lysing solution, samples were washed and fixed in 1% paraformaldehyde (PFA).  
Samples were analysed by FACS analysis after gating on the neutrophil population 
by forward and side scatter properties (figure 6.8A).  Neutrophils activated with 
galectin-3 undergo a shape change as demonstrated by altered forward and side 
scatter properties (figure 6.8A).  Figures 6.8B, C and D display representative 
histograms and pooled data showing decreased L-selectin expression and increased 
CD11b expression following treatment with galectin-3, fMLP or LPS.  Together 
these experiments prove that not only can galectin-3 prime neutrophils to subsequent 













Figure 6.8 – Exogenously added recombinant galectin-3 
mediates L-selectin (CD62L) shedding and CD11b 
upregulation on human peripheral blood neutrophils.
B)
Figure 6.8 (A, B)
Adhesion molecule expression. Human whole blood, treated with 0.1µM fMLP, 
or 10µg/ml recombinant human galectin-3, was incubated with anti-CD62L-PE 
and anti-CD11b-APC. (A) Samples gated on human neutrophils (R1) were 
analysed by FACS analysis. (B) Representative histograms showing L-selectin
shedding and CD11b upregulation on human neutrophils following treatment 
with fMLP (i) or galectin-3 (ii). Filled histogram indicates untreated blood.
L-selectin (CD62L-PE) CD11b-APC
L-selectin (CD62L-PE) CD11b-APC
= Human neutrophils + fMLP




Figure 6.8 (C, D)
Human whole blood, treated with 0.1µM fMLP, 100ng/ml LPS or various 
concentrations of recombinant human galectin-3, was incubated with anti-
CD62L-PE and anti-CD11b-APC. Samples gated on human neutrophils (R1) 
were analysed by FACS analysis (C) L-selectin shedding and (D) CD11b 











































6.2.9 Purification of mouse bone marrow neutrophils 
 Subsequent experiments were carried out to address the role of galectin-3 in 
the activation and apoptosis of mouse neutrophils from wild type and galectin-3-/- 
mice.  In addition, phagocytosis of apoptotic mouse neutrophils by macrophages and 
phagocytosis of bacteria by mouse neutrophils was assessed. 
 The number of neutrophils that can be obtained from mouse blood is very 
limited, therefore preparation of neutrophils from bone marrow is a useful technique 
to master.  Using this technique, neutrophils from transgenic mice can be easily 
compared with neutrophils from wild type mice.  Previous studies have reported that 
mouse bone marrow neutrophils show very similar morphology and function to 
neutrophils isolated from mouse whole blood (Boxio et al., 2004).  Furthermore, this 
technique has been shown to yield greater than 90% neutrophil purity (Looney et al., 
2006).  Following an infection, this fully competent neutrophil reservoir in the bone 
marrow is required to rapidly supplement peripheral neutrophils at times of increased 
demand (Boxio et al., 2004). 
 Neutrophils prepared from the bone marrow of wild type and galectin-3-/- 
mice were used to examine the role of galectin-3 on neutrophil function.  Neutrophil 
activation, phagocytosis of bacteria and phagcytosis of apoptotic mouse neutrophils 
by macrophages was assessed using these bone marrow derived neutrophils.  There 
are several described techniques to isolate granulocyte precursors from whole bone 
marrow using Percoll density gradient centrifugation (Boxio et al., 2004; Itou et al., 
2006; Lowell et al., 1996; Tanaka et al., 2004).  However, the method described by 
Looney et al. was utilised in this study as it gave a good yield and purity (Looney et 
al., 2006).    The full method is described in Materials and Methods.  Briefly, bone 
marrow was flushed out using PBS and treated with a short exposure to a hypotonic 
solution of 0.2% NaCl to lyse the red blood cells quickly followed by 1.2% NaCl to 
restore the isotonicity.  The solution was then filtered over a 70µm nylon cell strainer 
and spun on a 62% Percoll gradient and neutrophils were isolated from the cloudy 
pellet at the bottom of the tube.  To determine neutrophil purity, cytospins were 
performed and neutrophil preps were incubated with anti-GR-1-PE (clone RB6-8C5) 
1:200 and anti-CD11b-APC (clone M1/70) 1:50 for 30 minutes at 4°C in the dark 
and analysed using a BD FacsCalibur.   
 182
Figure 6.9 (A-D)
Bone marrow neutrophils were prepared as described in Materials and Methods. 
(A) Representative dot blot showing forward and side scatter properties of a bone 
marrow neutrophil prep. (B and C) FACS analysis of a WT (white bars) and 
galectin-3-/- (black bars) bone marrow neutrophil prep showing GR-1 and CD11b 
positivity (gated on R1). (D) Representative images of a cytospin from a bone 
marrow neutrophil prep (Arrows indicate examples of mature neutrophils).








































Figure 6.10 – Apoptosis of WT and galectin-3-/- mouse bone 



























Figure 6.10 (A, B)
Bone marrow neutrophils were prepared as described in Materials and Methods 
and cultured in RPMI containing 10% FSC for up to four days. At each time 
point, an aliquot of cells were analysed by flow cytometry and the percentage of 
dead, ToPro-3 positive, cells was determined. (A) FACS analysis of WT ( ) and 
galectin-3-/- ( ) neutrophils 24 to 96 hours in culture (n = 2). (B) Histogram 
overlays demonstrating ToPro-3 positivity of both WT and galectin-3-/-
neutrophils after 4 days in culture.
ToPro-3 (FL4)
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 Figure 6.9A illustrates forwards and side scatter properties of a bone marrow 
neutrophil prep.  The various cell populations observed most likely demonstrate 
neutrophils that are matured to different extents.  However when all cell populations 
are taken into account (gate R1), the percentage of both GR-1 and CD11b positive 
cells is approximately 80% (figure 6.9B and C).  Cytospins of these cells displayed 
neutrophil-type morphology with multi-lobular nuclei (arrows) (figure 6.9D). 
 
6.2.10 Apoptosis of mouse bone marrow derived neutrophils 
 It has been previously reported that human neutrophils become apoptotic 
after 24 hours in culture (Savill et al., 1989; Dransfield et al., 1994).  To assess 
mouse neutrophil apoptosis in vitro, wild type and galectin-3-/- mouse bone marrow 
derived neutrophils were incubated in RPMI containing 10% foetal bovine serum 
over 96 hours.  Percentage cell death at various time points was determined by 
incubating the cells with ToPro-3 and analysing samples by FACS analysis.  ToPro-3 
positive cells indicate dead cells.  At 24 hours, galectin-3-/- neutrophils showed 
greater ToPro-3 positivity compared to wild type neutrophils (figure 6.10A).  By 72 
hours in culture, around 70% of both wild type and galectin-3-/- neutrophils were 
dead.  Both wild type and galectin-3-/- neutrophils are ~90% ToPro-3 positive after 
96 hours in culture (figure 6.10A and B).  These results indicated that, in vitro, 
mouse neutrophils require longer in culture than human neutrophils to become 
apoptotic and there may be a difference in the rate at which wild type and galectin-3-
/- neutrophils become apoptotic when cultured in vitro, however this needs to be 
investigated further. 
 
6.2.11 Phagocytosis of apoptotic mouse neutrophils by mouse BMDMs 
 The results in section 6.2.7 indicated that galectin-3-/- macrophages may show 
a defect in phagocytosis of apoptotic neutrophils.  However, this was done using 
apoptotic human neutrophils.  Subsequent experiments were performed to assess 
phagocytosis of day 2 apoptotic wild type mouse neutrophils by BMDM by confocal 
microscopy.   
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Figure 6.11 (A-N)
Images showing phagocytosis of a 5:1 ratio of day 2 WT mouse bone marrow 
derived neutrophils by WT (A) and galectin-3-/- (B) BMDM after 1 hr incubation. 
(Scale bar: 50µm).  (C-N) Selected images of individual WT (C-H) and galectin-
3-/- (I–N) BMDMs phagocytosing apoptotic WT mouse neutrophils at higher 
magnification. (Scale bar: 5µm).
KO BMDM + WT day 2 neutsWT BMDM + WT day 2 neuts











 CellTracker Green-labelled apoptotic neutrophils were incubated for 1 hour 
in a 5:1 ratio with CellTracker Orange-labelled BMDMs on coverslips.  Images were 
captured using a Leica SP5 confocal microscope and subsequently processed using 
Adobe Photoshop (figure 6.11).  Galectin-3-/- BMDMs demonstrated equivalent 
levels of phagocytosis to wild type BMDMs.  Together with the apoptotic human 
neutrophil data, these results are as yet inconclusive, and more studies need to be 
carried out before a definitive conclusion can be drawn regarding the effect of 
galectin-3 on phagocytosis of apoptotic neutrophils. 
 
6.2.12 Phagocytosis of bacteria by mouse bone marrow neutrophils 
 Untreated wild type and galectin-3-/- bone marrow neutrophils incubated with 
opsonised FITC-labelled S. pn or E. coli showed similar levels of phagocytosis 
indicating that the presence of galectin-3 is not essential for effective phagocytosis in 
neutrophils.  However, after 1 hour incubation with 10µg/ml recombinant mouse 
galectin-3 purified using the baculovirus expression system, both wild type and 
galectin-3-/- bone marrow neutrophils enhanced their phagocytic capability (figure 
6.12A and B).  This indicated that exogenous galectin-3 can stimulate phagocytosis 
in neutrophils. 
 This data agrees with the hypothesis that galectin-3 secreted from resident 
and recruited leukocytes can work in a paracrine manner to activate recruited 
neutrophils, and augment the clearance of invading bacteria. 
 
6.2.13 Exogenously added recombinant galectin-3 activates both wild 
type and galectin-3-/- mouse peripheral neutrophils 
 To compare the activation of wild type versus galectin-3-/- neutrophils, mouse 
whole blood, treated with recombinant mouse galectin-3, was incubated with anti-
CD11b-APC or anti-GR-1-PE antibodies.  Samples were gated on GR-1 positive 
neutrophils by FACS analysis (figure 6.13A) and high CD11b expression (CD11bHI) 
on neutrophils in galectin-3-treated mouse whole blood was compared to those of 
untreated controls (figure 6.13B and C).  Both wild type and galectin-3-/- neutrophils 
demonstrated over 90% CD11b positivity when treated with galectin-3. 
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Figure 6.12 – Galectin-3 is not required for effective 
phagocytosis of S. pn or E. coli by mouse neutrophils but 



































Figure 6.12 (A, B)
WT (white bars) and galectin-3-/- (black bars) bone marrow neutrophils were 
prepared as described in Materials and Methods. Half were incubated with 
30µg/ml recombinant mouse galectin-3 for 1h at 37°C then incubated with a 10:1 
ratio of opsonised FITC-S. pn (A) or FITC-E. coli (B) for 1h at 37°C. Samples 







Mouse whole blood was incubated with anti-GR-1-PE. Samples gated on GR-1 
positive neutrophils were analysed by FACS analysis. (A) GR-1 positive 
neutrophils in mouse whole blood (R1).
Figure 6.13 – Exogenously added recombinant galectin-3 
increases CD11b expression on both wild type and galectin-

































Mouse whole blood was treated with 30µg/ml mouse galectin-3 and incubated 
with anti-CD11b-APC and anti-GR-1-PE. Samples gated on GR-1 positive 
neutrophils were analysed by FACS analysis. (B) CD11b positivity on 
neutrophils (gated on R1) from WT and galectin-3-/- mouse whole blood, treated 
with 30µg/ml mouse galectin-3. % in upper right quadrant indicates percentage 






















(C) Neutrophils expressing high levels of CD11b (CD11bHI) from WT (white 
bars) and galectin-3-/- (black bars) mouse whole blood. Whole blood was treated 
with 30µg/ml mouse galectin-3 and incubated with anti-CD11b-APC and anti-
GR-1-PE. Samples gated on GR-1 positive neutrophils were analysed by FACS 
analysis (n = 3).
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 Together with the results using human neutrophils, these data demonstrate 
that exogenously added galectin-3 can activate both human and mouse neutrophils.  
Furthermore, exogenous galectin-3 increases CD11b expression on both wild type an 
galectin-3-/- neutrophils to similar extents indicating that regardless of the initial 




 In vivo, galectin-3 plays an important role in the clearance of pneumococcal 
pneumonia but not in E. coli pneumonia.  Galectin-3-/- mice demonstrated a clearance 
defect of S. pn with increased septicaemia and a greater extent of lung damage 
compared to wild type mice.  This phenotype was markedly reduced in an E. coli 
pneumonia infection.  Galectin-3-/- macrophages and neutrophils phagocytosed S. pn 
just as efficiently as wild type.  However, addition of exogenous galectin-3 activated 
neutrophils and increased their ability to phagocytose bacteria.  Incubation of wild 
type macrophages with both S. pn and E. coli enhanced NO production which was 
not seen with galectin-3-/- macrophages, and galectin-3 had antimicrobial properties 
against S. pn.  This data is consistent with the hypothesis that galectin-3 released 
from macrophages in response to pneumococcal pneumonia infection can activate 
neutrophils and enhance their phagocytic capability so aiding the bacterial clearance 
observed in wild type mice following pneumococcal infection.  In addition, galectin-
3 may aid bacterial clearance by having a direct bactericidal effect on S. pn. 
 Data from the in vivo arm of this study demonstrated an increase in bacterial 
counts in lung homogenate, indicating a bacterial clearance defect, and the presence 
of bacteria in the blood (an indication of sepsis) of galectin-3-/- mice given an acute 
infection of S. pn when compared to strain, age and sex matched wild type mice.  
Lavages from these galectin-3-/- mice contained higher protein concentration, a well 
established assay of vasculature damage resulting in protein leakage into the lung 
space.  This study also demonstrated reduced neutrophil recruitment in the galectin-
3-/- mouse in response to a pneumococcal infection.  Therefore, galectin-3 may act as 
an adhesion molecule during neutrophil extravasation in response to pneumococcal 
pneumonia (Sato et al., 2002).  Sato et al. also reported that neutrophil extravasation 
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following E. coli pneumonia does not involve galectin-3.  However, it was not 
reported whether galectin-3 positive mice developed less severe injury in response to 
E. coli.  In this study, wild type and galectin-3-/- mice developed comparable blood 
sepsis and demonstrated similar levels of bacterial load in response to E. coli.  These 
results show that galectin-3 is important in regulating the host response to S. pn while 
the response to E. coli infection was less pronounced. 
 Alveolar macrophages and recruited macrophages and neutrophils play a key 
role in the clearance and killing of invading pathogens.  Subsequent in vitro assays 
were used to test the hypothesis that there may be a phagocytosis, killing or 
activation defect of galectin-3-/- macrophages and/or neutrophils in response to S. pn.  
In vitro phagocytosis assays revealed no phagocytosis defect of S. pn or E. coli by 
either alveolar macrophages or BMDM as tested by both FACS analysis and 
microscopy.  Disruption of the galectin-3 gene in macrophages resulted in a deficit of 
NO production after incubation with S. pn and E. coli.  Upon activation, neutrophils 
release superoxide (free radicals), upregulate CD11b and shed L-selectin (CD62L).  
Exogenously added galectin-3 increased CD11b and decreased L-selectin expression 
on human neutrophils from whole blood and increased CD11b expression on both 
wild type and galectin-3-/- neutrophils from whole blood.  Furthermore, addition of 
galectin-3 increased free radical production from human peripheral blood 
neutrophils.  These in vitro data suggest that the presence of galectin-3 is not 
necessary for successful phagocytosis of bacteria but may be essential for the killing 
mechanisms used by macrophages and neutrophils, which contribute to the 
eradication of a pneumonia infection. 
 Following phagocytosis, the internalised particle is transported to a 
phagosome containing proteins required for killing internalised pathogens.  This 
requires the maturation of the phagosome to a hydrolytic and acidic phagolysosome, 
which directly limits pathogen replication.  Following phagocytosis of latex beads or 
Mycobacterium tuberculosis by macrophages galectin-3 accumulates on the 
cytoplasmic surface of phagocytic cups and phagosomes (Beatty et al., 2002; Garin 
et al., 2001), where it may have a putative role in regulating phagosome maturation.  
As the mycobacteria is phagocytosed, galectin-3 associated with the extracellular 
surface is incorporated at the luminal face of the bacterial phagosome.  However, 
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over time galectin-3 is increasingly accumulated into the phagosome which would 
suggest that the additional source of galectin-3 may be vesicle-derived and/or 
originate from the cytoplasm. 
 There is growing evidence that bacterial pathogens have developed strategies 
to enhance entry into and survival within phagocytic cells, thereby bypassing normal 
host killing responses (Kang et al., 2005).  The net result is a phagosome that shows 
reduced fusion to late endocytotic compartments.  The specific molecular 
mechanisms involved in modifying phagosome maturation are unknown and may 
differ for gram-positive and gram-negative bacteria.  Therefore, as well as 
modulating the recruitment and function of leukocytes, galectin-3 may contribute to 
the overall outcome of bacterial invasion by modulating phagosome maturation and 
bacterial survival.  Further studies need to be performed to test this hypothesis. 
 The results from this study would suggest that galectin-3 plays a lesser role in 
the host response to E. coli pneumonia.  Sato et al. demonstrated that galectin-3 
concentration in the lung is increased in mice following S. pn but not E. coli infection 
and that this upregulation of galectin-3 correlates with the onset of neutrophil 
extravasation (Sato et al., 2002).  However it was not reported whether galectin-3 
positive mice developed less severe injury in response to E. coli.  It is important to 
note that the severity and progression of pneumonia in the study detailed in this 
chapter was less marked in wild type mice receiving E. coli compared to S. pn which 
makes direct comparisons difficult.  The finding that galectin-3-/- mice did not 
develop worse pneumonia in response to E. coli may be a reflection of the E. coli 
being a less severe model.  Infections involving gram-negative bacteria, including E. 
coli, are accompanied by the accumulation of LPS.  LPS has been shown to decrease 
galectin-3 expression in vitro (Liu et al., 1995; Sato and Hughes, 1994).  However, 
galectin-3 binds to LPS of the gram-negative E. coli and such recognition may 
mediate host cell-pathogen interactions (Mey et al., 1996).  Future studies using a 
higher inoculation or a more virulent strain of E. coli are required before it could be 
construed that galectin-3 does not play a role in E. coli pneumonia.  
 Interaction of pathogens with host cells and substances is an important step in 
microbial pathogenesis.  Specific recognition of bacterial carbohydrates by host 
lectins may also be important.  The capsules of some gram-positive bacteria, for 
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example type XIV S. pn, have evolved glycoconjugates that contain β-galactosides 
and it is proposed that lectins including galectin-3 can recognise these 
polylactosamine containing glycoconjugates on pathogens (Mandrell et al., 1994; 
Sato and Nieminen, 2004).  Galectin-3 may also bind to type III S. pn through a 
similar mechanism. 
 In summary, this study has shown that galectin-3 protects against 
pneumococcal pneumonia through a variety of mechanisms including modulation of 
immune cell function and exhibiting direct antimicrobial activity.  The increased 
expression of galectin-3 in the lungs of mice following S. pn would be sufficient to 
account for an antimicrobial effect of galectin-3 playing an important role.  A 
schematic representation showing how galectin-3 may influence the clearance of S. 
pn is shown in figure 6.14.  In wild type mice, administration of S. pn results in the 
secretion of galectin-3 from resident alveolar macrophages.  Secreted galectin-3 has 
a direct antimicrobial effect on S. pn and can modulate immune cell function.  
Phagocytosis of bacteria by wild type macrophages results in the production of NO 
helping to restrain bacterial growth.  Secreted galectin-3 activates recruited 
neutrophils resulting in increased phagocytosis of bacteria and the production of 
ROS, adding to the bactericidal activity of neutrophils.  Once phagocytosis has taken 
place, the neutrophil undergoes apoptosis.  Wild type macrophages efficiently 
phagocytose apoptotic cells, a crucial step for the resolution of inflammation and 
protection of lung tissues against the immunogenic components of dying cells (figure 
6.14A). 
 Administration of S. pn to a galectin-3-/- mouse causes greater damage than to 
a wild type mouse because many of the above anti-bacterial steps are hindered 
through a lack of galectin-3.  Galectin-3-/- macrophages still produce NO following 
phagocytosis of bacteria, however the amount secreted is significantly less than a 
wild type macrophage.  Recruited neutrophils are activated less, produce less ROS 
and phagocytose fewer bacteria compared to neutrophils in the lungs of a galectin-3 
positive mouse.  Galectin-3-/- neutrophils may apoptose more readily than wild type 
neutrophils resulting in an accumulation of dying cells in the lung and these 
apoptotic cells may not be cleared as efficiently by galectin-3-/- macrophages.  The 
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damage these apoptotic cells have on the lung tissue enables the bacteria to enter the 
blood stream resulting in sepsis (figure 6.14B). 
 Alveolar macrophages express and secrete galectin-3 and it is believed that 
macrophage-derived galectin-3 is crucial for the recovery from a pneumococcal 
infection.  This research has revealed an interesting therapeutic strategy for 
improving clinical outcomes following infection.  It is hoped that intratracheal 
administration of galectin-3 gene-modified macrophages into lungs will limit the 
severity of pneumococcal pneumonia.  Future work would therefore exploit gene-
therapy based strategies to treat pneumococcal pneumonia. 
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(A) Proposed model of pneumococcal pneumonia infection in wild type mice.
Macrophages release galectin-3 and nitric oxide (NO) following phagocytosis of 
S. pn. Galectin-3 accumulates in the alveolar space and together with NO helps to 
kill the bacteria directly. Galectin-3 activates recruited neutrophils to produce 
reactive oxygen species (ROS) and enhances their phagocytosis of bacteria. 
Neutrophils that have eaten bacteria undergo apoptosis and are phagocytosed by 
macrophages, a key process in the resolution of inflammation which limits the 











(B) Proposed model of pneumococcal pneumonia infection in galectin-3-/- mice.
Galectin-3-/- macrophages release less NO following phagocytosis of S. pn. The 
absence of galectin-3 causes reduced activation of neutrophils and consequently 
reduced production of ROS and phagocytosis of bacteria compared to the 
galectin-3-activated neutrophils in the wild type mouse. Galectin-3-/- neutrophils 
are more prone to ungergo apoptosis. Galectin-3-/- macrophages demonstrate 
reduced phagocytic activity of apoptotic neutrophils. Greater numbers of 
histotoxic apoptotic neutrophils damages the lung tissue enabling bacteria to 
enter the blood stream causing septicemia.
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Chapter 7 
Final conclusions and future directions 
 
 Galectin-3 plays many roles during an immune response.  Following an 
infection or chronic tissue injury, galectin-3 is secreted by resident macrophages 
where it subsequently functions as a paracrine and autocrine molecule.  Extracellular 
galectin-3 binds to cell surface β-galactosides containing glycans via the 
carbohydrate recognition domain (CRD).  One of these receptors is CD98, a 
disulfide-linked 125kDa heterodimeric type II transmembrane glycoprotein, 
promoting its dimerisation and, consequently, integrin activation (Dong and Hughes, 
1997; Hughes, 2001; Dong and Hughes, 1996; Henderson et al., 2004).  The majority 
of extracellular functions of galectin-3 are thought to be due to the galectin forming 
oligomers via its N-terminal domain after ligand binding by the C-terminal domain.  
This interaction creates a molecular lattice on the cell surface important for various 
biological activities of galectin-3 (Nieminen et al., 2006).  Extracellular functions 
include the modulation of cell-substrate or cell-cell adhesion, cell migration, cell 
activation, proliferation and survival.  In this way, galectin-3 is an important factor 
during the immune response, cancer progression, chronic inflammation and 
infection. 
 
 I have demonstrated that galectin-3 promotes the progression of fibrosis in 
multiple organs, including the liver and kidney.  Research carried out in this 
laboratory has also shown that lung fibrosis is perpetuated by the presence of 
galectin-3 (unpublished finding).  Initial findings demonstrated increased galectin-3 
expression in established human liver fibrosis with spatial and temporal relationship 
to fibrosis in a reversible rat model of liver fibrosis.  Following these findings, 
chronic liver and kidney fibrosis was induced in wild type and galectin-3-/- mice by 
chronic carbon tetrachloride (CCl4) administration or unilateral ureteric obstruction 
(UUO) respectively.  This in vivo study revealed that galectin-3 plays a critical role 
during both liver and kidney fibrosis, as galectin-3-/- mice showed a marked 
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reduction in α-smooth muscle actin (α-SMA) and collagen production.  Subsequent 
in vitro experiments revealed that galectin-3 is essential for transforming growth 
factor-β (TGF-β) driven myofibroblast activation.  However, to investigate whether 
galectin-3 signalling and induction of myofibroblast activation is dependent upon 
TGF-β, future experiments could include TGF-β siRNA of HSCs followed by 
treatment with recombinant galectin-3.  Future work would also involve experiments 
to elucidate the signalling pathways involved in galectin-3-induced myofibroblast 
activation. 
 β-catenin regulates α-SMA expression during TGF-β-induced epithelial to 
mesenchymal transition (EMT) (Masszi et al., 2004).  Galectin-3 has structural 
similarity to and is a binding partner of β-catenin.  It is therefore proposed that 
galectin-3 can stabilise β-catenin and this interaction may potentiate EMT and 
myofibroblast survival.  
 RNA interference of galectin-3 in mouse hepatic stellate cells (HSCs) in vitro 
resulted in inhibition of myofibroblast activation and procollagen (I) expression.  
Additional work from this laboratory has shown that administration of galectin-3 
siRNA via the portal vein in vivo reduced HSC activation in response to CCl4 
(Henderson et al., 2006).  In addition, preliminary work by N. Henderson has 
demonstrated a decrease in in vivo fibrosis following UUO by administration of 
galectin-3 siRNA via the renal artery (unpublished).  Improvements in siRNA design 
and delivery has resulted in an increasing amount of research being carried out in 
vivo.  Thus, therapeutic use of siRNA as agents capable of attenuating the expression 
of disease-causing genes holds great potential (Soutschek et al., 2004). 
 
 It has been hypothesised that alternative macrophage activation is one of the 
key steps toward the progression of fibrosis.  Stimulation of macrophages with the 
Th2 cytokines interleukin-4 (IL-4) or IL-13 results in L-arginine metabolism by 
arginase (figure 1.4).  L-ornithine is produced which is a necessary metabolite for the 
production of proline (a critical amino acid for the synthesis of collagen) thus linking 
arginase activity to fibrosis (Hesse et al., 2001; Misson et al., 2004; Endo et al., 
2003).  This is supported by numerous findings including increased arginase 
expression and activity in the blood and airways of patients with fibrotic diseases 
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(Grasemann et al., 2005; Grasemann et al., 2006; Mora et al., 2006) and in animal 
models of lung fibrosis (Hesse et al., 2001; Endo et al., 2003) and a shift to classical 
macrophage activation resulting in inducible nitric oxide synthase (NOS2) 
expression and a reduction of fibrosis severity (Wynn et al., 1995).   
 Work presented in Chapter 5 of this thesis detailed the initial work carried out 
to determine whether galectin-3 is involved in alternative macrophage activation.  
These results suggest that the key mechanism required for activation of an alternative 
macrophage phenotype is an IL-4-stimulated galectin-3 feed back loop which 
directly activates CD98 causing sustained phosphatidylinositol 3-kinase (PI3-K) 
activation.  Therefore, in addition to the regulation of myofibroblast activation, 
galectin-3 alternatively activates macrophages, both of which may contribute to the 
persistence of fibrosis seen in mice in vivo.  Ongoing studies in this laboratory will 
help to define the precise biological role of galectin-3-induced alternative 
macrophages in chronic inflammation and fibrosis.   
 Based on my results, my hypothesis is that alternative macrophages secrete 
galectin-3 which goes on to enhance fibroblast activation.  To further explore this, 
alternative macrophage activation or classical macrophage activation of wild type 
macrophages could be triggered by the addition of IL-4 or interferon-γ (IFNγ)/ 
lipopolysaccharide (LPS) respectively and galectin-3 secretion measured.  α-SMA 
expression and activation of fibroblasts co-cultured with galectin-3-/- macrophages or 
alternative or classically activated wild type macrophages could be assessed.  
Galectin-3 inhibitors could also be used to block any effect galectin-3 may have on 
alternative macrophage-induced fibroblast activation. 
 Macrophage ablation by the administration of diptheria toxin (DT) to CD11b- 
diptheria toxin receptor (DTR) mice is one way in which ongoing and future in vivo 
work will identify the role of macrophages during fibrosis.  These mice express the 
human DTR under the control of the CD11b promoter.  This system relies on the fact 
that the mouse DT receptor binds DT poorly compared with the human molecule.  
Thus, transgenic expression of the human DTR confers sensitivity to DT and permits 
ablation in vivo when DT is injected.  Renal fibrosis following UUO is being 
examined in CD11b-DTR mice.  Preliminary results suggest that obstructed kidneys 
of macrophage depleted mice demonstrate reduced α-SMA and collagen expression 
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compared to mice with no macrophage depletion.  Moreover, adoptive transfer of 
wild type macrophages into galectin-3-/- mice significantly increases α-SMA 
expression in the kidney in contrast to galectin-3-/- macrophages which did not.  
These results show that galectin-3-/- fibroblasts in the kidney have the potential to 
transdifferentiate into myofibroblasts when activated by wild type macrophages. 
 A macrophage/neutrophil specific IL-4 receptor-α (IL-4Rα) deficient mouse 
has been generated to investigate the role of alternative macrophage activation during 
schistosomiasis (Herbert et al., 2004).  This technology could be exploited to 
conditionally knockout galectin-3 from macrophages and study the affect this has on 
organ fibrosis. 
 
 In addition to galectin-3 playing a role in perpetuating chronic inflammation, 
I have shown that galectin-3 protects from acute lethal pneumococcal pneumonia 
through a variety of mechanisms including modulation of immune cell function.  In 
vivo, galectin-3 plays an important role in the clearance of the gram-positive 
Streptococcal pneumoniae (S. pn) but not in the gram-negative Escherichia coli (E. 
coli) pneumonia.  Galectin-3-/- mice demonstrate a clearance defect of S. pn with 
increased septicaemia and a greater extent of lung damage compared to wild type 
mice.  This phenotype is markedly reduced in an E. coli pneumonia infection.  Work 
from Sato et al. showed that galectin-3 accumulates in the lungs of mice infected 
with S. pn but not E. coli and this increase of galectin-3 correlates with the onset of 
neutrophil extravasation.  Findings from the study detailed in this thesis also showed 
reduced neutrophil recruitment to the alveolar space in the galectin-3-/- mouse.  These 
results provide further evidence in supporting the role of galectin-3 in pneumococcal 
pneumonia. 
 It is believed that numerous processes involving galectin-3 are occurring in 
the lung of the wild type mouse to clear pneumococcal pneumonia.  Phagocytosis of 
bacteria is a crucial step towards the clearance of an infection.  Galectin-3-/- 
macrophages and neutrophils phagocytose S. pn just as efficiently as wild type – 
however, addition of exogenous galectin-3 activates neutrophils and increases their 
ability to phagocytose bacteria.  Nitric oxide (NO) production from galectin-3-/- 
macrophages in response to bacteria is significantly reduced compared to wild type 
 202
macrophages, partially explaining the uncontrolled bacterial growth in the null 
mouse.  Furthermore, galectin-3 has antimicrobial properties against S. pn.  At 
present, studies are being performed to elucidate the concentration of galectin-3 in 
lungs of mice infected with S. pn.  This will determine whether bactericidal 
concentrations of galectin-3 in the lungs are reached following infection in vivo.   
 Clearance of potentially toxic apoptotic neutrophils by macrophages results in 
the release of anti-inflammatory and reparative cytokines such as TGF-β1.  These 
steps help to limit the degree of tissue injury.  Results indicate that galectin-3-/- 
neutrophils have a tendency to undergo apoptosis earlier than wild type neutrophils, 
and galectin-3-/- macrophages are less able to phagocytose apoptotic neutrophils 
compared to wild type macrophages.  Together, these data explain the increased 
protein content in bronchoalveolar lavage (BAL) and septicaemia in the null mice 
due to the presence of greater numbers of tissue damaging apoptotic neutrophils. 
 These results are consistent with the hypothesis that galectin-3 released from 
macrophages in response to pneumococcal pneumonia infection can activate 
neutrophils and enhance their phagocytic capability so aiding the bacterial clearance 
observed in wild type mice following pneumococcal infection. 
 Future work would involve expanding my in vitro studies to fully investigate 
the role of galectin-3 on neutrophil and macrophage activation and function.  This 
study provides some data regarding the role of galectin-3 in neutrophil apoptosis and 
phagocytosis of apoptotic neutrophils by macrophages, which would be expanded in 
future studies.  Phagosome maturation, an important process in limiting pathogen 
replication, could be assessed in wild type and galectin-3-/- macrophages and 
neutrophils following phagocytosis of S. pn and E. coli using LysoTracker probes 
which selectively label acidic organelles in live cells, including mature hydrolytic 
and acidic phagolysosomes. 
 In vivo studies would involve administration of galectin-3 intratracheally with 
S. pn in galectin-3-/- mice in an attempt to reduce the severity of pneumococcal 
pneumonia in these mice.  The dose of galectin-3 to be administered needs to be 
carefully thought out as a high dose of galectin-3 has been shown to be antimicrobial 
towards S. pn in vitro.  Other in vivo studies would include depleting various 
macrophage populations in the wild type mouse and reconstituting them with wild 
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type or galectin-3-/- macrophages followed by inoculation with S. pn.  Clodronate 
would be used to deplete alveolar macrophages and the role of resident or recruited 
macrophages would be assessed by giving wild type or galectin-3-/- macrophages 
intratracheally or intravenously respectively.  In a second approach, macrophage 
ablation could be carried out by the administration of diptheria toxin to CD11b-DTR 
mice followed by targeting wild type or galectin-3-/- macrophages to the site of 
infection.  A third approach could explore pneumonia infection in the 
macrophage/neutrophil-specific galectin-3 deficient mouse. 
 
 During an initial inflammatory response, for example following an acute 
infection with pneumococcal pneumonia, galectin-3 plays a beneficial role as it 
activates immune cells responsible for clearing the infection and recruits more cells 
to the site of infection.  Once the infection is cleared, the immune response is 
dampened down.  However, during a chronic inflammatory response resulting in 
fibrosis, galectin-3 is detrimental to the individual.  We hypothesise that chronic 
injury results in the enhanced secretion of galectin-3 from macrophages and this 
perpetuates the persistant paracrine and autocrine activation of fibroblasts and 
macrophages.  The consequence of this is enhanced collagen deposition and scarring.  
The plasticity of macrophage activation is crucial for the coordinated response to 
infection.  Galectin-3 may function to restrain the functional phenotype of 
macrophages and permit the development of anti-inflammatory alternatively 
activated macrophages.  Galectin-3-/- macrophages are unable to alternatively 
activate and this may result in a reduced capacity to dampen down inflammation in 
response to infection.  The macrophage specific IL-4Rα-/- mouse develops severe 
septicaemia following schistosomiasis infection due to unrestrained inflammation 
and mobilisation of gut flora (Herbert et al., 2004). 
 I have shown that the presence of galectin-3 is disadvantageous to the 
resolution of a fibrotic response.  However, during a pneumococcal pneumonia 
infection, the presence of galectin-3 is beneficial, and indeed critical, for the 
clearance of an infection.  Therefore, with regard to therapies, it is important to be 
able to specifically target galectin-3 to the site of an infection, for example by 
administering galectin-3 gene-modified macrophages.  Following treatment it is 
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essential to be able to control the levels of galectin-3 so that once an infection is 
cleared, the galectin-3 will not cause fibrosis which could be potentially more fatal 
than the initial infection.  Conversely, with regard to treating fibrotic injury with, for 
example, galectin-3 inhibitors or using RNA interference techniques, these need to 
be targeted to specific tissues/cell types, so that it does not result in an increased 
susceptibility to bacterial infections. 
 In conclusion, I have shown that galectin-3 plays a critical role in a variety of 
inflammatory disorders including fibrosis following chronic tissue injury in the liver 
and kidney and resolution of pneumococcal pneumonia infection, and may therefore 
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